

**IM CANNABIS CORP.**

and

**MYM NUTRACEUTICALS INC.**

and

**TRICHOME FINANCIAL CORP.**

---

**ARRANGEMENT AGREEMENT**

---

**March 31, 2021**

## TABLE OF CONTENTS

	Page
ARTICLE 1 INTERPRETATION.....	2
Section 1.1    Definitions .....	2
Section 1.2    Certain Rules of Interpretation .....	17
Section 1.3    Schedules .....	18
ARTICLE 2 THE ARRANGEMENT .....	18
Section 2.1    Arrangement .....	18
Section 2.2    Interim Order .....	19
Section 2.3    The Company Meeting .....	20
Section 2.4    The Company Circular.....	21
Section 2.5    Final Order.....	23
Section 2.6    Court Proceedings.....	24
Section 2.7    Other Securities.....	24
Section 2.8    The Arrangement and Effective Date .....	25
Section 2.9    Payment of Consideration.....	25
Section 2.10   Adjustment of Consideration .....	25
Section 2.11   Withholding Taxes.....	26
Section 2.12   Tax Matters .....	26
Section 2.13   United States Securities Law Matters .....	26
ARTICLE 3 REPRESENTATIONS AND WARRANTIES .....	28
Section 3.1    Representations and Warranties of the Company .....	28
Section 3.2    Representations and Warranties of the Purchaser.....	28
Section 3.3    Representations and Warranties of Trichome.....	28
ARTICLE 4 COVENANTS .....	29
Section 4.1    Conduct of Business of the Company.....	29
Section 4.2    Conduct of Business of the Purchaser .....	32
Section 4.3    Covenants Regarding the Arrangement .....	33
Section 4.4    Access to Information; Confidentiality.....	36
Section 4.5    Pre-Acquisition Reorganization.....	36
Section 4.6    Public Communications .....	38
Section 4.7    Notice and Cure Provisions .....	38
Section 4.8    Insurance and Indemnification.....	39
Section 4.9    Stock Exchange Matters .....	40
Section 4.10   Board of Directors and Officers.....	40
Section 4.11   Dissent Rights .....	<b>Error! Bookmark not defined.</b>
Section 4.12   Company Key Employees .....	<b>Error! Bookmark not defined.</b>
ARTICLE 5 ADDITIONAL COVENANTS REGARDING NON-SOLICITATION.....	41
Section 5.1    Non-Solicitation.....	41
Section 5.2    Notification of Acquisition Proposals.....	42
Section 5.3    Responding to an Acquisition Proposal.....	43
Section 5.4    Purchaser Right to Match .....	44
Section 5.5    Breach by Subsidiaries and Representatives.....	46

## TABLE OF CONTENTS

(continued)

	Page
ARTICLE 6 CONDITIONS .....	46
Section 6.1    Mutual Conditions Precedent.....	46
Section 6.2    Additional Conditions Precedent to the Obligations of the Purchaser.....	47
Section 6.3    Additional Conditions Precedent to the Obligations of the Company.....	48
Section 6.4    Satisfaction of Conditions.....	50
ARTICLE 7 TERM AND TERMINATION .....	50
Section 7.1    Term.....	50
Section 7.2    Termination.....	50
Section 7.3    Effect of Termination/Survival.....	52
ARTICLE 8 GENERAL PROVISIONS.....	52
Section 8.1    Amendments .....	52
Section 8.2    Termination Fees .....	53
Section 8.3    Expenses .....	54
Section 8.4    Notices .....	54
Section 8.5    Time of the Essence.....	55
Section 8.6    Injunctive Relief .....	55
Section 8.7    Third Party Beneficiaries .....	56
Section 8.8    Waiver.....	56
Section 8.9    Entire Agreement.....	56
Section 8.10   Successors and Assigns .....	56
Section 8.11   Severability .....	57
Section 8.12   Governing Law .....	57
Section 8.13   Rules of Construction .....	57
Section 8.14   No Liability.....	57
Section 8.15   Counterparts.....	57
SCHEDULE A PLAN OF ARRANGEMENT.....	A-1
SCHEDULE B ARRANGEMENT RESOLUTION .....	B-1
SCHEDULE C REPRESENTATIONS AND WARRANTIES OF THE COMPANY .....	C-1
SCHEDULE D REPRESENTATIONS AND WARRANTIES OF THE PURCHASER.....	D-1
SCHEDULE E REPRESENTATIONS AND WARRANTIES OF TRICHOME.....	E-1

## ARRANGEMENT AGREEMENT

**THIS AGREEMENT** is dated as of March 31, 2021,

**BETWEEN:**

**IM CANNABIS CORP.**, a company existing under the Laws of the Province of British Columbia

(the “**Purchaser**”)

- and -

**MYM NUTRACEUTICALS INC.**, a corporation existing under the Laws of the Province of British Columbia

(the “**Company**”)

- and –

**TRICHOME FINANCIAL CORP.**, a corporation existing under the Laws of the Province of Ontario

(“**Trichome**”)

**CONTEXT:**

- A. The Purchaser and the Company wish to propose an arrangement involving the acquisition by the Purchaser of all of the Company Shares in exchange for the Purchaser Shares;
- B. The Parties intend to carry out the transaction contemplated in this Agreement by way of a plan of arrangement under the provisions of the BCBCA;
- C. The Company Board has unanimously determined (with Howard Steinberg and Michael Wiener, directors of the Company, declaring conflicts and abstaining from voting thereon), after receiving the unanimous recommendation of the Company Special Committee and financial and legal advice, that the Consideration to be received by the Company Shareholders is fair, from a financial point of view, and that the Arrangement is in the best interests of the Company, and the Company Board (with Howard Steinberg and Michael Wiener, each a director of the Company, declaring a conflict and abstaining from voting thereon) has unanimously resolved to recommend that Company Shareholders vote in favour of the Arrangement Resolution, all subject to the terms and conditions contained in this Agreement;
- D. The Purchaser has entered into the Support and Voting Agreements and the Lock-up Agreements with all of the directors and executive officers of the Company and certain Company Shareholders, pursuant to which (among other things), such Persons have agreed to, in respect of the Support and Voting Agreements, vote all of the Company Shares held by them in favour of the Arrangement Resolution and, in respect of the Lock-up Agreements, not to dispose of Consideration Shares for a period of time following the Effective Time, in each case, on the terms and subject to the conditions set forth in such agreements;

**THEREFORE**, in consideration of the mutual covenants and agreements herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties and Trichome agree as follows:

## **ARTICLE 1 INTERPRETATION**

### **Section 1.1 Definitions**

In this Agreement, the following terms have the following meanings:

**“Acquisition Proposal”** means, other than the transactions contemplated by this Agreement, any bona fide offer, proposal or inquiry (written or oral), from any Person or group of Persons acting “jointly or in concert” (other than Purchaser and/or one or more of its wholly-owned Subsidiaries), whether or not delivered to the shareholders of the Company, after the date of this Agreement relating to:

- (a) any sale or disposition (or any licence, lease, long-term supply agreement or other arrangement having the same economic effect as a sale or disposition), direct or indirect, in a single transaction or a series of related transactions, of assets (including voting, equity or other securities of Subsidiaries) or alliance, joint venture, partnership or similar transaction representing 20% or more of the consolidated assets or contributing 20% or more of the consolidated revenue of the Company and its Subsidiaries, or of 20% or more of the voting or equity securities (or rights or interests in such voting or equity securities) of any of its Subsidiaries whose assets or revenues, individually or in the aggregate, represent 20% or more of the consolidated assets or consolidated revenues of the Company and its Subsidiaries;
- (b) any direct or indirect take-over bid, exchange offer, issuance of securities or other transaction that, if consummated, would result in such Person or group of Persons acting “jointly or in concert” beneficially owning (within the meaning of Securities Laws) or having the right to acquire 20% or more of any class of voting or equity securities of the Company or any of its Subsidiaries (including securities convertible, exercisable or exchangeable for voting, equity or other securities of the Company or any of its Subsidiaries) on a fully diluted basis;
- (c) any plan of arrangement, merger, amalgamation, consolidation, share exchange, debt exchange, business combination, reorganization, joint venture, exclusive licence, partnership or similar transaction, recapitalization, liquidation, dissolution or winding up or similar transaction involving the Company or any of its Subsidiaries; or
- (d) any other similar transaction or series of transactions involving the Company or any of its Subsidiaries whose assets or revenues, individually or in the aggregate, represent 20% or more of the consolidated assets or contribute 20% or more of the consolidated revenue of the Company and its Subsidiaries.

**“Agreement”** means this arrangement agreement, together with the Schedules attached hereto and the Company Disclosure Letter, as the same may be amended, supplemented or otherwise modified from time to time in accordance with the terms hereof.

“**Arrangement**” means an arrangement under Division 5 of Part 9 of the BCBCA on the terms and subject to the conditions set out in the Plan of Arrangement, subject to any amendments or variations to the Plan of Arrangement made in accordance with the terms of this Agreement and the provisions of the Plan of Arrangement or made at the direction of the Court in the Final Order with the prior written consent of the Company and the Purchaser, each acting reasonably.

“**Arrangement Resolution**” means the special resolution of Company Shareholders approving the Plan of Arrangement to be considered at the Company Meeting, substantially in the form of Schedule B.

“**Authorization**” means, with respect to any Person, any order, permit, approval, consent, waiver, licence, certificate, grant, agreement, classification, restriction, registration or similar authorization of, from or required by any Governmental Entity having jurisdiction over the Person or any Law applicable to the Person, including the Cannabis Licences.

“**BCBCA**” means the *Business Corporations Act* (British Columbia) and the regulations made thereunder, as now in effect and as they may be promulgated or amended from time to time.

“**Breaching Party**” has the meaning specified in Section 4.7(3).

“**Business Day**” means any day of the year, other than a Saturday, Sunday or any day on which major banks are closed for business in Toronto, Ontario or Vancouver, British Columbia, as the context requires.

“**Canadian Optionholder**” has the meaning specified in Section 2.7(2).

“**Cannabis Licences**” means both of (a) the cultivation, processing and sale for medical purposes licence held by Highland Grow Inc., a Subsidiary of the Company, under the *Cannabis Regulations* (Canada) of the *Cannabis Act* (Canada) and issued under the repealed *Access to Cannabis for Medical Purposes Regulations* (Canada) of the *Controlled Drugs and Substances Act* (Canada) on December 1, 2017 and (b) the cultivation licence issued on January 31, 2020 to, and held by, Sublime Culture Inc., a Subsidiary of the Company, under the *Cannabis Regulations* (Canada) of the *Cannabis Act* (Canada).

“**Change in Recommendation**” has the meaning specified in Section 7.2(1)(d)(iii).

“**Company**” has the meaning specified in the preamble.

“**Company Board**” means the board of directors of the Company, as constituted from time to time.

“**Company Board Recommendation**” has the meaning specified in Section 2.4(2).

“**Company Business**” means the current business of the Company, being the cultivation, processing and sale of cannabis and cannabis products pursuant to the Cannabis Licences, through two Subsidiaries, Sublime Culture Inc. and Highland Grow Inc., which operate from sites in Laval, Quebec, and Antigonish, Nova Scotia, respectively.

“**Company Business Assets**” means all tangible and intangible assets, properties, Authorizations, rights or other privileges (whether contractual or otherwise) owned (either directly or indirectly), leased, licensed, granted, loaned, operated or being developed or used, including all vendor lists, customer lists, Intellectual Property and related technologies, real property, fixed assets, facilities,

equipment, inventories and accounts receivable, by the Company and its Subsidiaries in connection with the Company Business.

**“Company Circular”** means the notice of the Company Meeting and accompanying management information circular, including all schedules, appendices and exhibits to, and information incorporated by reference in, such management information circular, to be sent to Company Shareholders in connection with the Company Meeting, as amended, supplemented or otherwise modified from time to time in accordance with the terms of this Agreement.

**“Company Convertible Securities”** means, collectively, the Company Options, the Company Warrants, and the Company Exchangeable Shares.

**“Company Data Room”** means the material contained in the Donnelley Financial Solutions Virtual Data Room established by the Company as at 10:00 p.m. on March 31, 2021, the index of documents of which is appended to the Company Disclosure Letter.

**“Company Disclosure Letter”** means the disclosure letter dated the date of this Agreement and delivered by the Company to the Purchaser with this Agreement.

**“Company Exchangeable Shareholders”** means the registered and beneficial holders of Company Exchangeable Shares.

**“Company Exchangeable Shares”** means the class A special shares in the capital of MYM International Brands Inc., a wholly-owned Subsidiary of the Company, which are exchangeable for Company Shares on a 1 to 1 basis.

**“Company Filings”** means all documents of the Company publicly filed under the profile of the Company on the System for Electronic Document Analysis Retrieval (SEDAR) since May 31, 2020.

**“Company Financial Statements”** has the meaning specified in Schedule C.

**“Company In-The-Money Option”** means a Company Option having an In-The-Money Amount at the Effective Time.

**“Company In-The-Money Warrant”** means a Company Warrant having an In-The-Money Amount at the Effective Time.

**“Company Intellectual Property Rights”** has the meaning specified in Schedule C.

**“Company Lease Documents”** has the meaning specified in Schedule C.

**“Company Leased Properties”** has the meaning specified in Schedule C.

**“Company Lender”** means 1909203 Ontario Inc., a corporation existing under the Laws of the Cayman Islands.

**“Company Loan”** means principal, accrued and unpaid interest, and any other amounts owing by the Company to the Company Lender under the loan agreement between the Company and Company Lender dated July 31, 2020, as amended on January 13, 2021 and January 26, 2021.

**“Company Material Adverse Effect”** means any change, event, occurrence, effect, state of fact or circumstance that, individually or in the aggregate with other such changes, events, occurrences, effects, state of facts or circumstances (including any escalation of COVID-19 after the date hereof), is or would reasonably be expected to be material and adverse to the business, operations, results of operations, assets, capitalization, financial condition, prospects or liabilities (contingent or otherwise), of the Company and its Subsidiaries, taken as a whole, except any such change, event, occurrence, effect, state of facts or circumstance resulting from or arising in connection with:

- (i) any change generally affecting the industries or markets in which the Company and its Subsidiaries operate;
- (ii) any change in general economic, business, political or market conditions or in financial or capital markets in Canada;
- (iii) any adoption, proposal, implementation or change in Law or any interpretation of Law by any Governmental Entity;
- (iv) any change, effect, event or development arising from or out of any change or proposed change in Law, IFRS or accounting rules or the interpretation thereof applicable to the industries or markets in which the Company or any of its Subsidiaries operate (and any changes resulting therefrom);
- (v) any act of terrorism or any outbreak of hostilities or war (or any escalation or worsening thereof), riots, insurrection, civil disorder, military conflicts, political instability or other armed conflict or any governmental response to any of the foregoing, in each case, whether occurring within or outside of Canada;
- (vi) any natural disaster, pandemic, outbreaks of illness or public health emergencies as declared by the World Health Organization (and the worsening thereof) or other acts of God, excluding in each case COVID-19 or any worsening thereof;
- (vii) any change in the market price or trading volume of any securities of the Company (provided, however, that the causes underlying such failure may be considered to determine whether such causes constitute a Company Material Adverse Effect);
- (viii) the failure of the Company to meet any internal or published projections, forecasts, guidance or estimates of revenues, earnings or cash flow for any period (provided, however, that the causes underlying such failure may be considered to determine whether such causes constitute a Company Material Adverse Effect);
- (ix) the announcement of this Agreement or the transactions contemplated hereby, including any drop in the market price of the Company Shares and any loss or threatened loss of, or adverse change or threatened adverse change in, the relationship of the Company or its Subsidiaries with the Company’s employees, customers, suppliers, partners and other Persons with which the Company or any of its Subsidiaries has business relations;
- (x) any matter which has been disclosed by the Company in the Company Disclosure Letter; or



- (xi) compliance with this Agreement and any action taken (or omitted to be taken) by the Company that is consented to by the Purchaser expressly in writing or that is taken (or omitted to be taken) upon the written request of the Purchaser,

provided, however, that with respect to clauses (i) through to and including (vi), such matter does not have a materially disproportionate effect on the Company and its Subsidiaries, taken as a whole, relative to other comparable companies and entities operating in the industry in which the Company and its Subsidiaries operate, and unless expressly provided in any particular section of this Agreement, references in certain sections of this Agreement to dollar amounts are not intended to be, and shall not be deemed to be, illustrative or interpretive for purposes of determining whether a “Company Material Adverse Effect” has occurred.

“**Company Meeting**” means the special meeting of Company Shareholders, including any adjournment or postponement of such special meeting in accordance with the terms of this Agreement, to be called and held in accordance with the Interim Order to consider the Arrangement Resolution and for any other purpose as may be set out in the Company Circular and agreed to in writing by the Purchaser.

“**Company Option Plan**” means the share option plan dated February 26, 2015, as amended and approved by the Company Shareholders on November 2, 2020.

“**Company Options**” means the outstanding options to purchase Company Shares issued pursuant to the Company Option Plan, as listed in the Company Disclosure Letter.

“**Company Out-Of-The-Money Option**” means a Company Option that is not a Company In-The-Money Option.

“**Company Out-Of-The-Money Warrant**” means a Company Warrant that is not a Company In-The-Money Warrant.

“**Company Owned Properties**” has the meaning specified in Schedule C.

“**Company Securityholders**” means holders of any of the Company’s securities and holders of the Company Exchangeable Shares.

“**Company Shareholders**” means the registered or beneficial holders of Company Shares, as the context requires, immediately before the Effective Time.

“**Company Shares**” means the common shares in the authorized share structure of the Company.

“**Company Special Committee**” means the special committee of independent directors of the Company.

“**Company Termination Fee**” has the meaning specified in Section 8.2(1).

“**Company Termination Fee Event**” has the meaning specified in Section 8.2(1).

“**Company Warrants**” means an aggregate of 77,368,607 common share purchase warrants of the Company with a weighted-average exercise price of \$0.22.

“**Confidentiality Agreement**” means the mutual non-disclosure agreement dated February 3, 2021 between the Company and the Purchaser.

“**Consideration**” means the consideration to be received by Company Shareholders pursuant to the Plan of Arrangement as consideration for their Company Shares, consisting of 0.022 of a Purchaser Share for each Company Share as set out in the Plan of Arrangement.

“**Consideration Shares**” means the Purchaser Shares to be issued as the Consideration pursuant to the Arrangement.

“**Constituting Documents**” means notice of articles, articles of incorporation, amalgamation, or continuation, as applicable, and by-laws and all amendments to such by-laws.

“**Contract**” means any legally binding agreement, commitment, contract, franchise, licence, obligation or undertaking (written or oral) to which any Party or any of its Subsidiaries is a party or by which it or any of its Subsidiaries is bound or affected or to which any of their respective properties or assets is subject.

“**Court**” means the Supreme Court of British Columbia, or other court as applicable.

“**COVID-19**” means the coronavirus disease 2019 (dubbed as COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and/or any evolutions thereof or any other virus or disease developing from or arising as a result of SARS-CoV-2 and/or COVID-19.

“**CSE**” means the Canadian Securities Exchange.

“**Depository**” means such Person as the Purchaser may appoint to act as depository for Company Shares in relation to the Arrangement, with the approval of the Company, acting reasonably, for the purpose of, among other things, exchanging certificates representing Company Shares for Consideration Shares.

“**Dissent Rights**” means the rights of dissent of Company Shareholders in respect of the Arrangement Resolution as described in the Plan of Arrangement.

“**Dissenting Holder**” has the meaning specified in the Plan of Arrangement.

“**Effective Date**” means the date upon which the Arrangement becomes effective, as set out in Section 2.8.

“**Effective Time**” means 12:01 a.m. (Pacific time) on the Effective Date, or such other time as the Parties agree to in writing before the Effective Date.

“**Employee Plans**” means all material health, welfare, supplemental unemployment benefit, change of control, bonus, profit sharing, option, insurance, incentive, incentive compensation, deferred compensation, share purchase, share compensation, disability, pension, vacation, severance or termination pay, retirement or retirement savings plans or other material employee benefit plans or agreements for the benefit of employees, former employees, directors or former directors of a Party or any of its Subsidiaries, which are maintained by or binding upon such Party or any of its Subsidiaries or in respect of which such Party or any of its Subsidiaries has an actual or contingent liability excluding all obligations for severance and termination pursuant to a statute or common law and excluding any Statutory Plan.

**“Environmental Laws”** means all Laws and agreements with Governmental Entities and all other statutory requirements relating to public health or the protection of the environment and all Authorizations issued pursuant to such Laws, agreements or other statutory requirements.

**“Fair Market Value”** means the volume weighted average trading price of the Company Shares on the CSE (or other recognized stock exchange on which the Company Shares are primarily traded) for the five trading day period immediately prior to the Effective Date.

**“Fairness Opinion”** means an opinion of the Financial Advisor (delivered orally and subsequently in writing) to the effect that, as of the date of such opinion, and subject to the assumptions, limitations and qualifications set forth therein, the Consideration to be received by Company Shareholders pursuant to the Arrangement is fair, from a financial point of view, to such holders.

**“Final Order”** means the final order of the Court approving the Arrangement under Section 291 of the BCBCA, in a form acceptable to the Company and the Purchaser, each acting reasonably, after a hearing upon the procedural and substantive fairness of the terms and conditions of the Arrangement, as such order may be amended by the Court (with the consent of both the Company and the Purchaser, each acting reasonably) at any time prior to the Effective Date or, if appealed, then, unless such appeal is withdrawn or denied, as affirmed or as amended (provided that any such amendment is acceptable to both the Company and the Purchaser, each acting reasonably) on appeal.

**“Financial Advisor”** means Hyperion Capital Inc., financial advisor to the Company Special Committee.

**“Focus”** means Focus Medical Herbs Ltd., a company existing under the Laws of the State of Israel.

**“Governmental Entity”** means (i) any international, multinational, national, federal, provincial, state, regional, municipal, local or other government, governmental or public department, central bank, court, tribunal, arbitral body, commission, commissioner, board, bureau, ministry, agency or instrumentality, domestic or foreign, (ii) any subdivision or authority of any of the above, (iii) any quasi-governmental or private body exercising any regulatory, expropriation or taxing authority under or for the account of any of the foregoing or (iv) any stock exchange, including the CSE and the Nasdaq.

**“IFRS”** means International Financial Reporting Standards, as issued by the International Accounting Standards Board, applicable as at the date on which the calculation is made or required to be made, applied on a consistent basis.

**“In-The-Money Amount”** at the Effective Time with respect to a Company Option or Company Warrant, means the amount, if any, by which the Fair Market Value of the relevant underlying security exceeds the exercise price of the relevant option or warrant, as applicable, at the Effective Time.

**“Indemnified Persons”** has the meaning specified in Section 8.7(1).

**“Intellectual Property”** means domestic and foreign: (i) patents, applications for patents and reissues, divisions, continuations, renewals, extensions and continuations-in-part of patents or patent applications; (ii) proprietary and nonpublic business information, including inventions (whether patentable or not), invention disclosures, improvements, discoveries, trade secrets, confidential information, know-how, methods, processes, designs, technology, technical data,

schematics, formulae and customer lists, and documentation relating to any of the foregoing; (iii) copyrights, copyright registrations and applications for copyright registration; (iv) trade names, business names, corporate names, domain names, website names and world wide web addresses, common law trade-marks, trade-mark registrations, trade mark applications, trade dress and logos, and the goodwill associated with any of the foregoing; (v) Software; and (vi) any other intellectual property and industrial property.

“**Interim Order**” means the interim order of the Court contemplated by Section 2.2, in a form acceptable to the Company and the Purchaser, each acting reasonably, providing for, among other things, the calling and holding of the Company Meeting, as such order may be amended by the Court with the consent of the Company and the Purchaser, each acting reasonably.

“**Key Consents/Waivers**” means the consents and/or waivers to be given or obtained, and other steps to be taken, in relation to certain Material Contracts and Authorizations as specified in Section 6.2(7) of the Company Disclosure Letter.

“**Law**” means, with respect to any Person, any and all applicable law (statutory, common or otherwise), constitution, treaty, convention, ordinance, code, rule, regulation, order, injunction, notice, judgment, decree, ruling or other similar requirement, whether domestic or foreign, enacted, adopted, promulgated or applied by a Governmental Entity that is binding upon or applicable to such Person or its business, undertaking, property or securities, and to the extent that they have the force of law, policies, guidelines, notices and protocols of any Governmental Entity, as amended.

“**Lien**” means any mortgage, charge, pledge, hypothec, security interest, prior claim, encroachments, option, right of first refusal or first offer, occupancy right, covenant, assignment, lien (statutory or otherwise), defect of title, or restriction or adverse right or claim, or other third party interest or encumbrance of any kind, in each case, whether contingent or absolute.

“**Lock-up Agreements**” means the lock-up agreements dated the date hereof between the Purchaser and each of the directors and executive officers of the Company, as well as certain other Company Shareholders.

“**Matching Period**” has the meaning specified in Section 5.4(1)(e).

“**Material Contract**” means any Contract: (i) that if terminated or modified or if it ceased to be in effect, would reasonably be expected to have a Company Material Adverse Effect; (ii) relating directly or indirectly to the guarantee of any liabilities or obligations or to indebtedness for borrowed money (in each case whether incurred, assumed, guaranteed or secured by any asset) in excess of \$150,000 in the aggregate; (iii) restricting, or which may in the future restrict, the incurrence of indebtedness by the Company or any of its Subsidiaries (including by requiring the granting of an equal and rateable Lien) or the incurrence of any Liens on any properties or assets of the Company or any of its Subsidiaries, or restricting, or which may in the future restrict, the payment of dividends by the Company or any of its Subsidiaries; (iv) providing for the establishment, investment in, organization, formation, or governance of any joint venture, limited liability company, strategic alliance, partnership or sharing of profits, revenue or proprietary information or similar arrangement that is material to the Company and its Subsidiaries; (v) that creates an exclusive dealing arrangement or right of first offer or refusal between the Company and any other Person; (vi) providing for the purchase, sale or exchange of, or option to purchase, sell or exchange, any property or asset where the purchase or sale price or agreed value or fair market value of such property or asset exceeds \$150,000; (vii) that requires the consent of any other party to the Contract to a change of control of the Company or any of its Subsidiaries and pursuant to

which the Company or any of its Subsidiaries may be required to pay, or expects to receive, amounts in excess of \$75,000 in any 12 month period; (viii) that is with any Person with whom the Company does not deal at arm's length within the meaning of the Tax Act, other than a wholly-owned Subsidiary; (ix) that constitutes a hedge contract, futures contract, swap contract, option contract or similar derivative Contract; (x) that constitutes an amendment, supplement, or modification in respect of any of the foregoing; (xi) in full force and effect, pursuant to which the Company or any of its Subsidiaries may be required to pay, or expects to receive, amounts in excess of \$150,000 in any 12 month period; (xii) that limits or restricts in any material respect (A) the ability of the Company or any of its Subsidiaries to engage in any line of business or carry on business in any geographic area, (B) the ability of the Company or any of its Subsidiaries to solicit or hire any Person, or (C) the scope of Persons to whom the Company or any of its Subsidiaries may sell products or deliver services; (xiii) that gives another Person the right to purchase or licence an unlimited quantity or volume of, or enterprise-wide scope of use of, the Company's products or services (or licenses to the Company's products or services) for a fixed aggregate price at no additional charge, or under which the Company grants most-favoured customer pricing, rights of first refusal or similar rights or terms to any Person; or (xiv) that remains in full force and effect and has been filed with the applicable Securities Authorities as a Material Contract in accordance with applicable Securities Laws.

**"MI 61-101"** means Multilateral Instrument 61-101 – *Protection of Minority Shareholders in Special Transactions*.

**"Misrepresentation"** means an untrue statement of a material fact or an omission to state a material fact required or necessary to make the statements contained therein not misleading in light of the circumstances in which they are made.

**"Money Laundering Laws"** has the meaning specified in Schedule C.

**"Nasdaq"** means the Nasdaq Capital Market.

**"Notice"** has the meaning specified in Section 8.4.

**"Officer"** has the meaning specified in the *Securities Act* (British Columbia).

**"Ordinary Course"** means, with respect to an action taken by a Party or any Subsidiary, that such action is consistent with the past practices of such Party or such Subsidiary and is taken in the ordinary course of the normal day-to-day operations of the business of such Party or such Subsidiary, or as commercially reasonable in light of changed circumstances of such Party or such Subsidiary, but excludes non-arm's length transactions.

**"Outside Date"** means August 31, 2021, or such later date as may be agreed to in writing by the Parties, provided that where the Effective Date has not occurred by the Outside Date (i) due to a situation or circumstances arising out of, or in connection with, COVID-19, or (ii) where the only condition to closing that is incapable of being satisfied by such Outside Date (prior to such postponement) is the obtaining of any required Regulatory Approval relating to the Cannabis Licenses, then either Party, provided it is not then in breach of this Agreement in any material respect, may on written notice to the other Party, extend the Outside Date by a period of thirty (30) days; provided further that in no event shall the Outside Date be postponed or extended without the prior written consent of the Purchaser (such consent not to be unreasonably withheld) to a date later than December 1, 2021.

“**Parties**” means the Company, on the one hand, and the Purchaser and Trichome on the other hand, and “**Party**” means either the Company, on the one hand, or the Purchaser and Trichome on the other hand.

“**Permitted Liens**” means, in respect of the Company or any of its Subsidiaries, any one or more of the following:

- (i) minor title defects or irregularities or easements, servitudes, restrictions, restrictive covenants, rights of way, licenses, permits and other similar rights in the Company Owned Properties or the Company Leased Properties that in each case do not materially impair the operation or enjoyment of such real property;
- (ii) Liens for Taxes which (i) are not yet due or delinquent; or (ii) are being contested in good faith by appropriate proceedings and for which adequate provisions have been made in accordance with IFRS;
- (iii) inchoate or statutory Liens of contractors, subcontractors, mechanics, workers, suppliers, materialmen, carriers and others in respect of the construction, maintenance, repair or operation of Company Business Assets, provided that such Liens are incurred in the Ordinary Course and related to obligations not due or delinquent, are not registered against title to any Company Business Assets, and in respect of which adequate holdbacks are being maintained as required by applicable Law;
- (iv) the right reserved to or vested in any Governmental Entity by any statutory provision or by the terms of any lease, licence, franchise, grant or permit of the Company or any of its Subsidiaries, to terminate any such lease, licence, franchise, grant or permit, or to require annual or other payments as a condition of their continuance;
- (v) in respect of the licensed Intellectual Property or Company Leased Properties, the rights of the owners, licensors and lessors expressly set forth therein;
- (vi) zoning and building by-laws and ordinances, regulations made by public authorities that in each case do not materially detract from the value or materially interfere with the use of the Company Owned Properties or the Company Leased Properties;
- (vii) agreements with any Governmental Entity and any public utilities or private suppliers of services that in each case do not materially detract from the value or materially interfere with the use of the real or immovable property subject thereto;
- (viii) any notices of leases registered on title and licenses of occupation;
- (ix) the reservations, limitations, provisos and conditions expressed in the original grant from the Crown and recorded against title and any statutory exceptions to title;
- (x) Liens in respect of pledges or deposits under workers’ compensation, social security or similar Laws, other than with respect to any amounts which are due or

delinquent, unless such amounts are being contested in good faith by appropriate proceedings;

- (xi) Liens imposed by applicable Law and incurred in the Ordinary Course for obligations not yet due or delinquent;
- (xii) such other imperfections or irregularities of title or Lien that, in each case, do not materially adversely affect the use of the properties or assets subject thereto or otherwise materially adversely impair business operations or enjoyment of such properties; and
- (xiii) the Liens listed and described in the Company Disclosure Letter.

“**Person**” includes any individual, partnership, association, body corporate, organization, trust, estate, trustee, executor, administrator, legal representative, government (including Governmental Entity), syndicate or other entity, whether or not having legal status.

“**Plan of Arrangement**” means the plan of arrangement, substantially in the form of Schedule A, subject to any amendments or variations to such plan made in accordance with Section 8.1 of this Agreement or Article 5 of the Plan of Arrangement, or made at the direction of the Court in the Final Order with the prior written consent of the Company and the Purchaser, each acting reasonably.

“**Purchaser**” has the meaning specified in the preamble.

“**Purchaser Board**” means the board of directors of the Purchaser as constituted from time to time.

“**Purchaser Business**” means the business of the Purchaser providing intellectual property and services to licensed cannabis producers in Israel and internationally, as well as the business of Focus, a licenced medical cannabis producer in Israel with whom the Purchaser has exclusive commercial agreements.

“**Purchaser Data Room**” means the material contained in the virtual data room established by the Purchaser as at 10:00 p.m. on March 31, 2021, the index of documents of which is appended to the Purchaser Disclosure Letter.

“**Purchaser Disclosure Letter**” means the disclosure letter dated the date of this Agreement and delivered by the Purchaser to the Company with this Agreement.

“**Purchaser Fairness Opinion**” means an opinion of the Purchaser Financial Advisor (delivered orally and subsequently in writing) to the effect that, as of the date of such opinion, and subject to the assumptions, limitations and qualifications set forth therein, the Consideration to be paid by the Purchaser pursuant to the Arrangement is fair, from a financial point of view, to the Purchaser.

“**Purchaser Financial Advisor**” means Desjardins Securities Inc., financial advisor to the Purchaser.

“**Purchaser Filings**” means all documents of the Purchaser publicly filed under the profile of the Purchaser on the System for Electronic Document Analysis and Retrieval (SEDAR) since October 11, 2019 and on the Electronic Data Gathering, Analysis and Retrieval system (EDGAR) since February 12, 2021.

**“Purchaser Financial Statements”** has the meaning specified in Schedule D.

**“Purchaser Intellectual Property Rights”** had the meaning specified in Schedule D.

**“Purchaser Lease Documents”** has the meaning specified in Schedule D.

**“Purchaser Leased Properties”** has the meaning specified in Schedule D.

**“Purchaser Material Adverse Effect”** means any change, event, occurrence, effect, state of fact or circumstance that, individually or in the aggregate with other such changes, events, occurrences, effects, state of facts or circumstances (including any escalation of COVID-19 after the date hereof), is or would reasonably be expected to be material and adverse to the business, operations, results of operations, assets, capitalization, financial condition or liabilities (contingent or otherwise), of the Purchaser and its Subsidiaries, taken as a whole, except any such change, event, occurrence, effect, state of facts or circumstance resulting from or arising in connection with:

- (i) any change generally affecting the industries or markets in which the Purchaser and its Subsidiaries operate;
- (ii) any change in general economic, business, political or market conditions or in financial or capital markets in Israel, Germany and Canada;
- (iii) any adoption, proposal, implementation or change in Law or any interpretation of Law by any Governmental Entity;
- (iv) any change, effect, event or development arising from or out of any change or proposed change in Law, IFRS or accounting rules or the interpretation thereof applicable to the industries or markets in which the Purchaser or any of its Subsidiaries operate (and any changes resulting therefrom);
- (v) any act of terrorism or any outbreak of hostilities or war (or any escalation or worsening thereof), riots, insurrection, civil disorder, military conflicts, political instability or other armed conflict or any governmental response to any of the foregoing, in each case, whether occurring within or outside of Canada;
- (vi) any natural disaster, pandemic, outbreaks of illness or public health emergencies as declared by the World Health Organization (and the worsening thereof) or other acts of God;
- (vii) any change in the market price or trading volume of any securities of the Purchaser (provided, however, that the causes underlying such failure may be considered to determine whether such causes constitute a Purchaser Material Adverse Effect);
- (viii) the failure of the Purchaser to meet any internal or published projections, forecasts, guidance or estimates of revenues, earnings or cash flow for any period (provided, however, that the causes underlying such failure may be considered to determine whether such causes constitute a Purchaser Material Adverse Effect);
- (ix) the announcement of this Agreement or the transactions contemplated hereby, including any drop in the market price of the Purchaser Shares and any loss or threatened loss of, or adverse change or threatened adverse change in, the



relationship of the Purchaser or its Subsidiaries with the Purchaser's employees, customers, suppliers, partners and other Persons with which the Purchaser or any of its Subsidiaries has business relations;

- (x) any matter which has been disclosed by the Purchaser in the Purchaser Disclosure Letter;
- (xi) compliance with this Agreement and any action taken (or omitted to be taken) by the Purchaser that is consented to by the Purchaser expressly in writing or that is taken (or omitted to be taken) upon the written request of the Purchaser; or
- (xii) any action taken by the Purchaser or any of its Subsidiaries which is required to be taken pursuant to this Agreement,

provided, however, that with respect to clauses (i) through to and including (vi) such matter does not have a materially disproportionate effect on the Purchaser and its Subsidiaries, taken as a whole, relative to other comparable companies and entities operating in the industry in which the Purchaser and its Subsidiaries operate, and unless expressly provided in any particular section of this Agreement, references in certain sections of this Agreement to dollar amounts are not intended to be, and shall not be deemed to be, illustrative or interpretive for purposes of determining whether a "Purchaser Material Adverse Effect" has occurred.

**"Purchaser Option Plan"** means the share option plan approved by the shareholders of the Purchaser on March 16, 2020.

**"Purchaser Shares"** means the common shares in the authorized share structure of the Purchaser.

**"Registrar"** means the Registrar of Companies appointed pursuant to Section 400 of the BCBCA.

**"Regulatory Approval"** means any consent, waiver, permit, exemption, review, order, decision or approval of, or any registration and filing with, any Governmental Entity, or the expiry, waiver or termination of any waiting period imposed by Law or a Governmental Entity, in each case required in connection with the Arrangement and as specified in the Company Disclosure Letter.

**"Replacement Options"** means the options to purchase Purchaser Shares to be issued by the Purchaser pursuant to the Purchaser Option Plan in exchange for each of the outstanding Company Out-Of-The-Money Options at the Effective Time pursuant to Section 2.4(b) of the Plan of Arrangement.

**"Replacement Warrants"** means the warrant to purchase Purchaser Shares to be issued by the Purchaser in exchange for each of the outstanding Company Out-Of-The-Money Warrants at the Effective Time pursuant to Section 2.3(1)(e) of the Plan of Arrangement.

**"Representative"** has the meaning specified in Section 5.1(1).

**"Required Approval"** has the meaning specified in Section 2.2(1)(c).

**"Sanctions"** has the meaning specified in Schedule C.

**"SEC"** means the United States Securities and Exchange Commission.

“**Section 3(a)(10) Exemption**” means the exemption from the registration requirements of the U.S. Securities Act provided by Section 3(a)(10) thereof.

“**Securities Authorities**” means the British Columbia Securities Commission and the applicable securities commission or securities regulatory authority of each of the other provinces and territories of Canada and the SEC.

“**Securities Laws**” means (a) the *Securities Act* (British Columbia) and any other applicable provincial securities Laws, (b) the U.S. Securities Act, the U.S. Exchange Act, to the extent applicable, and (c) the policies, rules and regulations of the CSE and/or the Nasdaq.

“**Settlement Agreement**” means the Settlement Agreement dated the date hereof between the Company and the Company Lender.

“**Software**” means computer software and programs (both source code and object code form), all proprietary rights in the computer software and programs and all documentation and other materials related to the computer software and programs.

“**Statutory Plans**” means benefit plans that a Party or any of its Subsidiaries is required by domestic or foreign statutes to participate in or contribute to in respect of employees, former employees, directors or former directors, including plans administered pursuant to applicable health, tax, workplace safety insurance, workers’ compensation and employment insurance legislation.

“**Superior Proposal**” means any unsolicited written Acquisition Proposal from a Person who is an arm’s length third party made after the date of this Agreement: (i) to acquire all of the outstanding Company Shares not beneficially owned by such arm’s length third party or all or substantially all of the assets of the Company on a consolidated basis; (ii) that complies with Securities Laws in all material respects and did not result from or involve a breach of Article 5; (iii) that is reasonably capable of being completed without undue delay, taking into account all financial, legal, regulatory and other aspects of such proposal and the Person making such proposal; (iv) that is not subject to any financing condition and in respect of which adequate arrangements have been made to ensure that the required funds or other consideration will be available to effect payment in full for all of the Company Shares or assets, as the case may be;<sup>1</sup> and (v) that in respect of which the Company Board determines in good faith (after receipt of advice from its outside legal counsel with respect to (x) below and financial advisors with respect to (y) below) that (x) failure to recommend such Acquisition Proposal to the Company Shareholders would be inconsistent with its fiduciary duties, and (y) which would, taking into account all of the terms and conditions of such Acquisition Proposal, if consummated in accordance with its terms (but not assuming away any risk of non-completion), result in a transaction more favourable to the Company Shareholders, taken as a whole, from a financial point of view, than the Arrangement (after taking into account any adjustment to the terms and conditions of the Arrangement proposed by the Purchaser pursuant to Section 5.4(2)). For the purposes of clause (iv), “adequate arrangements” will be considered to have been made if the Person making the Acquisition Proposal has confirmed that it has cash resources on hand available to fund the Acquisition Proposal or has obtained binding commitments (which may be subject only to customary conditions relating to completion of transaction documentation) that may be drawn upon on or prior to the proposed time of completion of the Acquisition Proposal.

---

<sup>1</sup> That a Superior Proposal is only permitted to have a due diligence period of 5 days is dealt with in Article 5.

“**Superior Proposal Notice**” has the meaning specified in Section 5.4(1)(c).

“**Support and Voting Agreements**” means each of the support and voting agreements dated the date hereof between the Purchaser and each of the directors and executive officers of the Company and certain other Company Shareholders.

“**Tax Act**” means the *Income Tax Act* (Canada) and the regulations promulgated thereunder, each as amended.

“**Tax Returns**” means any and all returns, reports, declarations, elections, notices, forms, designations, filings, and statements (including withholding tax returns and reports, and information returns and reports and whether in tangible or intangible form and including any amendments, schedules, attachments, supplements, appendices and exhibits thereto) filed or required to be filed in respect of the determination, assessment, collection or payment of any Tax or in connection with the administration, implementation or enforcement of any legal requirement relating to any Taxes.

“**Taxes**” means (i) any and all taxes, duties, fees, excises, premiums, assessments, imposts, levies and other charges or assessments in the nature of a tax imposed by any Governmental Entity, whether computed on a separate, consolidated, unitary, combined or other basis, including those levied on, or measured by, or described with respect to, income, gross receipts, profits, gains, windfalls, capital, capital stock, production, recapture, transfer, land transfer, licence, gift, occupation, wealth, environment, net worth, indebtedness, surplus, sales, goods and services, harmonized sales, provincial sales, use, value-added, excise, special assessment, stamp, withholding, business, franchising, real or personal property, health, employee health, payroll, workers’ compensation, employment or unemployment, severance, social services, social security, education, utility, surtaxes, customs, import or export, and including all licence and registration fees and all employment insurance, health insurance and government pension plan premiums or contributions; (ii) all interest, penalties, fines, additions to tax or other additional amounts imposed by any Governmental Entity on or in respect of amounts of the type described in clause (i) above or this clause (ii); (iii) any liability for the payment of any amounts of the type described in clauses (i) or (ii) as a result of being a member of an affiliated, consolidated, combined or unitary group for any period; and (iv) any liability for the payment of any amounts of the type described in clauses (i) or (ii) as a result of any express or implied obligation to indemnify any other Person or as a result of being a transferee or successor in interest to any party.

“**Terminating Party**” has the meaning specified in Section 4.7(3).

“**Termination Notice**” has the meaning specified in Section 4.7(3).

“**Trichome**” has the meaning specified in the preamble.

“**U.S. Exchange Act**” means the *United States Securities Exchange Act of 1934*, as amended, and the rules and regulations promulgated thereunder.

“**U.S. Securities Act**” means the *United States Securities Act of 1933*, as amended, and the rules and regulations promulgated thereunder.

“**Wilful Breach**” means a breach of this Agreement that is a consequence of any act undertaken by the breaching Party, or failure to take any action or permitting of any act to be undertaken, with the

actual knowledge that such act or omission would, or would be reasonably expected to, cause a material breach of this Agreement.

## **Section 1.2 Certain Rules of Interpretation**

- (1) **Gender, etc.** In this Agreement, words signifying the singular number include the plural and vice versa, and words signifying gender include all genders.
- (2) **Including.** Every use of the words “including” or “includes” in this Agreement is to be construed as meaning “including, without limitation” or “includes, without limitation”, respectively.
- (3) **Divisions and Headings.** The division of this Agreement into Articles and Sections, the insertion of headings and the inclusion of a table of contents are for convenience of reference only and do not affect the construction or interpretation of this Agreement.
- (4) **Articles, Sections, etc.** References in this Agreement to an Article, Section or Schedule are to be construed as references to an Article, Section or Schedule of or to this Agreement unless otherwise specified.
- (5) **Time Periods.** Unless otherwise specified in this Agreement, time periods within which or following which any calculation or payment is to be made, or action to be taken, will be calculated by excluding the day on which the period begins and including the day on which the period ends. If the last day of a time period is not a Business Day, the time period will end on the next Business Day.
- (6) **Statutory Instruments.** Unless otherwise specified, any reference in this Agreement to any statute includes all regulations and subordinate legislation made under or in connection with that statute at any time, and is to be construed as a reference to that statute as amended, modified, restated, supplemented, extended, re-enacted, replaced or superseded at any time. Any reference herein to a particular provision or part of any statute will include a reference to that provision or part as it may be renumbered or amended from time to time and any successor provision or part or any renumbering or amendment thereof. Any reference herein to the *Income Tax Act* (Canada) shall also include a reference to any applicable and corresponding provision under the income tax Laws of a province or territory of Canada.
- (7) **Knowledge.** Where any representation or warranty is expressly qualified by reference to the knowledge of the Company, it is deemed to refer to the actual knowledge, after making reasonable inquiries regarding the relevant matter, of Michael Wiener, Mark Forster, Robin Linden, James Andrews and Laird Choi.

Where any representation or warranty is expressly qualified by reference to the knowledge of the Purchaser, it is deemed to refer to the actual knowledge, after making reasonable inquiries regarding the relevant matter, of Oren Shuster, Roy Kait and Shai Shemesh.

- (8) **Time of Day.** Unless otherwise specified, references to time of day or date mean the local time or date in the City of Toronto, in the Province of Ontario or in the City of Vancouver, in the Province of British Columbia, as the context requires.
- (9) **Payment and Currency.** Unless otherwise specified, any money to be advanced, paid or tendered by a Party under this Agreement must be advanced, paid or tendered by bank draft, certified cheque or wire transfer of immediately available funds payable to the Person to whom the amount is due.

Unless otherwise specified, the word “dollar” and the “\$” sign refer to Canadian currency, and all amounts to be advanced, paid, tendered or calculated under this Agreement are to be advanced, paid, tendered or calculated in Canadian currency.

- (10) **Capitalized Terms.** All capitalized terms used in any Schedule or in the Company Disclosure Letter or in the Purchaser Disclosure Letter have the meanings ascribed to them in this Agreement.
- (11) **Accounting Terms.** Unless otherwise specified herein, all accounting terms are to be interpreted in accordance with IFRS and all determinations of an accounting nature in respect of either Party required to be made shall be made in a manner consistent with IFRS.
- (12) **Consent.** If any provision requires approval or consent of a Party and such approval or consent is not delivered within the specified time limit, the Party whose consent or approval is required shall be conclusively deemed to have withheld its approval or consent.
- (13) **Affiliates and Subsidiaries.** For the purpose of this Agreement, a Person is an “**affiliate**” of another Person if one of them is a Subsidiary of the other or each one of them is controlled, directly or indirectly, by the same Person. A “**Subsidiary**” means a Person that is controlled directly or indirectly by another Person and includes a Subsidiary of that Subsidiary. A Person is considered to “**control**” another Person if: (i) the first Person beneficially owns or directly or indirectly exercises control or direction over securities of the second Person carrying votes which, if exercised, would entitle the first Person to elect a majority of the directors of the second Person, unless that first Person holds the voting securities only to secure an obligation, or (ii) the second Person is a partnership, other than a limited partnership, and the first Person holds more than 50% of the interests of the partnership, or (iii) the second Person is a limited partnership, and the general partner of the limited partnership is the first Person. To the extent any covenants or agreements relate, directly or indirectly, to a Subsidiary of a Party, each such provision shall be construed as a covenant by the Party to cause (to the fullest extent to which it is legally capable) such Subsidiary to perform the required action.

### **Section 1.3 Schedules**

- (1) The schedules attached to this Agreement and the Company Disclosure Letter form an integral part of this Agreement for all purposes of it.
- (2) The Company Disclosure Letter and the Purchaser Disclosure Letter themselves and all information contained therein is confidential information and may not be disclosed except in accordance with the terms of the Confidentiality Agreement.

## **ARTICLE 2 THE ARRANGEMENT**

### **Section 2.1 Arrangement**

The Company and the Purchaser agree that the Arrangement will be implemented in accordance with and subject to the terms and conditions of this Agreement and the Plan of Arrangement and subject to such changes as may be mutually agreed to by the Parties in accordance with this Agreement. From and after the Effective Time, the Company and the Purchaser shall each effect and carry out the steps, actions or transactions to be carried out by them pursuant to the Plan of Arrangement. Without limitation to the foregoing, at the Effective Time, the Plan of Arrangement

shall become effective with the result that among other things, the Purchaser shall become the holder of all of the outstanding Company Shares.

## Section 2.2 Interim Order

- (1) As soon as reasonably practicable after the date of this Agreement, but in any event at a time so as to permit the Company Meeting to be held on or before the date specified in Section 2.3(1)(a), the Company shall apply to the Court in a manner reasonably acceptable to the Purchaser pursuant to Section 291 of the BCBCA and, in cooperation with the Purchaser, prepare, file and diligently pursue a motion for the Interim Order, which must provide, among other things:
  - (a) for the Persons and classes of Persons to whom notice is to be provided in respect of the Arrangement and the Company Meeting and for the manner in which such notice is to be provided;
  - (b) for confirmation of the record date for the Company Meeting referred to in Section 2.3(1)(c);
  - (c) that the required level of approval (the “**Required Approval**”) for the Arrangement Resolution shall be at least: (i) 66<sup>2/3</sup>% of the votes cast on the Arrangement Resolution by Company Shareholders and Company Exchangeable Shareholders, voting together as a single class; (ii) if required by applicable Law, a simple majority of the votes cast on the Arrangement Resolution excluding the votes for Company Shares held by “related parties” and “interested parties” as defined under MI 61-101; and (iii) any other shareholder approvals required by the CSE or the Nasdaq;
  - (d) that, in all other respects, the terms, restrictions and conditions of the Company’s Constating Documents, including quorum requirements and all other matters, shall (unless varied by the Interim Order) apply in respect of the Company Meeting;
  - (e) for the grant of the Dissent Rights only to those Company Shareholders who are registered Company Shareholders as contemplated in the Plan of Arrangement;
  - (f) for the notice requirements with respect to the presentation of the application to the Court for the Final Order;
  - (g) that the Company Meeting may be adjourned or postponed from time to time by the Company in accordance with the terms of this Agreement without the need for additional approval of the Court;
  - (h) that the Company Meeting may be held in-person or be an entirely virtual meeting or hybrid meeting whereby Company Securityholders may join virtually;
  - (i) that the record date for Company Securityholders entitled to notice of and to vote at the Company Meeting will not change in respect of any adjournment(s) or postponement(s) of the Company Meeting, unless required by Securities Law;
  - (j) that the deadline for submission of proxies by the Company Securityholders for the Company Meeting shall be 48 hours (excluding Saturdays, Sundays and statutory holidays in Toronto, Ontario and Vancouver, British Columbia) prior to the Company Meeting; and

- (k) that it is the intention of the Parties to rely, by virtue of the Final Order, upon the Section 3(a)(10) Exemption with respect to the issuance of the Consideration Shares, the Replacement Options and the Replacement Warrants to be issued pursuant to the Arrangement to Company Shareholders and holders of Company Convertible Securities, based on the Court's approval of the Arrangement.

### **Section 2.3 The Company Meeting**

- (1) The Company shall:

- (a) convene and conduct the Company Meeting in accordance with the Interim Order, the Company's Constatng Documents and applicable Laws as soon as reasonably practicable, and in any event, but subject to compliance by the Purchaser with its obligations in Section 2.4, on or before August 9, 2021 (or such later date as may be agreed to by the Parties in writing or required as a result of a delay by the Purchaser in providing the information required pursuant to Section 2.4(4)) for the purpose of considering the Arrangement Resolution and for any other proper purpose as may be set out in the Company Circular and agreed to in writing by the Purchaser, and not adjourn, postpone or cancel (or propose the adjournment, postponement or cancellation of) the Company Meeting without the prior written consent of the Purchaser, which consent shall not be unreasonably withheld or delayed, except:
  - (i) in the case of an adjournment, as required for quorum purposes (in which case the Company Meeting shall be adjourned and not canceled);
  - (ii) as required by Law or by a Governmental Entity; or
  - (iii) as required or permitted under Section 4.7(3) or Section 5.4(5);
- (b) use commercially reasonable efforts to solicit proxies in favour of the approval of the Arrangement Resolution and against any resolution submitted by any Company Shareholder that is inconsistent with the Arrangement Resolution and the completion of any of the transactions contemplated by this Agreement and reasonably consider the input of the Purchaser with respect to the solicitation of proxies in respect of the Company Meeting, including, if the Company has not already obtained one and it is requested by the Purchaser, using proxy solicitation services firms (at the sole expense of the Purchaser);
- (c) fix and publish a record date for the purposes of determining the Company Shareholders entitled to receive notice of and vote at the Company Meeting in accordance with the Interim Order;
- (d) consult with the Purchaser in fixing the date of the Company Meeting, give notice to the Purchaser of the Company Meeting and allow the Purchaser's representatives and legal counsel to attend the Company Meeting;
- (e) promptly advise the Purchaser, at such times as the Purchaser may reasonably request and at least on a daily basis on each of the last ten (10) Business Days prior to the date of the Company Meeting, as to the aggregate tally of the proxies received by the Company in respect of the Arrangement Resolution;

- (f) promptly advise the Purchaser of receipt by the Company of any written communication from any Company Shareholder or other security holder of the Company in opposition to the Arrangement, written notice of dissent, purported exercise or withdrawal of Dissent Rights, and written communications sent by or on behalf of the Company to any Company Shareholder exercising or purporting to exercise Dissent Rights;
- (g) not make any payment or settlement offer, or agree to any payment or settlement prior to the Effective Time with respect to Dissent Rights without the prior written consent of the Purchaser;
- (h) not, except as set out in the Interim Order and only with the consent of the Purchaser, which consent shall not be unreasonably withheld or delayed, change the record date for Company Shareholders entitled to vote at the Company Meeting in connection with any adjournment or postponement of the Company Meeting (unless required by Law); and
- (i) at the request of the Purchaser from time to time, provide the Purchaser with a list (in both written and electronic form as may be provided by the Company's registrar and transfer agent) of (i) Company Shareholders, together with their addresses and respective holdings of Company Shares, (ii) the names, addresses and holdings of all Persons having rights issued by the Company to acquire Company Shares (including holders of Company Convertible Securities), and (iii) to the extent available to the Company, participants and book based nominee registrants such as CDS & Co., CEDE & Co. and DTC, and non objecting beneficial owners of Company Shares and other security holders of the Company, together with their addresses and respective holdings of Company Shares and all other securities of the Company. The Company shall, from time to time, require that its registrar and transfer agent furnish the Purchaser with such additional information, including updated or additional lists of the Company Shareholders, and lists of securities positions and other assistance as the Purchaser may reasonably request in order to be able to communicate with respect to the Arrangement with the Company Shareholders.

#### **Section 2.4 The Company Circular**

- (1) The Company shall promptly prepare and complete, in reasonable consultation with the Purchaser, the Company Circular together with any other documents required by Law in connection with the Company Meeting and the Arrangement, and the Company shall, promptly after obtaining the Interim Order, cause the Company Circular and such other documents to be filed and sent to each Company Shareholder and other Person as required by the Interim Order and applicable Law, in each case so as to permit the Company Meeting to be held by the date specified in Section 2.3(1)(a).
- (2) The Company shall ensure that the Company Circular complies in all material respects with applicable Law and the Interim Order, does not contain any Misrepresentation other than in respect to any written information with respect to the Purchaser that is furnished in writing by or on behalf of the Purchaser for inclusion in the Company Circular regarding the Company and provides Company Shareholders with sufficient information to permit them to form a reasoned judgment concerning the matters to be placed before the Company Meeting. Without limiting the generality of the foregoing, the Company Circular must include: (i) a copy of the Fairness Opinion; (ii) a statement that the Company Special Committee has received the Fairness Opinion, and the Company Board, after receiving the unanimous recommendation of the Company Special Committee and financial and legal advice, has unanimously determined (with Howard Steinberg and Michael Wiener, each a director of the Company, declaring a conflict and abstaining from voting thereon) that the Consideration to be received by Company Shareholders is fair, from a



financial point of view, and that the Arrangement is in the best interests of the Company and that the Company Board (excluding Howard Steinberg and Michael Wiener) unanimously recommends that Company Shareholders vote in favour of the Arrangement Resolution (the “**Company Board Recommendation**”); (iii) a statement that each director and executive officer of the Company intends to vote all of such individual’s Company Shares in favour of the Arrangement Resolution and against any resolution submitted by any Company Shareholder that is inconsistent with the Arrangement, the whole in accordance with their Support and Voting Agreements; and (iv) a statement that each director and executive officer of the Company, as well as certain other Company Shareholders, has entered into Support and Voting Agreements and each director and executive officer of the Company has entered into Lock-up Agreements and specifying the percentage of the issued and outstanding Company Shares covered by such Support and Voting Agreements and Lock-up Agreements, as applicable.

- (3) The Company shall indemnify and save harmless the Purchaser and each of its representatives from and against any and all liabilities, claims, demands, losses, costs, damages and expenses to which they may be subject or may suffer, in any way caused by, or arising, directly or indirectly, from or in consequence of:
  - (a) any Misrepresentation or alleged Misrepresentation in any information included in the Company Circular, other than the information relating to the Purchaser (including information provided by the Purchaser in connection with the preparation of any *pro forma* financial statements for inclusion in the Company Circular), its affiliates or the Consideration Shares furnished to the Company in writing by the Purchaser for inclusion in the Company Circular; and
  - (b) any order made, or any inquiry, investigation or proceeding by any Securities Authority or other Governmental Entity, to the extent based on any Misrepresentation or any alleged Misrepresentation in the Company Circular other than the information relating to the Purchaser (including information provided by the Purchaser in connection with the preparation of any *pro forma* financial statements for inclusion in the Company Circular), its affiliates or the Consideration Shares furnished to the Company in writing by the Purchaser for inclusion in the Company Circular.
- (4) The Company shall not be responsible for any information in the Company Circular relating to the Purchaser (including information provided by the Purchaser in connection with the preparation of any *pro forma* financial statements for inclusion in the Company Circular), its affiliates or the Consideration Shares.
- (5) The Company shall give the Purchaser and its legal counsel a reasonable opportunity to review and comment on drafts of the Company Circular and other related documents, and shall give reasonable consideration to any comments made by them, and agrees that all information relating solely to the Purchaser, its affiliates and the Consideration Shares included in the Company Circular must be in a form and content reasonably satisfactory to them.
- (6) The Purchaser shall as soon as reasonably practicable after the date hereof, and in any event within twenty-five (25) Business Days of the date hereof, provide the Company with all information regarding the Purchaser (including any *pro forma* financial statements, as required by Law and reasonably requested by the Company in writing for inclusion in the Company Circular), its affiliates and the Consideration Shares, as required by Law (and in particular, Securities Law), including any *pro forma* financial statements, for inclusion in the Company Circular or in any amendments or supplements to such Company Circular. The Purchaser shall ensure that such

information does not include any Misrepresentation concerning the Purchaser, its affiliates and the Consideration Shares.

- (7) The Purchaser shall indemnify and save harmless the Company and each of its representatives from and against any and all liabilities, claims, demands, losses, costs, damages and expenses to which they may be subject or may suffer, in any way caused by, or arising, directly or indirectly, from or in consequence of:
  - (a) any Misrepresentation or alleged Misrepresentation in any information included in the Company Circular relating to the Purchaser (including information provided by the Purchaser in connection with the preparation of any *pro forma* financial statements for inclusion in the Company Circular), its affiliates or the Consideration Shares furnished to the Company in writing by the Purchaser for inclusion in the Company Circular pursuant to Section 2.4(6); and
  - (b) any order made, or any inquiry, investigation or proceeding by any Securities Authority or other Governmental Entity, to the extent based on any Misrepresentation or any alleged Misrepresentation in any information included in the Company Circular relating to the Purchaser (including information provided by the Purchaser in connection with the preparation of any *pro forma* financial statements for inclusion in the Company Circular), its affiliates or the Consideration Shares furnished to the Company in writing by the Purchaser for inclusion in the Company Circular pursuant to Section 2.4(6);
- (8) The Purchaser shall not be responsible for any information in the Company Circular relating to the Company (including information provided by the Company in connection with the preparation of any *pro forma* financial statements for inclusion in the Company Circular).
- (9) The Purchaser and the Company shall also use their commercially reasonable efforts to obtain any necessary consents from any of their respective auditors and any other advisors to the use of any financial, technical or other expert information required to be included in the Company Circular and to the identification in the Company Circular of each such advisor.
- (10) Each Party shall promptly notify the other if, at any time before the Effective Date, it becomes aware (in the case of the Company only with respect to the Company, and in the case of the Purchaser only with respect to the Purchaser (including information provided by the Purchaser in connection with the preparation of any *pro forma* financial statements for inclusion in the Company Circular) that the Company Circular contains a Misrepresentation, or otherwise requires an amendment or supplement). The Parties shall cooperate in the preparation of any such amendment or supplement to the Company Circular as required or appropriate, and the Company shall promptly send, file or otherwise publicly disseminate any such amendment or supplement to the Company Circular to Company Shareholders and, if required by the Court or by applicable Laws, file the same with the Securities Authorities or any other Governmental Entity as required.

## **Section 2.5 Final Order**

- (1) Following approval of the Arrangement Resolution at the Company Meeting, the Company shall take all steps necessary or desirable to submit the Arrangement to the Court and diligently pursue an application for the Final Order pursuant to Section 291 of the BCBCA, as soon as reasonably practicable, but in any event not later than three (3) Business Days after the Arrangement Resolution is passed at the Company Meeting as provided for in the Interim Order.

## **Section 2.6 Court Proceedings**

- (1) The Purchaser shall cooperate with and assist the Company in seeking the Interim Order and the Final Order, including by providing to the Company on a timely basis any information required by applicable Law to be supplied by the Purchaser in connection therewith as requested by the Company in writing. In connection with all Court proceedings relating to obtaining the Interim Order and the Final Order, the Company shall:
  - (a) diligently pursue, and reasonably cooperate with the Purchaser in diligently pursuing, the Interim Order and, subject to the approval of the Arrangement Resolution at the Company Meeting, the Final Order;
  - (b) provide legal counsel to the Purchaser with a reasonable opportunity to review and comment upon drafts of all material to be filed with the Court in connection with the Arrangement, and give reasonable consideration to all such comments;
  - (c) provide legal counsel to the Purchaser with copies of any notice of appearance, evidence or other documents served on the Company or its legal counsel in respect of the motion for the Interim Order or the application for the Final Order or any appeal from them, and any notice, written or oral, indicating the intention of any Person to appeal, or oppose the granting of, the Interim Order or the Final Order;
  - (d) ensure that all material filed with the Court in connection with the Arrangement is consistent with this Agreement and the Plan of Arrangement and that reasonable opportunity has been provided to the Purchaser to review such material and reasonable consideration given by the Company to all comments of the Purchaser prior to filing; provided the Purchaser shall have the right to consent, in its sole discretion, with respect to any increase in or variation in the form of the Consideration or other modification or amendment to such filed or served materials that expands or increases the Purchaser's obligations, or diminishes or limits the Purchaser's rights, set forth in any such filed or served materials or under this Agreement;
  - (e) oppose any proposal from any Person that the Final Order contain any provision inconsistent with this Agreement, and if required by the terms of the Final Order or by Law to return to Court with respect to the Final Order do so only after notice to, and in reasonable consultation and cooperation with, the Purchaser; and
  - (f) not object to legal counsel to the Purchaser appearing at and making such submissions on both the hearing of the motion for the Interim Order and the application for the Final Order as such counsel considers appropriate, provided the Purchaser advises the Company of the nature of any such submissions prior to the hearing and such submissions are consistent with this Agreement and the Plan of Arrangement.

## **Section 2.7 Other Securities**

- (1) The Parties acknowledge and agree that all Company Convertible Securities that are not settled or exercised in accordance with their terms, whether conditionally or otherwise, prior to the Effective Time shall be treated in accordance with the provisions of the Plan of Arrangement, and the Company and the Purchaser shall take all such reasonable steps as may be necessary or desirable to give effect to the foregoing.

- (2) The Parties acknowledge that no deduction will be claimed by the Company or any Person not dealing at arm's length with the Company in respect of any payment made to a holder of Company In-the-Money Options in respect of the Company In-the-Money Options pursuant to this Agreement or the Plan of Arrangement who is a resident of Canada or who is employed in Canada (all within the meaning of the Tax Act), to the extent that the deduction under Section 110(1)(d) of the Tax Act would otherwise be available to such holder (each, a "**Canadian Optionholder**"), in computing the taxable income of any of the Company or any Person not dealing at arm's length with the Company under the Tax Act and the Purchaser will cause the Company and each applicable Person not dealing at arm's length with the Company to: (i) where applicable, make an election pursuant to Subsection 110(1.1) of the Tax Act in respect of the payments made to Canadian Optionholders in exchange for the surrender of Company In-the-Money Options; and (ii) provide evidence in writing of such election to Canadian Optionholders as contemplated by the Tax Act, it being understood that Canadian Optionholders will be entitled to claim any deductions available to such Person pursuant to the Tax Act in respect of the calculation of any benefit arising from the surrender or other disposition of Company In-the-Money Options.

## **Section 2.8 The Arrangement and Effective Date**

The Effective Date shall occur on the earlier of (a) the date which is five (5) Business Days after the date on which all conditions set forth in Section 6.1, Section 6.2 and Section 6.3 have been satisfied or waived (excluding conditions that, by their terms, cannot be satisfied until the Effective Date, but subject to the satisfaction or, where not prohibited, the waiver by the applicable Party or Parties in whose favour the condition is, of those conditions as of the Effective Date), and (b) the date that is the last Business Day prior to the Outside Date (provided that the conditions set forth in Section 6.1, Section 6.2 and Section 6.3 have been satisfied or waived), unless another time or date is agreed to in writing by the Parties. From and after the Effective Time, the Plan of Arrangement will have all of the effects provided by applicable Law, including the BCBCA. The Company shall file on the Effective Date all records and information with the Registrar that are required to be filed with the Registrar under Section 292 of the BCBCA.

## **Section 2.9 Payment of Consideration**

The Purchaser will, as soon as possible after the receipt by the Company of the Final Order and, in any event, on the Effective Date, deposit in escrow with the Depository (the terms and conditions of such escrow to be satisfactory to the Parties, acting reasonably) a sufficient number of Purchaser Shares to satisfy the aggregate Consideration payable to Company Shareholders (other than Company Shareholders who have validly exercised Dissent Rights and who have not withdrawn their notice of objection) pursuant to the Plan of Arrangement.

## **Section 2.10 Adjustment of Consideration**

- (1) If, on or after the date of this Agreement, the Company sets a record date for any distribution on the Company Shares that is prior to the Effective Date, then: (i) to the extent that the amount of such dividends or distributions per Company Share does not exceed the fair market value of the Consideration, the Consideration shall be reduced by the amount of such dividends or distributions; and (ii) to the extent that the amount of such dividends or distributions per Company Share exceeds the fair market value of the Consideration, such excess amount shall be placed in escrow for the benefit of the Purchaser or another Person designated by the Purchaser.
- (2) Notwithstanding anything in this Agreement to the contrary, if, between the date of this Agreement and the Effective Time, the issued and outstanding Purchaser Shares shall have changed into a different number of shares or a different class by reason of any split, combination, consolidation,

reclassification, dividend or the like, provided any such action is permitted by Section 4.2(c) or Section 4.2(f), then the Consideration to be paid per Company Share shall be appropriately adjusted to provide to Company Shareholders the same economic effect as contemplated by this Agreement and the Plan of Arrangement prior to such action and as so adjusted shall, from and after the date of such event, be the Consideration to be paid per Company Share, subject to further adjustment in accordance with this Section 2.10(1).

### **Section 2.11 Withholding Taxes**

The Purchaser, the Company and the Depositary, as applicable, shall be entitled to deduct or withhold from any amount payable to any Person under the Plan of Arrangement (including Company Shareholders exercising Dissent Rights) and from all dividends, other distributions or other amounts otherwise payable to any former Company Shareholders, such amounts as the Purchaser, the Company or the Depositary is required to deduct and withhold with respect to such payment under the Tax Act, or any provision of any other Law. To the extent that amounts are so withheld, such withheld amounts shall be treated for all purposes under this Agreement as having been paid to the Person in respect of which such withholding was made, provided that such amounts are actually remitted to the appropriate Governmental Entity. Each of the Purchaser, the Company and the Depositary shall be permitted to sell or otherwise dispose of, on behalf of any Person, such portion of the Purchaser Shares or any other consideration deliverable under the Arrangement to such Person as is necessary to provide sufficient funds to enable the Purchaser, the Company or the Depositary to deduct, withhold or remit any amount for purposes of this Section 2.11 and the Purchaser, the Company or the Depositary, as the case may be, shall notify the applicable Person of the details of such disposition, including the gross and net proceeds and any adjustments thereto, and shall remit any unapplied balance of the net proceeds of such sale or other disposition to the Person.

### **Section 2.12 Tax Matters**

Notwithstanding any representations and covenants set forth in this Agreement, it is understood and agreed that none of the Purchaser or the Company provides any assurances to any security holder of the Company regarding the income tax consequences of the Arrangement to any securityholder of the Company, except as may otherwise be provided in the Company Circular.

### **Section 2.13 United States Securities Law Matters**

The Parties agree that the Arrangement will be carried out with the intention that, assuming the Final Order is granted by the Court, all Purchaser Shares issued under the Arrangement (including pursuant to the surrender and cancellation of Company In-The-Money Options and the surrender and cancellation of Company In-The-Money Warrants), all Replacement Options issued under the Arrangement in exchange for the Company Out-Of-The Money Options, and all Replacement Warrants issued under the Arrangement in exchange for the Company Out-Of-The Money Warrants will be issued by the Purchaser in reliance on the Section 3(a)(10) Exemption. In order to ensure the availability of the exemption under the Section 3(a)(10) Exemption, the Parties agree that the Arrangement will be carried out on the following basis:

- (a) the procedural and substantive fairness of the terms and conditions of the Arrangement will be subject to the approval of the Court;
- (b) the Court will be advised as to the intention of the Parties to rely on the Section 3(a)(10) Exemption prior to the hearing required to approve the procedural and substantive fairness of the terms and conditions of the Arrangement;

- (c) the Court will be required to satisfy itself as to the procedural and substantive fairness of the terms and conditions of the Arrangement to Company Shareholders and the holders of Company Convertible Securities subject to the Arrangement;
- (d) the Company will ensure that each Person entitled to receive Consideration Shares, Replacement Options and Replacement Warrants on completion of the Arrangement will be given adequate notice advising them of their right to attend the hearing of the Court to give approval of the procedural and substantive fairness of the terms and conditions of the Arrangement and providing them with sufficient information necessary for them to exercise that right and that there shall not be any improper impediments to the appearance at the hearing of any Company Shareholder and any holder of Company Convertible Securities;
- (e) the Court will hold a hearing before approving the procedural and substantive fairness of the terms and conditions of the Arrangement;
- (f) each Company Shareholder and each holder of Company Convertible Securities entitled to receive Consideration Shares, Replacement Options and Replacement Warrants pursuant to the Arrangement will be advised that such Consideration Shares, Replacement Options and Replacement Warrants issued pursuant to the Arrangement have not been and will not be registered under the U.S. Securities Act and will be issued by the Purchaser in reliance on the Section 3(a)(10) Exemption, and in the case of any Company Shareholder and any holder of Company Convertible Securities that is an “affiliate” (within the meaning of applicable rules under the U.S. Securities Act) of the Purchaser, or was such an “affiliate” within 90 days of the Effective Time, will be subject to restrictions on resale under the applicable securities laws of the United States, including Rule 144 under the U.S. Securities Act;
- (g) the Interim Order approving the Company Meeting will specify that each Company Shareholder and each holder of Company Convertible Securities will have the right to appear before the Court at the hearing of the Court to give approval of the Arrangement so long as they deliver an appearance within a reasonable time; and
- (h) the Final Order approving the terms and conditions of the Arrangement that is obtained from the Court will expressly state that the Arrangement is approved by the Court as being procedurally and substantively fair to the Company Shareholders and the holders of Company Convertible Securities. The Company shall request that the Final Order shall include a statement to substantially the following effect:
  - “AND UPON BEING ADVISED by counsel for MYM Nutraceuticals Inc. that this Court’s approval of the arrangement and its determination that the arrangement is fair to the persons to be issued securities pursuant to the arrangement will serve as the basis of a claim to an exemption from the registration requirements of the United States Securities Act of 1933, as amended, pursuant to Section 3(a)(10) thereof, regarding the exchange of securities of IM Cannabis Corp. pursuant to the Plan of Arrangement”;
  - and
- (i) the Parties further agree that each of them shall use commercially reasonable efforts to cause the issuance of the Consideration Shares, Replacement Options and Replacement Warrants to Company Shareholders and holders of Company Convertible Securities, as

applicable, pursuant to the Arrangement to be exempt from, or otherwise be in compliance with, all applicable U.S. state securities laws.

### **ARTICLE 3 REPRESENTATIONS AND WARRANTIES**

#### **Section 3.1 Representations and Warranties of the Company**

- (1) The Company represents and warrants to the Purchaser, except as set forth in the Company Disclosure Letter, the matters set forth in Schedule C and acknowledges and agrees that the Purchaser is relying upon such representations and warranties in connection with the entering into of this Agreement and agreeing to complete the Arrangement.
- (2) The representations and warranties of the Company contained in this Agreement shall not survive the completion of the Arrangement and shall expire and be terminated on the earlier of the Effective Time and the date on which this Agreement is terminated in accordance with its terms. This Section 3.1 will not limit any covenant or agreement of the Parties, which, by its terms, contemplates performance after the Effective Date or the date on which this Agreement is terminated, as the case may be. Any investigation by the Purchaser and its advisors shall not mitigate, diminish or affect the representations and warranties of the Company contained in this Agreement.

#### **Section 3.2 Representations and Warranties of the Purchaser**

- (1) The Purchaser represents and warrants to the Company, except as set forth in the Purchaser Disclosure Letter, the matters set forth in Schedule D and acknowledges and agrees that the Company is relying upon such representations and warranties in connection with the entering into of this Agreement and agreeing to complete the Arrangement.
- (2) The representations and warranties of the Purchaser contained in this Agreement shall not survive the completion of the Arrangement and shall expire and be terminated on the earlier of the Effective Time and the date on which this Agreement is terminated in accordance with its terms. This Section 3.2 will not limit any covenant or agreement of the Parties, which, by its terms, contemplates performance after the Effective Date or the date on which this Agreement is terminated, as the case may be. Any investigation by the Company and its advisors shall not mitigate, diminish or affect the representations and warranties of the Purchaser contained in this Agreement.

#### **Section 3.3 Representations and Warranties of Trichome**

- (1) Trichome represents and warrants to the Company the matters set forth in Schedule E and acknowledges and agrees that the Company is relying upon such representations and warranties in connection with the entering into of this Agreement and agreeing to complete the Arrangement.
- (2) The representations and warranties of Trichome contained in this Agreement shall not survive the completion of the Arrangement and shall expire and be terminated on the earlier of the Effective Time and the date on which this Agreement is terminated in accordance with its terms. This Section 3.3 will not limit any covenant or agreement of the Parties, which, by its terms, contemplates performance after the Effective Date or the date on which this Agreement is terminated, as the case may be. Any investigation by the Company and its advisors shall not

mitigate, diminish or affect the representations and warranties of Trichome contained in this Agreement.

## **ARTICLE 4 COVENANTS**

### **Section 4.1 Conduct of Business of the Company**

- (1) The Company covenants and agrees that, during the period from the date of this Agreement until the earlier of the Effective Time and the time that this Agreement is terminated in accordance with its terms, except (i) with the express prior written consent of the Purchaser not to be unreasonably withheld, or (ii) as required or permitted by this Agreement or the Plan of Arrangement; (iii) as required by applicable Law; or (iv) as expressly contemplated by the Company Disclosure Letter, the Company shall, and shall cause its Subsidiaries to, conduct their business in the Ordinary Course, and the Company shall use commercially reasonable efforts to maintain and preserve its and its Subsidiaries' business organization, assets (including, for greater certainty, Company Business Assets), goodwill and business relationships with other Persons with which the Company or any of its Subsidiaries have business relations.
  
- (2) Without limiting the generality of Section 4.1(1), the Company covenants and agrees that, during the period from the date of this Agreement until the earlier of the Effective Time and the time that this Agreement is terminated in accordance with its terms, except (i) pursuant to the transactions contemplated under the Settlement Agreement; (ii) with the express prior written consent of the Purchaser not to be unreasonably withheld or delayed, (iii) as required or permitted by this Agreement or the Plan of Arrangement; (iv) as required by applicable Law; or (v) as expressly contemplated by the Company Disclosure Letter, the Company shall not, and the Company shall not permit any of its Subsidiaries to, directly or indirectly:
  - (a) amend its Constatng Documents or, in the case of any Subsidiary which is not a corporation, its similar organizational documents;
  - (b) split, combine, consolidate or reclassify any of its common shares, or declare, set aside or pay any dividend or other distribution thereon in stock or property or any combination thereof, or amend or modify any term of any outstanding debt security;
  - (c) redeem, purchase, or otherwise acquire or offer to redeem, purchase or otherwise acquire any of the Company Shares, any of its other outstanding securities or the outstanding securities of its Subsidiaries, other than redemptions, repurchases or other acquisitions of Company Shares made pursuant to rights of exchange or conversion attached to Company Exchangeable Shares issued and outstanding as of the date of this Agreement;
  - (d) issue, deliver, sell, pledge or otherwise encumber, or authorize the issuance, delivery, sale, pledge or other encumbrance of its common shares or other equity or voting interests, or any options, warrants or similar rights or convertible securities exercisable or exchangeable for or convertible into such common shares or other equity or voting interests (including Company Shares), or any stock appreciation rights, phantom stock awards or other rights that are linked to the price or the value of such common shares or other equity or voting interests (including Company Convertible Securities), except for the issuance of Company Shares issuable upon the exercise of the currently outstanding Company Convertible Securities in accordance with their terms;



- (e) reduce its stated capital or reorganize, arrange, restructure, amalgamate or merge with any Person;
- (f) adopt a plan of liquidation or resolutions providing for the liquidation or dissolution of the Company or any of its Subsidiaries;
- (g) acquire (by merger, consolidation, acquisition of stock or assets or otherwise), directly or indirectly, in one transaction or in a series of related transactions, assets, securities, properties, interests or businesses or make any investment either by the purchase of securities, contribution of capital, property transfer or purchase of any other property or assets of any other Person, or acquire any licence rights;
- (h) sell, pledge, lease, dispose of, lose the right to use, mortgage, licence, encumber (in each case other than a Permitted Lien) or otherwise transfer any assets of the Company or of any of its Subsidiaries or any interest in any assets of the Company and its Subsidiaries having a value greater than \$75,000 individually and subject to a maximum of \$200,000 in the aggregate, other than assets sold in the Ordinary Course;
- (i) make any capital expenditure or commitment to do so which, individually exceeds \$50,000 or in the aggregate exceeds \$150,000;
- (j) amend or modify, or terminate or waive any right under, any Material Contract or enter into any contract or agreement that would be a Material Contract if in effect on the date hereof, other than any Contract relating to the acquisition of cannabis in the Ordinary Course (which for greater clarity shall include any Contract in the Ordinary Course concerning the acquisition of cannabis of a value of under \$250,000);
- (k) in respect of any Company Business Assets, waive, release, surrender, abandon, let lapse, grant or transfer any material right or amend, modify or change, or agree to amend, modify or change, any existing material Authorization, right to use, lease or contract;
- (l) except as contemplated in Section 4.8 [*Director & Officer Insurance*] amend, modify or terminate, cancel or let lapse any material insurance (or re-insurance) policy of the Company or any Subsidiary in effect on the date of this Agreement, unless simultaneously with such termination, cancellation or lapse, replacement policies underwritten by insurance and re-insurance companies of nationally recognized standing providing coverage equal to or greater than the coverage under the terminated, cancelled or lapsed policies are in full force and effect;
- (m) prepay any indebtedness before its scheduled maturity, or increase, create, incur, assume or otherwise become liable for any indebtedness for borrowed money or guarantees thereof;
- (n) make any loan or advance to, or any capital contribution or investment in, or assume, guarantee or otherwise become liable with respect to the liabilities or obligations of, any Person other than advances and capital contributions to wholly-owned Subsidiaries of the Company in the Ordinary Course;
- (o) enter into any interest rate, currency, equity or commodity swaps, hedges, derivatives, forward sales contracts or similar financial instruments;

- (p) grant any Lien (other than Permitted Liens) on any assets of the Company or its Subsidiaries;
- (q) make, amend or rescind any Tax election or designation, settle or compromise any Tax claim, action, suit, litigation, proceeding, investigation, audit, controversy, assessment, reassessment or liability, file any amended Tax Return, make a request for a tax ruling, enter into any agreement with a Governmental Entity with respect to Taxes, surrender any right to claim a Tax abatement, reduction, deduction, exemption, credit or refund, consent to the extension or waiver of the limitation period applicable to any Tax matter, change any annual Tax accounting period, or amend or change any of its methods of reporting income, deductions or accounting for income Tax purposes except as may be required by Law;
- (r) make any change in the Company's methods of accounting, except as required by concurrent changes in IFRS;
- (s) except as disclosed in the Company Disclosure Letter, grant any increase in the rate of wages, salaries, bonuses or other remuneration of any employee or independent contractor or make any bonus or profit sharing distribution or similar payment of any kind;
- (t) (i) adopt any new Employee Plan or any amendment or modification of an existing Employee Plan; (ii) pay any benefit to any director or officer of the Company or any of its Subsidiaries or to any employee or independent contractor that is not required under the terms of any Employee Plan in effect on the date of this Agreement; or (iii) grant, accelerate, increase or otherwise amend any Employee Plan payment or award to any director or officer of the Company or any of its Subsidiaries or to any employee or officer of the Company;
- (u) enter into any agreement or arrangement that limits or otherwise restricts in any material respect the Company or any successor thereto, or that would, after the Effective Time, limit or restrict in any material respect the Company or any of its affiliates from competing in any manner;
- (v) cancel, waive, release, assign, settle or compromise any material claims or rights or take any action or fail to take any action that would result in termination of any material claims or rights;
- (w) commence, waive, release, assign, settle, compromise or settle any litigation, proceeding or governmental investigation relating to the assets or the business of the Company in excess of an aggregate amount of \$100,000 other than amounts or liabilities disclosed in the Company Filings which are resolved for an amount equal to or less than the amount disclosed, or which could reasonably be expected to impede, prevent or delay the consummation of the transaction contemplated by this Agreement;
- (x) knowingly take any action or fail to take any action which action or failure to act would result in the material loss, expiration or surrender of, or the loss of any material benefit under, or reasonably be expected to cause any Governmental Entity to institute proceedings for the suspension, revocation or limitation of rights under, any material Authorization necessary to conduct the Company Business, or fail to prosecute any pending application to any Governmental Entities for material Authorizations necessary to conduct the Company Business;

- (y) abandon or fail to diligently pursue any application for any material Authorizations or take any action, or fail to take any action, that could lead to a material modification, suspension or revocation of any material Authorizations;
  - (z) grant or commit to grant an exclusive licence or otherwise transfer any Intellectual Property or exclusive rights in or in respect thereto that is material to the Company and its Subsidiaries taken as a whole, other than to wholly-owned Subsidiaries;
  - (aa) materially change its business or regulatory strategy;
  - (bb) enter into any Contract with a Person (other than a wholly-owned Subsidiary of the Company) that does not deal at arm's length with the Company within the meaning of the Tax Act;
  - (cc) enter into or amend any Contract with any broker, finder or investment banker, including any amendment of any of the Contracts listed in the Company Disclosure Letter; or
  - (dd) authorize, agree, resolve or otherwise commit, whether or not in writing, to do any of the foregoing.
- (3) The Company covenants and agrees that, during the period from the date of this Agreement until the earlier of the Effective Time and the time that this Agreement is terminated in accordance with its terms, the Company shall forthwith notify the Purchaser in writing of:
- (a) any Company Material Adverse Effect; or
  - (b) any penalty, filing, action, suit, claim, investigation, audit inquiry, assessment or proceeding commenced or, to its knowledge, threatened against, relating to or involving or otherwise affecting the Company or its Subsidiaries.

#### **Section 4.2 Conduct of Business of the Purchaser**

The Purchaser covenants and agrees that, during the period from the date of this Agreement until the earlier of the Effective Time and the time that this Agreement is terminated in accordance with its terms, the Purchaser shall, and shall cause its Subsidiaries to, conduct its and their business in the Ordinary Course, and the Purchaser shall use commercially reasonable efforts to maintain and preserve its and its Subsidiaries' business organization, properties, employees, goodwill and business relationships with customers, suppliers, partners and other Persons with which the Purchaser or any of its Subsidiaries has material business relations, and the Purchaser shall not, and shall not permit any of its Subsidiaries to, directly or indirectly:

- (a) split, combine, consolidate, reclassify or amend the terms of the Purchaser Shares;
- (b) amend its Constatng Documents, or in the case of any Subsidiary which is not a corporation, its similar organizational documents;
- (c) declare, set aside or pay any dividend or other distribution of securities or property or any combination thereof in respect of any Purchaser Shares;

- (d) redeem, purchase or otherwise acquire or offer to redeem, purchase or otherwise acquire any Purchaser Shares, other than redemptions or repurchases of Purchaser Shares in connection with the administration of equity or employee incentive plans;
  - (e) take any action that would result in the need for shareholder approval of the Purchaser of the transactions contemplated by this Agreement;
  - (f) reduce its stated capital or reorganize, arrange, restructure, amalgamate or merge with any Person, except for any transaction including only the Purchaser and one or more of its Subsidiaries or any transaction that does not materially impede the completion of the transactions contemplated by this Agreement or result in a Purchaser Material Adverse Effect;
  - (g) issue, deliver or sell, or authorize the issuance, delivery or sale, of any shares of its capital stock or other equity or voting interests which exceed 20% of the Purchaser's existing voting securities, other than the issuance of awards under the Purchaser's equity-based compensation arrangements outstanding from time to time, and other than in connection with (i) an arm's length acquisition by the Purchaser; (ii) a prospectus offering; or (iii) a private placement with any arm's length party;
  - (h) adopt a plan of liquidation or resolutions providing for the liquidation or dissolution of the Purchaser; or
  - (i) authorize, agree, resolve or otherwise commit, whether or not in writing, to do any of the foregoing.
- (2) The Purchaser shall forthwith notify the Company in writing of:
- (a) any Purchaser Material Adverse Effect; and
  - (b) any material penalty, filing, action, suit, claim, investigation, audit inquiry, assessment or proceeding commenced or, to its knowledge, threatened against, relating to or involving or otherwise affecting the Company or its Subsidiaries.

#### **Section 4.3 Covenants Regarding the Arrangement**

- (1) Subject to the terms and conditions of this Agreement, the Company shall, and shall cause its Subsidiaries to, perform all obligations required to be performed by the Company or any of its Subsidiaries under this Agreement, reasonably cooperate with the Purchaser in connection therewith, and do all such other commercially reasonable acts and things as may be necessary or desirable to consummate and make effective, as soon as reasonably practicable, the Arrangement and, without limiting the generality of the foregoing, the Company shall and, where appropriate, shall cause each of its Subsidiaries to:
- (a) use its commercially reasonable efforts to obtain and maintain all third party or other consents, waivers, permits, exemptions, orders, approvals, agreements, amendments or confirmations that are (i) necessary or advisable under its Material Contracts and Authorizations in connection with the Arrangement or (ii) required in order to maintain its Material Contracts and Authorizations in full force and effect following completion of the Arrangement (including the Key Consents/Waivers to the extent not obtained prior to execution of this Agreement), in each case, on terms that are reasonably satisfactory to the

Purchaser, and without paying, and without committing itself or the Purchaser to pay, any consideration or incur any liability or obligation without the prior written consent of the Purchaser;

- (b) prepare and file, as promptly as practicable, all necessary documents, registrations, statements, petitions, filings and applications for the Regulatory Approvals required to be obtained by the Company or any of its Subsidiaries and use its commercially reasonable efforts to obtain and maintain all such Regulatory Approvals, and provide or submit all documentation and information that is required, or in the reasonable opinion of the Purchaser, advisable, in connection with obtaining such Regulatory Approvals and to keep the Purchaser reasonably apprised of the status of such Regulatory Approvals (but only to the extent that the Company has knowledge of such status) and make available to the Purchaser all copies of such materials;
  - (c) use its commercially reasonable efforts to oppose, lift or rescind any injunction, restraining or other order, decree or ruling seeking to restrain, enjoin or otherwise prohibit or adversely affect the consummation of the Arrangement and use its commercially reasonable efforts to defend, or cause to be defended, any proceedings to which it is a party or brought against it or its directors or officers challenging the Arrangement or this Agreement;
  - (d) carry out the terms of the Interim Order and the Final Order applicable to it and comply promptly with all requirements imposed by Law on it or its Subsidiaries with respect to this Agreement or the Arrangement;
  - (e) not take any action, or refrain from taking any commercially reasonable action, or permit any action to be taken or not taken, which is inconsistent with this Agreement or which would reasonably be expected to prevent, delay or otherwise impede the consummation of the Arrangement;
  - (f) comply with CSE requirements relevant to this Agreement; and
  - (g) use commercially reasonable efforts to satisfy all conditions precedent set forth in Section 6.1 and Section 6.2 of this Agreement.
- (2) Subject to the terms and conditions of this Agreement, the Purchaser shall, and shall cause its Subsidiaries to, perform all obligations required to be performed by the Purchaser or any of its Subsidiaries under this Agreement, reasonably cooperate with the Company in connection therewith, and do all such other commercially reasonable acts and things as may be necessary or desirable to consummate and make effective, as soon as reasonably practicable, the Arrangement and, without limiting the generality of the foregoing, the Purchaser shall and, where appropriate, shall cause each of its Subsidiaries to:
- (a) use its commercially reasonable efforts to oppose, lift or rescind any injunction, restraining or other order, decree or ruling seeking to restrain, enjoin or otherwise prohibit or adversely affect the consummation of the Arrangement and use its commercially reasonable efforts to defend, or cause to be defended, any proceedings to which it is a party or brought against it or its directors or officers challenging the Arrangement or this Agreement;
  - (b) carry out the terms of the Interim Order and the Final Order applicable to it and comply promptly with all requirements imposed by Law on it or its Subsidiaries with respect to this Agreement or the Arrangement;

- (c) not take any action, or refrain from taking any commercially reasonable action, or permit any action to be taken or not taken, which is inconsistent with this Agreement or which would reasonably be expected to prevent, delay or otherwise impede the consummation of the Arrangement;
  - (d) as soon as practical after execution of this Agreement, and in any event no later than ten (10) Business Days after execution of this Agreement, provide the Company with the following information:
    - (i) a detailed post-Arrangement corporate structure showing where the holders of the Cannabis Licences will be located relative to the Purchaser, the Company and any other Subsidiaries or other Persons other than individuals;
    - (ii) a list of all officers and directors of any Persons shown in the corporate structure detailed in Section 4.3(2)(d)(i) of this Agreement; and
    - (iii) a list of proposed Responsible Persons for each of the Cannabis Licences;
  - (e) take all such commercially reasonable actions as may be necessary or desirable, in the opinion of the Company, acting reasonably, to obtain any necessary Regulatory Approvals;
  - (f) on or before the Effective Date reserve a sufficient number of Consideration Shares to be issued upon completion of the Arrangement;
  - (g) on or before the Effective Date, notify the CSE and Nasdaq of the Arrangement in accordance with the rules of the CSE and Nasdaq, as applicable;
  - (h) comply with CSE and Nasdaq requirements relevant to this Agreement; and
  - (i) use commercially reasonable efforts to satisfy all conditions precedent set forth in Section 6.1 and Section 6.3 of this Agreement.
- (3) Each of the Parties shall promptly, and in any event within two (2) Business Days of each of the following, notify the other Party of:
- (a) any notice or other communication from any Person alleging (i) that the consent (or waiver, permit, exemption, order, approval, agreement, amendment or confirmation) of such Person is required in connection with this Agreement or the Arrangement, or (ii) that such Person is terminating or may terminate or is otherwise materially adversely modifying or may materially adversely modify its relationship with the Party as a result of this Agreement or the Arrangement; and
  - (b) any notice or other communication from any Governmental Entity in connection with this Agreement (and such Party shall contemporaneously provide a copy of any such written notice or communication to the other Party).
- (4) The Company consents to disclosure by Purchaser (and any affiliate thereof or successor thereto) in any offering memorandum, information circular, prospectus, take-over bid circular, business acquisition report, press release or other document, the form and content of which are subject to or prescribed by Securities Laws (collectively, "**Disclosure Documents**"), of a description of the assets and businesses of the Company and such historical financial and operational information for

the Company as may be required by Securities Laws to be included in any Disclosure Documents, including any *pro forma* financial statements. The Company shall use reasonable commercial efforts, exercised in a timely manner so as to permit Purchaser (and any affiliate thereof or successor thereto) to comply with Securities Laws, to obtain the cooperation of its auditors and accounting advisors with Purchaser or its Representatives, including Purchaser's auditors, in connection with the review and audit of the financial information respecting the Company to be contained, if required by Securities Laws, in any Disclosure Document. In addition, the Company shall use reasonable commercial efforts, exercised in a timely manner so as to permit Purchaser (and any affiliate thereof or successor thereto) to obtain from its auditors and accounting advisors any required "comfort letter" regarding any of the aforesaid financial information contained in any Disclosure Document and to obtain the consent of its auditors to the inclusion of the auditors' report or reports in respect of any audited financial statements of the Company in any Disclosure Document.

#### **Section 4.4 Access to Information; Confidentiality**

- (1) The Company shall give the Purchaser and its Representatives: (a) upon reasonable notice, reasonable access during normal business hours to its: (i) premises; (ii) property and assets (including all books and records, whether retained internally or otherwise); (iii) Contracts; and (iv) senior personnel, so long as the access does not unduly interfere with the Ordinary Course conduct of the business of the Company or its Subsidiaries; and (b) copies of all management reports, reports or presentations to the Company Board relating to its or its Subsidiaries' financial condition and operations, and such other financial and operating data or other information with respect to the assets or business of it or its Subsidiaries as the Purchaser from time to time reasonably requests.
- (2) Investigations made by or on behalf of the Purchaser, whether under this Section 4.4 or otherwise, will not waive, diminish the scope of, or otherwise affect any representation or warranty made by the Company in this Agreement unless such matter is set forth in the Company Disclosure Letter.
- (3) The Purchaser shall give the Company and its Representatives upon reasonable notice, reasonable access during normal business hours to its: (i) books and records, (ii) Contracts and (iii) senior personnel and auditors, so long as the access does not unduly interfere with the Ordinary Course conduct of the business of the Purchaser or its Subsidiaries.
- (4) Investigations made by or on behalf of the Company, whether under this Section 4.4 or otherwise, will not waive, diminish the scope of, or otherwise affect any representation or warranty made by the Purchaser in this Agreement unless such matter is set forth in the Purchaser Disclosure Letter.
- (5) The Purchaser acknowledges that the Confidentiality Agreement continues to apply and that any information provided under this Section 4.4 that is non-public and/or proprietary in nature shall be subject to the terms of the Confidentiality Agreement. If this Agreement is terminated in accordance with its terms, the obligations under the Confidentiality Agreement shall survive the termination of this Agreement.

#### **Section 4.5 Pre-Acquisition Reorganization**

- (1) Subject to Section 4.5(2), Section 4.5(3) and Section 4.5(4), upon request of the Purchaser, the Company shall: (a) undertake such transactions and reorganizations of its corporate structure, business, operations and assets as the Purchaser may request, acting reasonably (each a "**Pre-Acquisition Reorganization**"); and (b) cooperate with the Purchaser and its advisors to determine

the nature of the Pre-Acquisition Reorganizations that might be undertaken and the manner in which they would most effectively be undertaken.

- (2) The Company will not be obligated to undertake any Pre-Acquisition Reorganization unless:
  - (a) prior to implementation of the Pre-Acquisition Reorganization, the Purchaser irrevocably waives or confirms that all of the conditions set out in Section 6.1 and Section 6.2 have been satisfied;
  - (b) any Pre-Acquisition Reorganization:
    - (i) is not, in the opinion of the Company Board, prejudicial to the Company or to the Company Shareholders, including with respect to the Cannabis Licences;
    - (ii) does not impair the ability of the Company to consummate, and would not reasonably be expected to impede or delay the consummation of, the Arrangement in any material respect;
    - (iii) does not unreasonably interfere with the ongoing operations of the Company and its Subsidiaries;
    - (iv) does not result in any breach by the Company or any of its Subsidiaries of any Material Contract or Authorization or any breach by the Company of the Company's Constatng Documents or by any of its Subsidiaries of their respective Constatng Documents or Law;
    - (v) does not result in any Taxes being imposed on, or any adverse Tax or other consequences to, any Company Securityholders;
    - (vi) does not require the Company to obtain the approval of the Company Shareholders or the Court; and
    - (vii) does not require the directors, officers, employees or agents of the Company or any of its Subsidiaries to take any action in any capacity other than as a director, officer, employee or agent of the Company or any of its Subsidiaries, as applicable.
- (3) The Purchaser shall provide written notice to the Company of any proposed Pre-Acquisition Reorganization at least 30 days prior to the Effective Date. Subject to Section 4.5(2), upon receipt of such notice, the Company and the Purchaser shall work cooperatively and use their commercially reasonable efforts to prepare prior to the Effective Time all documentation necessary and do such other acts and things as are necessary to give effect to such Pre-Acquisition Reorganization, including any amendment to this Agreement or the Plan of Arrangement, and shall seek to have any such Pre-Acquisition Reorganization made effective after the Purchaser has waived or confirmed that all of the conditions set out in Section 6.1 and Section 6.2 have been satisfied and that it is prepared to promptly without condition proceed to effect the Arrangement, provided that no Pre-Acquisition Reorganization will be made effective unless such Pre-Acquisition Reorganization would not result in any adverse effect to Company Shareholders or other Company Securityholders, the Company or any of its Subsidiaries in the event the Arrangement does not become effective and this Agreement is terminated for which they are not indemnified under Section 4.5(5).



- (4) The Purchaser shall be responsible for all fees, costs and expenses (including professional fees and expenses) associated with each Pre-Acquisition Reorganization to be carried out at its request and all cooperation provided by the Company, its Subsidiaries and their respective Representatives pursuant to this Section 4.5 and agrees that any Pre-Acquisition Reorganization will not be considered in determining whether a representation, warranty or covenant of the Company under this Agreement has been breached (including where any such Pre-Acquisition Reorganization requires the consent of any third party under a Contract) or if a condition for the benefit of the Purchaser has been satisfied.
- (5) The Purchaser shall indemnify and save harmless the Company and its affiliates and their respective officers, directors and employees (to the extent that such Persons are assessed with statutory liability thereto) from and against any and all liabilities, losses, damages, claims, fees, costs, expenses, interest awards, judgements and penalties suffered or incurred by any of them in connection with or as a result of any such Pre-Acquisition Reorganization, the unwinding or reversing of any such Pre-Acquisition Reorganization in the event the Arrangement is not completed, and all cooperation provided by the Company, its Subsidiaries and their respective Representatives pursuant to this Section 4.5. The obligations of the Purchaser pursuant to this Section 4.5(4) shall survive the termination of this Agreement, whether or not the Arrangement is completed. The indemnity in respect of the unwinding or reversing of any such Pre-Acquisition Reorganization in the event the Arrangement is not completed shall apply only if the Purchaser is consulted on the steps for unwinding or reversing any such Pre-Acquisition Reorganization in the event the Arrangement is not completed.

#### **Section 4.6 Public Communications**

A Party must not issue any press release or make any other public statement or disclosure with respect to this Agreement or the Arrangement without the consent of the other Party (which consent shall not be unreasonably withheld or delayed). The Parties shall co-operate in the preparation of presentations, if any, to Company Shareholders regarding the Arrangement. The Company must not make any filing with any Governmental Entity with respect to this Agreement or the Arrangement without the consent of the Purchaser (which consent shall not be unreasonably withheld or delayed); provided that if the Company is required to make disclosure by Law, it shall use its commercially reasonable efforts to give the Purchaser prior oral or written notice and a reasonable opportunity to review or comment on the disclosure or filing (other than with respect to confidential information contained in such disclosure or filing). The Company shall give reasonable consideration to any comments made by the Purchaser or its counsel, and if such prior notice is not possible, shall give such notice immediately following the making of such disclosure or filing. Each of the Company and the Purchaser agrees that the Company will file the material change report required to be filed following the public announcement of this Agreement by the Company not later than the tenth (10<sup>th</sup>) day following the date this Agreement is entered into, and that the copy of this Agreement to be publicly filed in connection with such material change report will contain such redactions as each Party may reasonably request, provided such redactions are permitted by applicable Law.

#### **Section 4.7 Notice and Cure Provisions**

- (1) Each Party shall promptly notify the other Party of the occurrence, or failure to occur, of any event or state of facts which occurrence or failure would, or would be reasonably likely to:
  - (a) cause any of the representations or warranties of such Party contained in this Agreement to be untrue or inaccurate in any respect at any time from the date of this Agreement to the Effective Time;

- (b) result in the failure to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied by such Party under this Agreement; or
  - (c) result in the failure to satisfy any of the conditions precedent in favour of the other Party hereto contained in Section 6.1, Section 6.2 and Section 6.3, as the case may be.
- (2) Notification provided under this Section 4.7 will not affect the representations, warranties, covenants, agreements or obligations of the Parties (or remedies with respect thereto) or the conditions to the obligations of the Parties under this Agreement.
- (3) The Purchaser may not elect to exercise its right to terminate this Agreement pursuant to Section 7.2(1)(d)(i) and the Company may not elect to exercise its right to terminate this Agreement pursuant to Section 7.2(1)(c)(i), unless such Party seeking to terminate the Agreement (the “**Terminating Party**”) has delivered a written notice (“**Termination Notice**”) to the other such Party (the “**Breaching Party**”) specifying in reasonable detail all breaches of covenants, representations and warranties or other matters which the Terminating Party asserts as the basis for the non-fulfillment of the applicable condition precedent or for termination, as applicable. After delivering a Termination Notice, provided the Breaching Party is proceeding diligently to cure such matter and such matter is capable of being cured prior to the Outside Date (with any Wilful Breach being deemed to be incurable), the Terminating Party may not exercise such termination right until the earlier of (a) the Outside Date, and (b) if such matter has not been cured by the date that is fifteen (15) Business Days following receipt of such Termination Notice by the Breaching Party, such date. If the Terminating Party delivers a Termination Notice prior to the date of the Company Meeting, unless the Parties agree otherwise, the Company shall, to the extent permitted by Law, postpone or adjourn the Company Meeting to the earlier of (a) five (5) Business Days prior to the Outside Date and (b) the date that is fifteen (15) Business Days following receipt of such Termination Notice by the Breaching Party. If such notice has been delivered prior to the making of the application for the Final Order, such application shall be postponed until the expiry of such period. For greater certainty, in the event that such matter is cured within the time period referred to herein, without a Company Material Adverse Effect or Purchaser Material Adverse Effect, as applicable, this Agreement may not be terminated as a result of such matter.
- (4) If no notice has been sent by the Purchaser or the Company pursuant to this Section 4.7 prior to the Effective Time, the conditions precedent set out in Section 6.1, Section 6.2 or Section 6.3 hereof shall be conclusively deemed to have been satisfied, fulfilled or waived as of the Effective Time.

#### **Section 4.8 Insurance and Indemnification**

- (1) Prior to the Effective Date, the Company shall purchase customary “tail” policies of directors’ and officers’ liability insurance providing protection no less favourable in the aggregate to the protection provided by the policies maintained by the Company and its Subsidiaries which are in effect immediately prior to the Effective Date and providing protection in respect of claims arising from facts or events which occurred on or prior to the Effective Date and the Purchaser shall, or shall cause the Company and its Subsidiaries to maintain such tail policies in effect without any reduction in scope or coverage for six (6) years from the Effective Date, provided that the Purchaser shall not be required to pay any amounts in respect of such coverage prior to the Effective Time and provided further that the aggregate cost of such policies over such six (6) year period shall not exceed 300% of the Company’s current annual aggregate premium for policies currently maintained by the Company or its Subsidiaries as set forth in the Company Disclosure Letter.

- (2) The Purchaser shall, from and after the Effective Date, honour all rights to indemnification or exculpation now existing in favour of present and former employees, officers and directors of the Company and its Subsidiaries to the extent that they (i) are included in the Constatting Documents of the Company or any of its Subsidiaries, (ii) are disclosed in Section 4.8(2) of the Company Disclosure Letter, or (iii) exist under common law (including, without limitation, vicarious liability), statute or legislation (including, without limitation, health and safety legislation), and acknowledges that such rights shall survive the completion of the Plan of Arrangement and shall continue in full force and effect in accordance with their terms for a period of not less than six (6) years from the Effective Date.
- (3) This Section 4.8 shall survive the completion of the Plan of Arrangement and is intended to be for the benefit of, and shall be enforceable by, all present and former employees, directors and officers of the Company, its Subsidiaries and their respective heirs, executors, administrators and personal representatives and if the Company or any of its Subsidiaries or any of their respective successors or assigns (i) consolidates with or merges into any other Person and is not a continuing or surviving corporation or entity of such consolidation or merger, or (ii) transfers all or substantially all of its properties and assets to any Person, the Purchaser shall ensure that any such successor or assign (including, as applicable, any acquirer of substantially all of the properties and assets of the Company or its Subsidiaries) assumes all of the obligations set forth in this Section 4.8 and, for such purpose, the Company hereby confirms it is acting as agent and trustee on behalf of present and former employees, directors and officers of the Company, its Subsidiaries and their respective heirs, executors, administrators and personal representatives.

#### **Section 4.9 Stock Exchange Matters**

The Purchaser and the Company shall, prior to the Effective Time, notify the CSE and the Nasdaq of the Arrangement and the issuance of the Consideration Shares and, promptly following the Effective Time and subject to applicable Laws, use their commercially reasonable efforts to cause the Company Shares to be de-listed from the CSE and the Consideration Shares, together with such other Purchaser Shares issuable pursuant to the Plan of Arrangement to be listed on the CSE and the Nasdaq, with effect promptly following the Effective Time.

#### **Section 4.10 Board of Directors and Officers**

Prior to the Effective Time, the Company shall use its best efforts to cause, and it shall cause each of its Subsidiaries to use their respective best efforts to cause, any director or officer of the Company or any of its Subsidiaries specified by the Purchaser, to provide resignations and mutual releases or failing which the Company shall terminate, or cause the Subsidiaries to terminate, such officers effective as at the Effective Time. The Purchaser agrees that the Company, its Subsidiaries and any successor to the Company (including any surviving corporation) shall honour and comply with the terms of the indemnity provisions in the Company's Constatting Documents and the Constatting Documents of the Subsidiaries as of the date of this Agreement (and the Purchaser agrees that it shall not take any action to amend such provisions, insofar as they relate to such officers and directors) and all of the severance payment obligations of the Company or its Subsidiaries under the existing employment, consulting, change of control and severance agreements of the Company or its Subsidiaries that were in effect prior to the Effective Time, provided such indemnity provisions and severance payments were not adopted or entered into by the Company or its Subsidiaries in violation of this Agreement. All such obligations to make payments under such indemnity and severance provisions shall be fully and completely disclosed by the Company to the Purchaser in writing as they become determinable up until the Effective Time. The Company will use commercially reasonable efforts to cause the parties receiving severance payments to execute full and final mutual releases releasing each of such party and the Company and its Subsidiaries from all liability and obligations owed

to one another, including in respect of the change of control entitlements in favour of the Company and in form and substance satisfactory to the Purchaser, acting reasonably.

#### **Section 4.11 Company Key Employees**

The Purchaser hereby covenants and agrees to continue to employ or, in the case of a subsidiary of the Purchaser, cause to be employed, the individuals listed in Section 4.12 of the Company Disclosure Letter in the roles set forth therein on the same or no less favorable terms as their employment with the Company as of the date prior to the Effective Date.

### **ARTICLE 5 ADDITIONAL COVENANTS REGARDING NON-SOLICITATION**

#### **Section 5.1 Non-Solicitation**

- (1) Except as expressly provided in this Article 5, the Company shall not, directly or indirectly, through any officer, director, employee, representative (including any financial or other advisor) or an agent of the Company or any of its respective Subsidiaries (collectively “**Representatives**”), and shall not permit any such Representative to:
  - (a) make, solicit, initiate, knowingly facilitate, encourage or promote (including by way of furnishing or providing copies of, access to, or disclosure of, any confidential information, properties, facilities, books or records of the Company or any Subsidiary or entering into any form of agreement, arrangement or understanding) any inquiry, proposal or offer that constitutes or may reasonably be expected to constitute or lead to an Acquisition Proposal;
  - (b) enter into or otherwise engage or participate in any discussions or negotiations with any Person (other than the Purchaser, Trichome or any of their respective affiliates) regarding any inquiry, proposal or offer that constitutes or may reasonably be expected to constitute or lead to, an Acquisition Proposal, it being acknowledged and agreed that the Company may communicate with any Person for purposes of advising such Person of the restrictions in this Agreement and also advising such Person that their Acquisition Proposal does not constitute a Superior Proposal or is not reasonably expected to constitute or lead to a Superior Proposal;
  - (c) enter into or publicly propose to enter into any agreement, understanding or arrangement in respect of an Acquisition Proposal (other than in accordance with Section 5.3); or
  - (d) make a Change in Recommendation; or
  - (e) accept, approve, endorse or recommend, or publicly propose to accept, approve, endorse or recommend, or take no position or remain neutral with respect to, any publicly announced or otherwise publicly disclosed Acquisition Proposal in respect of the Company (it being understood that taking no position or a neutral position with respect to a publicly announced or otherwise public disclosed Acquisition Proposal in respect of the Company for a period of no more than five (5) Business Days following the announcement or disclosure of such Acquisition Proposal will not be considered to be in violation of this Section 5.1 provided the Company Board has rejected such Acquisition Proposal and reaffirmed the Company Board Recommendation before the end of such five (5) Business Day period),

provided, however, that nothing in this Section 5.1(1) or any other provision of this Agreement shall prevent the Company from, and the Company shall be permitted to: (i) engage in discussions or negotiations with, or respond to, enquiries from any Person that has made a bona fide unsolicited written Acquisition Proposal after the date hereof and prior to the Company meeting, that did not result from a breach of this Section 5.1, and, subject to the Company's compliance with Section 5.2(1) that the Company Board has determined constitutes or could reasonably be expected to result in a Superior Proposal, or (ii) provide information and access to properties, facilities, books or records of the Company pursuant to Section 5.3 to any Person where the requirements of Section 5.3 are met.

- (2) The Company shall, and shall cause its Subsidiaries and its Representatives to, immediately cease and terminate, and cause to be terminated, any solicitation, encouragement, discussion, negotiations, or other activities commenced prior to the date of this Agreement with any Person (other than the Purchaser, Trichome or their respective affiliates) with respect to any inquiry, proposal or offer that constitutes, or may reasonably be expected to constitute or lead to, an Acquisition Proposal, and in connection with such termination: (a) shall no longer provide access to any data room or provide any new disclosure of information, or access to properties, facilities, books and records of the Company or any of its Subsidiaries; and (b) as soon as possible following the execution of this Agreement request, and use commercially reasonable efforts to require, to the extent that it is entitled to do so: (i) the return or destruction of all copies of any confidential information regarding the Company or any Subsidiary provided to any Person who could reasonably be expected to make an Acquisition Proposal other than the Purchaser and its affiliates; or (ii) the destruction of all material including or incorporating or otherwise reflecting such confidential information regarding the Company or any Subsidiary, using its commercially reasonable efforts to ensure that such requests are fully complied with in accordance with the terms of such rights or entitlements.
- (3) The Company represents and warrants that the Company has not waived any confidentiality, standstill or similar agreement to which the Company or any Subsidiary is a party, and covenants and agrees that (i) the Company shall take all necessary action to enforce each confidentiality, standstill or similar agreement to which the Company or any of its Subsidiaries is a party, and (ii) neither the Company, nor any of its Subsidiaries nor any of their respective Representatives will, without the prior written consent of the Purchaser (which may be withheld or delayed in the Purchaser's sole and absolute discretion), release any Person from, or waive, amend, suspend or otherwise modify such Person's obligations respecting the Company, or any of its Subsidiaries, under any confidentiality, standstill or similar agreement to which the Company or any of its Subsidiaries is a party (it being acknowledged and agreed that the automatic termination of any standstill provisions of any such agreement or restriction as a result of the entering into and announcement of this Agreement by the Company pursuant to the express terms of any such agreement or restriction, shall not be a violation of this Section 5.1 and that the Company shall not be prohibited from considering a Superior Proposal from a party whose obligations so terminated automatically upon the entering into and announcement of this Agreement).

## **Section 5.2 Notification of Acquisition Proposals**

- (1) If the Company or any of its Subsidiaries or any of their respective Representatives, receives, or otherwise becomes aware of any inquiry, proposal or offer that constitutes or may reasonably be expected to constitute or lead to an Acquisition Proposal, or any request for copies of, access to, or disclosure of, confidential information that is made, or that may reasonably be perceived to be made, in connection with an Acquisition Proposal, including but not limited to information, access, or disclosure relating to the properties, facilities, books or records of the Company or any of its

Subsidiaries, the Company shall (i) immediately notify the Purchaser, at first orally, and then promptly and in any event within 24 hours in writing, of such Acquisition Proposal, inquiry, proposal, offer or request, including a description of its material terms and conditions and the identity of all Persons making the Acquisition Proposal, inquiry, proposal, offer or request, and shall provide the Purchaser with copies of any written Acquisition Proposal received in respect of, from or on behalf of any such Person and (ii) may contact the Person making such Acquisition Proposal, inquiry, proposal, offer or request and its Representatives solely for the purpose of clarifying the terms and conditions of such Acquisition Proposal, inquiry, proposal, offer or request so as to determine whether such Acquisition Proposal, inquiry, proposal, offer or request is, or would reasonably be expected to lead to, a Superior Proposal. The Company shall keep the Purchaser reasonably informed on a current basis of the status of developments and (to the extent permitted by Section 5.3) negotiations with respect to such Acquisition Proposal, inquiry, proposal, offer or request, including any material changes, modifications or other amendments to any such Acquisition Proposal, inquiry, proposal, offer or request.

### **Section 5.3 Responding to an Acquisition Proposal**

- (1) Notwithstanding Section 5.1, if at any time, prior to obtaining the approval by Company Shareholders of the Arrangement Resolution, the Company receives a written Acquisition Proposal, the Company may engage in or participate in discussions or negotiations with such Person regarding such Acquisition Proposal, and may provide copies of, access to or disclosure of confidential information, properties, facilities, books or records of the Company and its Subsidiaries for a period of not more than five Business Days, if, and only if:
  - (a) the Company Board first determines in good faith, after consultation with its Financial Advisors and its outside legal counsel, that such Acquisition Proposal constitutes or could reasonably be expected to constitute or lead to a Superior Proposal (provided that, for the purposes of this Section 5.3(1) only such Acquisition Proposal may be subject to a diligence condition for a period of not more than five Business Days and such Person's satisfactory review of such information);
  - (b) such Person was not restricted from making such Acquisition Proposal pursuant to an existing standstill or similar restriction with the Company or its Subsidiaries;
  - (c) the Company has been, and continues to be, in compliance with its obligations under this Article 5;
  - (d) prior to providing any such copies, access, or disclosure, the Company enters into a confidentiality agreement with such Person having terms that are not less onerous than those set out in the Confidentiality Agreement and any such copies, access or disclosure provided to such Person shall have already been (or simultaneously be) provided to the Purchaser; and
  - (e) the Company promptly provides the Purchaser with: (i) prior written notice stating the Company's intention to participate in such discussions or negotiations and to provide such copies, access or disclosure, and the Company Board has determined that failure to take such action would be inconsistent with its fiduciary duties; and (ii) the Company promptly provides the Purchaser with, prior to providing any such copies, access or disclosure, a true, complete and final executed copy of the confidentiality agreement referred to in Section 5.3(1)(d).

- (2) Notwithstanding any of the provisions of this Agreement
- (a) the Company Board has the right to respond, within the time and in the manner required by National Instrument 62-104 – *Takeover Bids and Issuer Bids* and similar provisions under Securities Laws relating to the provision of a directors’ circular in respect of an Acquisition Proposal or otherwise as required by applicable Securities Laws to an Acquisition Proposal that it determines is not a Superior Proposal. Further, nothing in this Agreement shall prevent the Company Board from making any disclosure to the Company Shareholders if the Company Board, acting in good faith and upon the advice of its outside legal and financial advisors, shall have determined that the failure to make such disclosure would be inconsistent with the fiduciary duties of the Company Board or such disclosure is otherwise required under Law; or
  - (b) prior to the Company Meeting, the Company and the Company Board shall not be prohibited from making any disclosure to the Company Shareholders, if:
    - (i) a Purchaser Material Adverse Effect has occurred and is continuing; and
    - (ii) the Company Board has reasonably determined in good faith after consultation with its outside legal counsel that the failure to do so would be inconsistent with the duties of the members of the Company Board, under applicable Law; and
  - (c) prior to the Company Meeting, the Company and the Company Board shall not be prohibited from making a Change in Recommendation if:
    - (i) a Purchaser Material Adverse Effect has occurred and is continuing; and
    - (ii) the Company Board has reasonably determined in good faith after consultation with its outside legal counsel that the failure to do so would be inconsistent with its fiduciary duties.

#### **Section 5.4 Purchaser Right to Match**

- (1) If the Company receives an Acquisition Proposal that constitutes a Superior Proposal prior to the approval of the Arrangement Resolution by the Company Shareholders, the Company Board may authorize the Company to, subject to compliance with Section 8.2, make a Change in Recommendation and enter into a definitive agreement with respect to such Superior Proposal, if and only if:
- (a) the Person making the Superior Proposal was not restricted from making such Superior Proposal pursuant to an existing standstill or similar restriction;
  - (b) the Company has been, and continues to be, in compliance with its obligations under Article 5;
  - (c) the Company has delivered to the Purchaser a written notice of the determination of the Company Board that such Acquisition Proposal constitutes a Superior Proposal and of the intention of the Company Board to enter into such definitive agreement with respect to such Superior Proposal, together with a written notice from the Company Board regarding the value and financial terms that the Company Board, in consultation with its Financial

Advisors, has determined should be ascribed to any non cash consideration offered under such Superior Proposal (the “**Superior Proposal Notice**”);

- (d) the Company has provided the Purchaser a copy of the proposed definitive agreement for the Superior Proposal;
  - (e) at least seven (7) Business Days (the “**Matching Period**”) have elapsed from the date that is the later of the date on which the Purchaser received the Superior Proposal Notice from the Company and the date on which the Purchaser received a copy of the proposed definitive agreement for the Superior Proposal from the Company;
  - (f) during any Matching Period, the Purchaser has had the opportunity (but not the obligation), in accordance with Section 5.4(2), to offer to the Company to amend this Agreement and the Arrangement in order for such Acquisition Proposal to cease to be a Superior Proposal;
  - (g) if the Purchaser has offered to the Company to amend this Agreement and the Arrangement under Section 5.4(2), the Company Board has determined in good faith, after consultation with the Company’s outside legal counsel and Financial Advisors, that such Acquisition Proposal continues to constitute a Superior Proposal compared to the terms of the Arrangement as proposed to be amended by the Purchaser under Section 5.4(2);
  - (h) the Company Board has determined in good faith, after consultation with the Company’s outside legal counsel that it is appropriate for the Company Board to enter into a definitive agreement with respect to such Superior Proposal; and
  - (i) prior to or concurrent with entering into such definitive agreement, the Company terminates this Agreement pursuant to Section 7.2(1)(c)(iii) and pays the Company Termination Fee pursuant to Section 8.2.
- (2) During the Matching Period, or such longer period as the Company may approve in writing (in its sole discretion) for such purpose: (a) the Company Board shall review any offer made by the Purchaser under Section 5.4(1)(f) to amend the terms of this Agreement and the Arrangement in good faith, in consultation with the Company’s outside legal counsel and Financial Advisors, in order to determine whether such proposal would, upon acceptance, result in the Acquisition Proposal previously constituting a Superior Proposal ceasing to be a Superior Proposal; and (b) if the Company Board determines that such Acquisition Proposal would cease to be a Superior Proposal as a result of such amendment, the Company shall negotiate in good faith with the Purchaser to make such amendments to the terms of this Agreement and the Arrangement as would enable the Purchaser to proceed with the transactions contemplated by this Agreement on such amended terms. If the Company Board determines that such Acquisition Proposal would cease to be a Superior Proposal, the Company shall promptly so advise the Purchaser and the Parties shall amend this Agreement to reflect such offer made by the Purchaser, and shall take and cause to be taken all such actions as are necessary to give effect to the foregoing.
- (3) Each successive amendment or modification to any Acquisition Proposal in respect of the Company shall constitute a new Acquisition Proposal for the purposes of this Section 5.4, and the Purchaser shall be afforded a new Matching Period from the later of the date on which the Purchaser received the new Superior Proposal Notice from the Company and the date on which the Purchaser received a copy of the proposed definitive agreement for the new Superior Proposal from the Company.



- (4) At the Purchaser's request, the Company Board shall promptly reaffirm the Company Board Recommendation by press release after the Company Board determines that an Acquisition Proposal is not a Superior Proposal or the Company Board determines that a proposed amendment to the terms of this Agreement as contemplated under Section 5.4(2) would result in an Acquisition Proposal no longer being a Superior Proposal. The Company shall provide the Purchaser and its outside legal counsel with a reasonable opportunity to review the form and content of any such press release and shall make all reasonable amendments to such press release as requested by the Purchaser and its outside legal counsel.
- (5) If the Company provides a Superior Proposal Notice to the Purchaser on or after a date that is less than five (5) Business Days before the Company Meeting, the Company shall postpone the Company Meeting to a date acceptable to both Parties (acting reasonably) that is not more than ten (10) Business Days after the scheduled date of the Company Meeting but in any event to a date that is not less than five (5) Business Days before the Outside Date.
- (6) Nothing contained in this Section 5.4 shall limit in any way the obligation of the Company to convene and hold the Company Meeting in accordance with Section 2.3 of this Agreement while this Agreement remains in force.

#### **Section 5.5 Breach by Subsidiaries and Representatives**

Without limiting the generality of the foregoing, the Company shall advise its Subsidiaries and their respective Representatives of the prohibitions set out in this Article 5 and any violation of the restrictions set forth in this Article 5 by the Company, its Subsidiaries or their respective Representatives is deemed to be a breach of this Article 5 by the Company.

### **ARTICLE 6 CONDITIONS**

#### **Section 6.1 Mutual Conditions Precedent**

- (1) The Parties are not required to complete the Arrangement unless each of the following conditions is satisfied, which conditions may only be waived, in whole or in part, by the mutual consent of each of the Parties:
  - (a) **Arrangement Resolution.** The Arrangement Resolution has been approved and adopted by the Company Shareholders at the Company Meeting in accordance with the Interim Order.
  - (b) **Interim and Final Order.** The Interim Order and the Final Order have both been obtained on terms consistent with this Agreement, and have not been set aside or modified in a manner unacceptable to either the Company or the Purchaser, each acting reasonably, on appeal or otherwise.
  - (c) **Consideration Shares and Exchange Notices.** The CSE and Nasdaq shall be notified of the Arrangement in advance of the Effective Date, and, if required, the CSE and Nasdaq shall have accepted notice for filing of all transactions of the Parties contemplated herein or necessary to complete the Arrangement, subject only to compliance with the customary requirements of the CSE and Nasdaq.

- (d) **Illegality.** No Law is in effect that makes the consummation of the Arrangement illegal or otherwise prohibits or enjoins the Company or the Purchaser from consummating the Arrangement.
- (e) **Regulatory Approvals.** All Regulatory Approvals and all third Person and other consents, waivers, permits, exemptions, orders, approvals, agreements and amendments and modifications to agreements, indentures or arrangements, in each case, the failure of which to obtain or the non-expiry of which would, or could reasonably be expected to have, a Company Material Adverse Effect or Purchaser Material Adverse Effect, as the case may be, or materially impede the completion of the Arrangement, shall have been obtained or received.

## **Section 6.2 Additional Conditions Precedent to the Obligations of the Purchaser**

The Purchaser is not required to complete the Arrangement unless each of the following conditions is satisfied, which conditions are for the exclusive benefit of the Purchaser and may only be waived, in whole or in part, by the Purchaser in its sole discretion:

- (1) **Representations and Warranties.** The representations and warranties of the Company set forth in: (i) Section 2 [*Organization and Qualification*] and 3 [*Authority Relative to this Agreement*] of Schedule C shall be true and correct in all respects as of the date of this Agreement, and as of the Effective Time as if made as at and as of such time; (ii) the representations and warranties of the Company set forth in Section 6 [*Capitalization*] of Schedule C shall be true and correct in all respects as of the date of this Agreement and as of the Effective Time except for *de minimis* inaccuracies as if made as at and as of such time; and (iii) all other representations and warranties of the Company set forth in this Agreement shall be true and correct in all respects (disregarding for purposes of this Section 6.2(1) any materiality or Company Material Adverse Effect qualification contained in any such representation or warranty) as of the Effective Time as if made at and as of such time (except that any such representation and warranty that by its terms speaks specifically as of the date of this Agreement or another date shall be true and correct in all respects as of such date), except in the case of this clause (iii) where the failure to be so true and correct in all respects, individually and in the aggregate, has not had or would not reasonably be expected to have a Company Material Adverse Effect, and the Company has delivered a certificate confirming same to the Purchaser, executed by two (2) senior officers of the Company (in each case without personal liability) addressed to the Purchaser and dated the Effective Date.
- (2) **Performance of Covenants.** The Company has fulfilled or complied in all material respects with each of its covenants contained in this Agreement to be fulfilled or complied with by it on or prior to the Effective Date, and has delivered a certificate confirming same to the Purchaser, executed by two (2) senior officers of the Company (in each case without personal liability) addressed to the Purchaser and dated the Effective Date.
- (3) **No Legal Action.** There is no action or proceeding pending or threatened by any Person (other than the Purchaser or its affiliates) in any jurisdiction that is reasonably likely to:
  - (a) cease trade, enjoin, prohibit, or impose any limitations, damages or conditions on, the Purchaser's ability to acquire, hold, or exercise full rights of ownership over, any Company Shares, including the right to vote Company Shares;
  - (b) prohibit or restrict the Arrangement, or the ownership or operation by the Company of a material portion of the business or assets of the Company or any of the Company's

Subsidiaries, or compel the Company to dispose of or hold separate any material portion of the business or assets of the Company or any of the Company's Subsidiaries, as a result of the Arrangement;

- (c) seek to obtain from the Company or the Purchaser any material damages directly or indirectly in connection with the Arrangement or the transactions contemplated by this Agreement; or
  - (d) prevent or materially delay the consummation of the Arrangement, or if the Arrangement is consummated, have or be reasonably expected to have a Company Material Adverse Effect or a Purchaser Material Adverse Effect, as applicable.
- (4) **Material Adverse Effect.** Since the date of this Agreement until the Effective Time, there shall not have occurred or have been disclosed to the public (if previously undisclosed to the public), a Company Material Adverse Effect, and the Company has delivered a certificate confirming same to the Purchaser, executed by two (2) senior officers of the Company (in each case without personal liability) addressed to the Purchaser and dated the Effective Date.
  - (5) **Dissent Rights.** Dissent Rights have not been exercised (excluding any Dissent Rights that have been exercised and subsequently withdrawn) with respect to more than 5% of the issued and outstanding Company Shares on a fully diluted basis.
  - (6) **Resignations and No Change of Control Payments.** The Company shall have received resignations from each director and officer of the Company requested by the Purchaser, effective as of the Effective Date, upon exchange between such Persons and the Company of full and final mutual releases (subject to customary exceptions) acceptable to the Purchaser.
  - (7) **Key Consents/Waivers.** Each of the Key Consents/Waivers has been given or obtained, or the steps to be taken have occurred, on terms acceptable to the Purchaser, acting reasonably, and the Company has delivered a certificate confirming same to the Purchaser, executed by two (2) senior officers of the Company (in each case without personal liability) addressed to the Purchaser and dated the Effective Date.
  - (8) **Litigation.** No litigation or arbitration shall have been commenced nor shall any demand letter have been received which, in the Purchaser's opinion, acting reasonably, could result in (individually or in the aggregate) claims against the Company (or any of its Subsidiaries) that could reasonably be expected to have a Company Material Adverse Effect.
  - (9) **Company Loan.** The Settlement Agreement shall remain in full force and effect and all conditions to the settlement of the Company Loan except for completion of the Arrangement shall have been completed or waived.
  - (10) **Releases.** The Company shall have terminated such employees and consultants as requested by the Purchaser and such employees and consultants shall have delivered full and final releases (subject to customary exceptions) to the Company.

### **Section 6.3 Additional Conditions Precedent to the Obligations of the Company**

The Company is not required to complete the Arrangement unless each of the following conditions is satisfied, which conditions are for the exclusive benefit of the Company and may only be waived, in whole or in part, by the Company in its sole discretion:

- (1) **Representations and Warranties.** The representations and warranties of the Purchaser set forth in: (i) Sections 1 [*Organization and Qualification*] and 2 [*Authority Relative to this Agreement*] of Schedule D shall be true and correct in all respects as of the date of this Agreement, and as of the Effective Time as if made as at and as of such time; (ii) the representations and warranties of the Purchaser set forth in Section 6 [*Consideration Shares*] of Schedule D shall be true and correct in all material respects as of the date of this Agreement, and as of the Effective Time as if made as at and as of such time; and (iii) all other representations and warranties of the Purchaser set forth in this Agreement shall be true and correct in all respects (disregarding for purposes of this Section 6.3(1) any materiality or Purchaser Material Adverse Effect qualification contained in any such representation or warranty) as of the Effective Time as if made at and as of such time (except that any such representation and warranty that by its terms speaks specifically as of the date of this Agreement or another date shall be true and correct in all respects as of such date), except in the case of this clause (iii) where the failure to be so true and correct in all respects, individually and in the aggregate, has not had or would not reasonably be expected to have a Purchaser Material Adverse Effect, and the Purchaser has delivered a certificate confirming same to the Company, executed by two (2) senior officers thereof (in each case without personal liability) addressed to the Company and dated the Effective Date.
- (2) **Performance of Covenants.** The Purchaser has fulfilled or complied in all material respects with each of its covenants contained in this Agreement to be fulfilled or complied with by it on or prior to the Effective Date, and has delivered a certificate confirming same to the Company, executed by two (2) senior officers of the Purchaser (in each case without personal liability) addressed to the Company and dated the Effective Date.
- (3) **No Legal Action.** There is no action or proceeding pending or threatened by any Person (other than the Company) in any jurisdiction that is reasonably likely to:

  - (a) cease trade, enjoin, prohibit, or impose any limitations, damages or conditions on, Purchaser's ability to issue the Consideration Shares;
  - (b) prohibit or restrict the Arrangement, or the ownership or operation by the Purchaser of a material portion of the business or assets of the Company or any of the Company's Subsidiaries, or compel the Purchaser to dispose of or hold separate any material portion of the business or assets of the Company or any of the Company's Subsidiaries, as a result of the Arrangement;
  - (c) seek to obtain from the Company or the Purchaser any material damages directly or indirectly in connection with the Arrangement or the transactions contemplated by this Agreement; or
  - (d) prevent or materially delay the consummation of the Arrangement, or if the Arrangement is consummated, have or be reasonably expected to have a Purchaser Material Adverse Effect.
- (4) **Material Adverse Effect.** Since the date of this Agreement, there shall not have occurred, or have been disclosed to the public (if previously undisclosed to the public) a Purchaser Material Adverse Effect, and the Purchaser has delivered a certificate confirming same to the Company, executed by two (2) senior officers of the Purchaser (in each case without personal liability) addressed to the Company and dated the Effective Date.

- (5) **Resale Restrictions.** The distribution of the Consideration Shares pursuant to the Arrangement shall be exempt from the prospectus and registration requirements of applicable Securities Laws in Canada either by virtue of exemptive relief from the securities regulatory authorities of each of the provinces of Canada or by virtue of exemptions under applicable Securities Laws and shall not be subject to resale restrictions under applicable Securities Laws (other than as applicable to control persons or pursuant to Section 2.6 of National Instrument 45-102 – Resale of Securities).
- (6) **U.S. Securities Laws.** The Consideration Shares to be issued pursuant to the Arrangement shall be exempt from the registration requirements of the U.S. Securities Act pursuant to Section 3(a)(10) thereof and pursuant to exemptions from applicable state securities laws, provided, however, that the Company shall be not entitled to the benefit of the conditions in this Section 6.3(6), and shall be deemed to have waived such condition, in the event that the Company fails to: (A) advise the Court prior to the hearing in respect of the Interim Order that the Parties intend to rely on the exemption from registration afforded by Section 3(a)(10) of the U.S. Securities Act based on the Court's approval of the Arrangement; or (B) comply with the requirements set forth in Section 2.13.

#### **Section 6.4 Satisfaction of Conditions**

The conditions precedent set out in Section 6.1, Section 6.2 and Section 6.3 will be conclusively deemed to have been satisfied, waived or released at the Effective Time.

### **ARTICLE 7 TERM AND TERMINATION**

#### **Section 7.1 Term**

This Agreement shall be effective from the date hereof until the earlier of the Effective Time and the termination of this Agreement in accordance with its terms.

#### **Section 7.2 Termination**

- (1) This Agreement may be terminated prior to the Effective Time (notwithstanding any approval of this Agreement or the Arrangement Resolution by the Company Shareholders or the approval of the Arrangement by the Court) by:
  - (a) the mutual written agreement of the Parties; or
  - (b) either the Company or the Purchaser if:
    - (i) the Required Approval is not obtained at the Company Meeting in accordance with the Interim Order, provided that a Party may not terminate this Agreement pursuant to this Section 7.2(1)(b)(i) if the failure to obtain the Required Approval has been caused by, or is a result of, a breach by such Party of any of its representations or warranties or the failure of such Party to perform any of its covenants or agreements under this Agreement;
    - (ii) after the date of this Agreement, any Law is enacted, made, enforced or amended, as applicable, that makes the consummation of the Arrangement illegal or otherwise permanently prohibits or enjoins the Company or the Purchaser from consummating the Arrangement, and such Law has, if applicable, become final

and non-appealable, provided the Party seeking to terminate this Agreement pursuant to this Section 7.2(1)(b)(ii) has used its commercially reasonable efforts to, as applicable, appeal or overturn such Law or otherwise have it lifted or rendered non-applicable in respect of the Arrangement;

- (iii) the Effective Time has not occurred by the Outside Date, provided that a Party may not terminate this Agreement pursuant to this Section 7.2(1)(b)(iii) if the failure of the Effective Time to so occur has been caused by, or is a result of, a breach by such Party of any of its representations or warranties or the failure of such Party to perform any of its covenants or agreements under this Agreement;
- (c) the Company if:
- (i) a breach of any representation or warranty or failure to perform any covenant or agreement on the part of the Purchaser under this Agreement occurs that would cause any condition in Section 6.3(1) [*Purchaser Representations and Warranties Condition*], Section 6.3(2) [*Purchaser Covenants Condition*] or Section 6.3(5) [*Resale Restrictions*], not to be satisfied, and such breach or failure is incapable of being cured or is not cured on or prior to the Outside Date in accordance with the terms of Section 4.7(3); provided that, in the case of Section 6.3(1) and Section 6.3(2), the Company is not then in breach of this Agreement so as to cause any condition in Section 6.2(1) [*Company Representations and Warranties Condition*] and 6.2(2) [*Company Covenants Condition*] not to be satisfied, and provided further that a Wilful Breach shall not be capable of being cured;
  - (ii) the Company Board authorizes the Company to accept, approve or recommend or enter into a definitive written agreement with respect to, a Superior Proposal (other than a confidentiality agreement permitted by and in accordance with Section 5.3), provided the Company is then in compliance with Article 5 and that prior to or concurrent with such termination the Company pays the Company Termination Fee in accordance with Section 8.2; or
  - (iii) since the date of this Agreement, there has occurred and is continuing a Purchaser Material Adverse Effect.
- (d) The Purchaser if:
- (i) a breach of any representation or warranty or failure to perform any covenant or agreement on the part of the Company under this Agreement occurs that would cause any condition in Section 6.2(1) [*Company Representations and Warranties Condition*] or Section 6.2(2) [*Company Covenants Condition*] not to be satisfied, and such breach or failure is incapable of being cured on or prior to the Outside Date or is not cured in accordance with the terms of Section 4.7(3); provided that the Purchaser is not then in breach of this Agreement so as to cause any condition in Section 6.3 not to be satisfied, and provided further that a Wilful Breach shall not be capable of being cured;
  - (ii) other than as permitted by Article 5, the Company Board or any committee of the Company Board fails to unanimously recommend or withdraws, amends, modifies or qualifies, publicly proposes or states its intention to do so, or fails to public reaffirm (without qualification) within five (5) Business Days after having been

requested in writing by the Purchaser to do so, the Company Board Recommendation, or takes no position or a neutral position with respect to an Acquisition Proposal for more than five (5) Business Days after first learning of an Acquisition Proposal or takes any other action that is or becomes disclosed publicly and which can reasonably be interpreted to indicate that the Company Board or a committee of the Company Board does not unanimously support (excluding conflicted directors) the Arrangement and this Agreement or does not unanimously believe (excluding conflicted directors) that the Arrangement and this Agreement are in the best interests of the Company and its security holders (in each case, a “**Change in Recommendation**”), or the Company Board or any committee of the Company Board resolves or proposes to take any of the foregoing actions, unless the Company provides a Superior Proposal Notice to the Purchaser within such timeframe in which case the Company will have until the end of the Matching Period to reaffirm the Company Board Recommendation;

- (iii) the Company breaches Article 5 in any material respect;
- (iv) any event occurs as a result of which the condition set forth in Section 6.2(5) [*Dissent Rights*] is not capable of being satisfied by the Outside Date; or
- (v) since the date of this Agreement, there has occurred and is continuing a Company Material Adverse Effect.

- (2) The Party desiring to terminate this Agreement pursuant to this Section 7.2 (other than pursuant to Section 7.2(1)(a)) shall give written notice of such termination to the other Party, specifying in reasonable detail the basis for such Party’s exercise of its termination right.

### **Section 7.3 Effect of Termination/Survival**

- (1) If this Agreement is terminated or is no longer effective pursuant to Section 7.2, this Agreement shall become void and of no further force or effect without liability of any Party (or any shareholder, director, officer, employee, agent, consultant or representative of such Party) to any other Party to this Agreement, except that this Section 7.3, Section 8.2 through to and including Section 8.14, and the provisions of the Confidentiality Agreement shall survive in accordance with their terms, and provided further that no Party shall be relieved of any liability for any Wilful Breach by it of this Agreement occurring prior to such termination.

## **ARTICLE 8 GENERAL PROVISIONS**

### **Section 8.1 Amendments**

This Agreement and the Plan of Arrangement may, at any time and from time to time before or after the holding of the Company Meeting but not later than the Effective Time, be amended by mutual written agreement of the Parties, and any such amendment may, subject to the Plan of Arrangement, Interim Order and the Final Order and applicable Law, without limitation:

- (a) change the time for performance of any of the obligations or acts of the Parties;
- (b) waive any inaccuracies or modify any representation or warranty contained in this Agreement or in any document delivered pursuant to this Agreement;

- (c) waive compliance with or modify any inaccuracies or any of the covenants contained in this Agreement and waive or modify performance of any of the obligations of the Parties; and/or
- (d) waive compliance with or modify any mutual conditions contained in this Agreement.

## **Section 8.2 Termination Fees**

(1) For the purposes of this Agreement, “**Company Termination Fee**” means \$1,200,000, and “**Company Termination Fee Event**” means the termination of this Agreement:

- (a) by the Purchaser, pursuant to Section 7.2(1)(d)(ii) [*Change in Recommendation*] or Section 7.2(1)(d)(iii) [*Breach of Article 5*];
- (b) by the Company pursuant to Section 7.2(1)(c)(ii) [*Superior Proposal*]; or
- (c) by the Company or the Purchaser pursuant to Section 7.2(1)(b)(i) [*Failure of Company Shareholders to Approve*] or Section 7.2(1)(d)(i) [*Breach of Reps, Warranties or Covenants by the Company*] on the basis of a Wilful Breach, if:
  - (i) prior to such termination, an Acquisition Proposal is publicly announced or otherwise publicly disclosed by any Person (other than the Purchaser or any of its affiliates) or any Person (other than the Purchaser or any of its affiliates) shall have publicly announced an intention to make an Acquisition Proposal; and
  - (ii) within nine (9) months following the date of such termination, (A) an Acquisition Proposal (whether or not such Acquisition Proposal is the same Acquisition Proposal referred to in clause (i) above) is consummated, or (B) the Company or one or more of its Subsidiaries, directly or indirectly, in one or more transactions, enters into a definitive agreement in respect of an Acquisition Proposal (whether or not such Acquisition Proposal is the same Acquisition Proposal referred to in clause (i) above), and such Acquisition Proposal is later consummated (whether or not within nine (9) months after such termination),

in which case the Company Termination Fee shall be payable on or prior to consummation of the application transaction referred to therein. The Company Termination Fee shall be paid by or as directed by Company as proceeds of disposition of the Purchaser’s rights under this Agreement. For purposes of the foregoing, the term “**Acquisition Proposal**” shall have the meaning assigned to such term in Section 1.1, except that references to “20% or more” shall be deemed to be references to “50% or more”.

- (2) The Company Termination Fee shall be paid by the Company to the Purchaser by wire transfer of immediately available funds to an account designated by the Purchaser as follows:
- (a) if a Company Termination Fee Event occurs due to a termination of this Agreement described in Section 8.2(1)(a), within two (2) Business Days of the occurrence of such Company Termination Fee Event; and
  - (b) if a Company Termination Fee Event occurs due to a termination of this Agreement described in Section 8.2(1)(b), concurrently with such termination.



- (3) Each of the Purchaser and the Company acknowledge that the agreements contained in this Section 8.2 are an integral part of the transactions contemplated by this Agreement, and that without these agreements neither the Purchaser nor the Company would enter into this Agreement, and that the amounts set out in this Section 8.2 represent liquidated damages which are a genuine pre-estimate of the damages, including opportunity costs, which the Purchaser or the Company, as applicable, will suffer or incur as a result of the event giving rise to such damages and resultant termination of this Agreement, and is not a penalty. Each of the Purchaser and the Company irrevocably waives any right it may have to raise as a defence that any such liquidated damages are excessive or punitive.
- (4) Subject to Section 7.3, the Purchaser hereby expressly acknowledges and agrees that, upon any termination of this Agreement under circumstances where the Purchaser is entitled to the Company Termination Fee and such Company Termination Fee is paid in full within the prescribed time period, the Purchaser shall be precluded from any other remedy against the Company or its Subsidiaries and shall not seek to obtain any recovery, judgment or damages of any kind against the Company or its Subsidiaries in connection with this Agreement. Notwithstanding the foregoing, nothing in this Agreement shall preclude the Purchaser from seeking and being awarded damages in respect of losses incurred or suffered by the Purchaser as a result of any Wilful Breach of this Agreement by the Company, seeking and obtaining injunctive relief to restrain any such Wilful Breach of threatened Wilful Breach of the covenants or agreements set forth in this Agreement or the Confidentiality Agreement or otherwise, or seeking and being awarded specific performance of any such covenants or agreements subject to a Wilful Breach or threatened Wilful Breach, without the necessity of posting a bond or security in connection therewith.

### **Section 8.3 Expenses**

- (1) All out-of-pocket third party transaction expenses incurred in connection with this Agreement and the Plan of Arrangement, including all costs, expenses and fees of the Company incurred prior to or after the Effective Date in connection with, or incidental to, the Plan of Arrangement, shall be paid by the Party incurring such expenses, whether or not the Arrangement is consummated.
- (2) Except as disclosed in the Company Disclosure Letter, the Company confirms that no broker, finder or investment banker is or will be entitled to any brokerage, finder's or other fee or commission in connection with the transactions contemplated by this Agreement.

### **Section 8.4 Notices**

Any notice, direction or other communication given pursuant to this Agreement (each a "**Notice**") must be in writing, sent by hand delivery, courier or email and is deemed to be given and received: (i) on the date of delivery by hand or courier if it is a Business Day and the delivery was made prior to 4:00 p.m. (local time in the place of receipt), and otherwise on the next Business Day; or (ii) if sent by email on the date of transmission if it is a Business Day and transmission was made prior to 5:00 p.m. (local time in the place of receipt) and otherwise on the next Business Day, in each case to the Parties at the following addresses (or such other address for a Party as specified by like Notice):

- (a) to the Company at:

Bay Adelaide Centre, East Tower  
22 Adelaide Street West, Suite 3400  
Toronto, Ontario

M5H 4E3

Attention: Andrew Powers and Cameron MacDonald  
E-mail: [redacted], [redacted]

(b) to the Purchaser or Trichome at:

550 Burrard Street  
Suite 2300  
Vancouver, British Columbia  
V6C 2B5

Attention: Oren Shuster, Chief Executive Officer and Yael Harrosh, General Counsel  
and Corporate Secretary  
E-mail: [redacted], [redacted]

and

Trichome Financial Corp.  
150 King Street West, Suite 214  
Toronto, Ontario  
M5H 1J9

Attention: Michael Ruscetta, Chief Executive Officer and Dan Cohen, VP General  
Counsel  
Email: [redacted], [redacted]

with a copy (which will not constitute Notice) to:

Torys LLP  
Suite 3300, 79 Wellington Street West  
Toronto, Ontario  
M5K 1N2

Attention: Janan Paskaran and Frazer House  
E-mail: [redacted], [redacted]

Rejection or other refusal to accept, or inability to deliver because of changed address of which no Notice was given, shall be deemed to be receipt of the Notice as of the date of such rejection, refusal or inability to deliver. Sending a copy of a Notice to a Party's legal counsel as contemplated above is for information purposes only and does not constitute delivery of the Notice to that Party. The failure to send a copy of a Notice to legal counsel does not invalidate delivery of that Notice to a Party.

#### **Section 8.5 Time of the Essence**

Time is of the essence in this Agreement.

#### **Section 8.6 Injunctive Relief**

The Parties agree that irreparable harm may occur for which money damages would not be an adequate remedy at Law in the event that any of the provisions of this Agreement were not performed by a Party in

accordance with their specific terms or were otherwise breached by a Party. It is accordingly agreed that each Party shall be entitled to seek injunctive and other equitable relief to prevent breaches of this Agreement, and to seek to enforce compliance with the terms of this Agreement against the other Party without any requirement for the securing or posting of any bond in connection with the obtaining of any such injunctive or other equitable relief, this being in addition to any other remedy to which a Party may be entitled at Law or in equity.

### **Section 8.7 Third Party Beneficiaries**

- (1) Except as provided in Section 2.7 and Section 4.8, which, without limiting its terms, is intended as stipulations for the benefit of the third parties mentioned in such provisions (such third parties referred to in this Section 8.7 as the “**Indemnified Persons**”), the Parties intend that this Agreement will not benefit or create any right or cause of action in favour of any Person, other than the Parties and that no Person, other than the Parties, shall be entitled to rely on the provisions of this Agreement in any action, suit, proceeding, hearing or other forum.
- (2) Despite the foregoing, the Purchaser acknowledges to each of the Indemnified Persons their direct rights against it under Section 4.8 of this Agreement, which is intended for the benefit of, and shall be enforceable by, each Indemnified Person, his or her heirs and his or her legal representatives, and for such purpose, the Company confirms that it is acting as trustee on their behalf, and agrees to enforce such provision on their behalf. The Parties reserve their right to vary or rescind the rights at any time and in any way whatsoever, if any, granted by or under this Agreement to any Person who is not a Party, without notice to or consent of that Person, including any Indemnified Person.

### **Section 8.8 Waiver**

No waiver of any of the provisions of this Agreement will constitute a waiver of any other provision (whether or not similar). No waiver will be binding unless executed in writing by the Party to be bound by the waiver. A Party’s failure or delay in exercising any right under this Agreement will not operate as a waiver of that right. A single or partial exercise of any right will not preclude a Party from any other or further exercise of that right or the exercise of any other right.

### **Section 8.9 Entire Agreement**

This Agreement, together with the Confidentiality Agreement, constitutes the entire agreement between the Company, on one hand, and the Purchaser, on the other hand, with respect to the transactions contemplated by this Agreement and supersedes all prior agreements, understandings, negotiations and discussions, whether oral or written, between the Company, on one hand, and the Purchaser, on the other hand. There are no representations, warranties, covenants, conditions or other agreements, express or implied, collateral, statutory or otherwise, between the Company, on one hand, and the Purchaser, on the other hand in connection with the subject matter of this Agreement, except as specifically set forth in this Agreement. The Company, on one hand, and the Purchaser, on the other hand, have not relied and are not relying on any other information, discussion or understanding in entering into and completing the transactions contemplated by this Agreement.

### **Section 8.10 Successors and Assigns**

- (1) This Agreement becomes effective only when executed by the Company and the Purchaser. After that time, it will be binding upon and enure to the benefit of the Company and the Purchaser and their respective successors and permitted assigns.

- (2) Neither this Agreement nor any of the rights or obligations under this Agreement are assignable or transferable by any Party without the prior written consent of the other Party, provided however that the Purchaser (or any permitted assign of the Purchaser) may, at any time, assign its rights and obligations under this Agreement without such consent to an affiliate of the Purchaser if such assignee delivers an instrument in writing confirming that it is bound by and shall perform all of the obligations of the assigning party under this Agreement as if it were an original signatory and provided further that the assigning party shall not be relieved of its obligations hereunder.

#### **Section 8.11 Severability**

If any provision of this Agreement is determined to be illegal, invalid or unenforceable by an arbitrator or any court of competent jurisdiction, that provision will be severed from this Agreement and the remaining provisions shall remain in full force and effect. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the fullest extent possible.

#### **Section 8.12 Governing Law**

- (1) This Agreement will be governed by and interpreted and enforced in accordance with the Laws of the Province of British Columbia and the federal Laws of Canada applicable in the Province of British Columbia.
- (2) Each Party irrevocably attorns and submits to the non-exclusive jurisdiction of the courts situated in the City of Vancouver and waives objection to the venue of any proceeding in such court or that such court provides an inconvenient forum.

#### **Section 8.13 Rules of Construction**

The Parties to this Agreement waive the application of any Law or rule of construction providing that ambiguities in any agreement or other document shall be construed against the party drafting such agreement or other document.

#### **Section 8.14 No Liability**

No director or officer of the Purchaser or any of its Subsidiaries shall have any personal liability whatsoever to the Company under this Agreement or any other document delivered on behalf of the Purchaser or any of its Subsidiaries under this Agreement. No director or officer of the Company or any of its Subsidiaries shall have any personal liability whatsoever to the Purchaser under this Agreement or any other document delivered on behalf of the Company or any of its Subsidiaries under this Agreement.

#### **Section 8.15 Counterparts**

This Agreement may be executed in any number of counterparts (including counterparts by facsimile) and all such counterparts taken together shall be deemed to constitute one and the same instrument. The Parties shall be entitled to rely upon delivery of an executed facsimile or similar executed electronic copy of this Agreement, and such facsimile or similar executed electronic copy shall be legally effective to create a valid and binding agreement between the Parties.

*[Remainder of page intentionally blank; signature page follows]*

**IN WITNESS WHEREOF** the Parties have executed this Arrangement Agreement.

**IM CANNABIS CORP.**

By: signed "Oren Shuster"  
Authorized Signing Officer

**MYM NUTRACEUTICALS INC.**

By: signed "Robert Wolf"  
Authorized Signing Officer

**TRICHOME FINANCIAL CORP.**

By: signed "Michael Ruschetta"  
Authorized Signing Officer

**SCHEDULE A  
PLAN OF ARRANGEMENT**

**PLAN OF ARRANGEMENT UNDER SECTION 288 OF THE  
*BUSINESS CORPORATIONS ACT (BRITISH COLUMBIA)***

**ARTICLE 1  
INTERPRETATION**

**1.1 Definitions**

Unless indicated otherwise, where used in this Plan of Arrangement, capitalized terms used but not defined shall have the meanings ascribed thereto in the Arrangement Agreement and the following terms shall have the following meanings (and grammatical variations of such terms shall have corresponding meanings):

“**Arrangement**” means an arrangement under Division 5 of Part 9 of the BCBCA on the terms and subject to the conditions set out in this Plan of Arrangement, subject to any amendments or variations to this Plan of Arrangement made in accordance with the terms of the Arrangement Agreement or the provisions of this Plan of Arrangement or made at the direction of the Court in the Final Order with the prior written consent of the Company and the Purchaser, each acting reasonably.

“**Arrangement Agreement**” means the arrangement agreement dated as of March 31, 2021 among the Purchaser the Company, including the schedules and exhibits thereto, and as the same may be amended, supplemented or otherwise modified from time to time in accordance with the terms thereof prior to the Effective Time, providing for, among other things, the Arrangement.

“**Arrangement Resolution**” means the special resolution of the Company Shareholders approving this Plan of Arrangement to be considered at the Company Meeting, with such amendments or variations as the Court may direct in the Interim Order with the consent of the Company and the Purchaser, each acting reasonably.

“**Award Agreement**” means any agreement between the Company and a participant in, or pursuant to, the Company Option Plan setting out the participant’s entitlement to receive Company Options, and the Company Shares issuable pursuant thereto upon exercise.

“**BCBCA**” means the *Business Corporations Act* (British Columbia) and the regulations made thereunder, as now in effect and as they may be promulgated or amended from time to time.

“**Business Day**” means any day of the year, other than a Saturday, Sunday or any day on which major banks are closed for business in Toronto, Ontario or Vancouver, British Columbia, as the context requires.

“**Company**” means MYM Nutraceuticals Inc., a corporation existing under the Laws of the Province of British Columbia.

“**Company Circular**” means the notice of the Company Meeting and accompanying management information circular, including all schedules, appendices and exhibits to, and information incorporated by reference in, such management information circular, to be sent to the Company

Shareholders in connection with the Company Meeting, as amended, supplemented or otherwise modified from time to time in accordance with the terms of the Arrangement Agreement.

**“Company Exchangeable Shareholders”** means the registered and beneficial holders of Company Exchangeable Shares.

**“Company Exchangeable Shares”** means the Class A special shares in the capital of MYM International Brands Inc., a wholly-owned Subsidiary of the Company, which are exchangeable for Company Shares on a 1 to 1 basis.

**“Company In-The-Money Option”** means a Company Option having an In-The-Money Amount at the Effective Time.

**“Company In-The-Money Warrant”** means a Company Warrant having an In-The-Money Amount at the Effective Time.

**“Company Meeting”** means the special meeting of Company Shareholders, including any adjournment or postponement of such special meeting in accordance with the terms of the Arrangement Agreement, to be called and held in accordance with the Interim Order to consider the Arrangement Resolution and for any other purpose as may be set out in the Company Circular and agreed to in writing by the Purchaser.

**“Company Option Plan”** means the share option plan dated February 26, 2015, as amended and approved by the Company Shareholders on November 2, 2020.

**“Company Option Shares”** means the Company Shares to be issued to holders of Company In-The-Money Options pursuant to Section 2.4(d) of the Plan of Arrangement.

**“Company Optionholder”** means a holder of one or more Company Options.

**“Company Options”** means options to acquire Company Shares granted pursuant to the Company Option Plan.

**“Company Out-Of-The-Money Option”** means a Company Option that is not a Company In-The-Money Option.

**“Company Out-Of-The-Money Warrant”** means a Company Warrant that is not a Company In-The-Money Warrant.

**“Company Shareholders”** means the registered or beneficial holders of Company Shares, as the context requires, except that with respect to Dissent Rights, Company Shareholders refers only to registered holders of Company Shares.

**“Company Shares”** means the common shares in the authorized share structure of the Company.

**“Company Warrant Shares”** means the Company Shares to be issued to holders of Company In-The-Money Warrants pursuant to Section 2.3(1)(f) of the Plan of Arrangement

**“Company Warrant holder”** means a holder of one or more Company Warrants.

**“Company Warrants”** means an aggregate of 77,368,607 common share purchase warrants of the Company with a weighted-average exercise price of \$0.22.

**“Consideration”** means the consideration to be received by Company Shareholders (other than Dissenting Holders) pursuant to this Plan of Arrangement, as consideration for their Company Shares, consisting of that number of Purchaser Shares equal to the product of such Company Shares multiplied by the Exchange Ratio.

**“Consideration Shares”** means the Purchaser Shares to be issued to the Company Shareholders as the Consideration pursuant to the Arrangement.

**“Court”** means the Supreme Court of British Columbia.

**“Depositary”** means any depositary or trust company, bank or financial institution as the Purchaser may appoint to act as depositary with the approval of the Company, acting reasonably, for the purpose of, among other things, exchanging certificates representing Company Shares for Consideration Shares.

**“Dissent Rights”** has the meaning specified in Section 3.1.

**“Dissenting Holder”** means a registered Company Shareholder who has validly exercised Dissent Rights in accordance with Section 3.1 and has not withdrawn or been deemed to have withdrawn such exercise of Dissent Rights and who is ultimately entitled to be paid the fair value of the Company Shares held by such registered Company Shareholder.

**“Effective Date”** means the date upon which the Arrangement becomes effective, as set out in Section 2.8 of the Arrangement Agreement.

**“Effective Time”** means 12:01 a.m. (Pacific time) on the Effective Date, or such other time as the Parties agree to in writing before the Effective Date.

**“Exchange Ratio”** means 0.022 of a Purchaser Share to be issued by the Purchaser for each one Company Share exchanged pursuant to the Arrangement.

**“Fair Market Value”** means the volume weighted average trading price of the Company Shares on the CSE (or other recognized stock exchange on which the Company Shares are primarily traded) for the five trading day period immediately prior to the Effective Date.

**“Final Order”** means the final order of the Court approving the Arrangement under Section 291 of the BCBCA, in a form acceptable to the Company and the Purchaser, each acting reasonably, after a hearing upon the procedural and substantive fairness of the terms and conditions of the Arrangement, as such order may be amended by the Court (with the consent of both the Company and the Purchaser, each acting reasonably) at any time prior to the Effective Date or, if appealed, then, unless such appeal is withdrawn or denied, as affirmed or as amended (provided that any such amendment is acceptable to both the Company and the Purchaser, each acting reasonably) on appeal.

**“Governmental Entity”** means (i) any international, multinational, national, federal, provincial, state, regional, municipal, local or other government, governmental or public department, central bank, court, tribunal, arbitral body, commission, commissioner, board, bureau, ministry, agency or instrumentality, domestic or foreign, (ii) any subdivision or authority of any of the above, (iii) any quasi-governmental or private body exercising any regulatory, expropriation or taxing authority under or for the account of any of the foregoing or (iv) any stock exchange, including the CSE and the Nasdaq.



**“In-The-Money Amount”** at the Effective Time with respect to a Company Option or Company Warrant, means the amount, if any, by which the Fair Market Value of the relevant underlying security exceeds the exercise price of the relevant option or warrant, as applicable, at the Effective Time.

**“Interim Order”** means the interim order of the Court in a form acceptable to the Company and the Purchaser, each acting reasonably, providing for, among other things, the calling and holding of the Company Meeting, as such order may be amended by the Court with the consent of the Company and the Purchaser, each acting reasonably.

**“Law”** means, with respect to any Person, any and all applicable law (statutory, common or otherwise), constitution, treaty, convention, ordinance, code, rule, regulation, order, injunction, notice, judgment, decree, ruling or other similar requirement, whether domestic or foreign, enacted, adopted, promulgated or applied by a Governmental Entity that is binding upon or applicable to such Person or its business, undertaking, property or securities, and to the extent that they have the force of law, policies, guidelines, notices and protocols of any Governmental Entity, as amended.

**“Letter of Transmittal”** means the letter of transmittal to be delivered by the Company to the Company Shareholders for use in connection with the Arrangement.

**“Lien”** means any mortgage, charge, pledge, hypothec, security interest, prior claim, encroachments, option, right of first refusal or first offer, occupancy right, covenant, assignment, lien (statutory or otherwise), defect of title, or restriction or adverse right or claim, or other third party interest or encumbrance of any kind, in each case, whether contingent or absolute.

**“Option Exchange”** has the meaning attributed to that term in Section 2.4(b) of this Plan of Arrangement.

**“Parties”** means the Company and the Purchaser, and **“Party”** means either of them.

**“Person”** includes any individual, partnership, association, body corporate, organization, trust, estate, trustee, executor, administrator, legal representative, government (including Governmental Entity), syndicate or other entity, whether or not having legal status.

**“Plan of Arrangement”** means this plan of arrangement and any amendments or variations made in accordance with Section 8.1 of the Arrangement Agreement and this plan of arrangement or made at the direction of the Court in the Final Order with the written consent of the Company and the Purchaser, each acting reasonably.

**“Purchaser”** means IM Cannabis Corp., a company existing under the Laws of the Province of British Columbia.

**“Purchaser Option Plan”** means the share option plan approved by the shareholders of the Purchaser on March 16, 2020.

**“Purchaser Shares”** means the common shares in the authorized share structure of the Purchaser.

**“Registrar”** means the Registrar of Companies appointed pursuant to Section 400 of the BCBCA.

**“Replacement Option In-The-Money Amount”** at a particular time with respect to a Replacement Option, means the amount, if any, by which the volume weighted average trading price of a

Purchaser Share on the CSE (or other recognized stock exchange on which the Purchaser Shares are primarily traded) for the five trading day period immediately prior to the Effective Date exceeds the exercise price per Purchaser Share subject to a Replacement Option.

“**Replacement Options**” means the options to purchase Purchaser Shares to be issued by the Purchaser pursuant to the Purchaser Option Plan in exchange for each of the outstanding Company Out-Of-The-Money Options at the Effective Time pursuant to Section 2.4(b) hereto.

“**Replacement Warrants**” means the warrant to purchase Purchaser Shares to be issued by the Purchaser in exchange for each of the outstanding Company Out-Of-The-Money Warrants at the Effective Time pursuant to Section 2.3(1)(e) hereto.

“**Section 3(a)(10) Exemption**” means the exemption from the registration requirements of the U.S. Securities Act provided by Section 3(a)(10) thereof.

“**Tax Act**” means the *Income Tax Act* (Canada) and the regulations promulgated thereunder, each as amended.

“**Trichome**” means Trichome Financial Corp., a corporation incorporated pursuant to the Laws of the Province of Ontario and a wholly-owned subsidiary of the Purchaser.

“**Trichome Shares**” means common shares in the authorized capital of Trichome.

“**U.S. Securities Act**” means the United States *Securities Act of 1933*, as amended, and the rules and regulations promulgated thereunder.

## **1.2 Interpretation Not Affected by Headings**

The headings contained in this Plan of Arrangement are for convenience of reference only and shall not affect in any way the meaning or interpretation of this Plan of Arrangement. The terms “this Plan of Arrangement”, “hereof”, “herein”, “hereto”, “hereunder” and similar expressions refer to this Plan of Arrangement and not to any particular Article, Section or Subsection hereof and include any agreement or instrument supplementary or ancillary hereto.

## **1.3 Date for any Action**

If the date on which any action is required to be taken hereunder is not a Business Day, such action shall be required to be taken on the next succeeding day which is a Business Day.

## **1.4 Number and Gender**

In this Plan of Arrangement, unless the context otherwise requires, words importing the singular include the plural and vice versa, and words importing gender include all genders and neuter.

## **1.5 References to Persons and Statutes**

A reference to a Person includes any successor to that Person. Any reference to a statute or to a rule of a self-regulatory organization, including any stock exchange, refers to such statute or rule, and all rules and regulations, administrative policy statements, instruments, blanket orders, notices, directions and rulings issued or adopted under it, as it or they may have been or may from time to time be amended or re-enacted, unless stated otherwise. Any reference herein to a particular provision or part of any statute will include a

reference to that provision or part as it may be renumbered or amended from time to time and any successor provision or part or any renumbering or amendment thereof. Any reference herein to the *Income Tax Act* (Canada) shall also include a reference to any applicable and corresponding provision under the income tax Laws of a province or territory of Canada.

## **1.6 Currency**

Unless otherwise stated in this Plan of Arrangement, all references herein to amounts of money are expressed in lawful money of Canada.

## **1.7 Computation of Time**

A period of time is to be computed as beginning on the day following the event that began the period and ending at 4:30 p.m. on the last day of the period, if the last day of the period is a Business Day, or at 4:30 p.m. on the next Business Day if the last day of the period is not a Business Day. If the date on which any action is required or permitted to be taken under this Plan of Arrangement by a Person is not a Business Day, such action shall be required or permitted to be taken on the next succeeding day that is a Business Day.

## **1.8 Time References**

Time shall be of the essence in every matter or action contemplated hereunder. References to time are to Pacific time.

## **1.9 Certain Phrases, etc.**

Wherever the word “including,” “includes” or “include” is used in this Plan of Arrangement, it shall be deemed to be followed by the words “without limitation”. The word “or” shall be disjunctive but not exclusive. The phrase “the aggregate of,” “the total of,” “the sum of” or a phrase of similar meaning means “the aggregate (or total or sum), without duplication of.” References herein to a Person in a particular capacity or capacities shall exclude such Person in any other capacity.

# **ARTICLE 2 THE ARRANGEMENT**

## **2.1 Arrangement Agreement**

This Plan of Arrangement is made pursuant to and subject to the provisions of the Arrangement Agreement.

## **2.2 Binding Effect**

This Plan of Arrangement and the Arrangement will become effective at, and be binding at and after, the Effective Time on: (i) the Company; (ii) the Purchaser; (iii) Trichome; (iv) the Depositary; (v) the registrar and transfer agent of the Company; (vi) Company Optionholders; (vii) Company Warrantholders; (viii) Company Exchangeable Shareholders; and (ix) registered and beneficial Company Shareholders (including Dissenting Holders), in each case, without any further act or formality required on the part of any Person.

## **2.3 Effective Time of Arrangement**

The exchanges, issuances and cancellations provided for in Section 2.4 shall be deemed to occur at the time and in the order specified in Section 2.4.

## 2.4 Arrangement

Commencing at the Effective Time, each of the transactions or events set out below shall occur and shall be deemed to occur in the following sequence, in each case, without any further authorizations, act or formality on the part of any Person, effective as at two-minute intervals starting at the Effective Time:

- (a) each of the Company Shares held by a Dissenting Holder in respect of which Dissent Rights have been validly exercised shall be deemed to have transferred, without further act or formality by or on behalf of any Dissenting Holder, to the Purchaser in consideration for a debt claim against the Purchaser for the amount determined under Article 3, and:
  - (i) such Dissenting Holder shall cease to be the holder of such Company Shares and to have any rights as a Company Shareholder other than the right to be paid fair value for such Company Shares, as set out in Section 3.1;
  - (ii) such Dissenting Holder's name shall be removed as the holder of Company Shares from the applicable register of Company Shareholders maintained by or on behalf of the Company; and
  - (iii) the Purchaser shall be deemed to be the transferee of such Company Shares, free and clear of all Liens (other than the right to be paid fair value for such Company Shares as set out in Section 3.1), and shall be entered into the applicable register of Company Shareholders maintained by or on behalf of the Company; and
- (b) each Company Out-Of-The Money Option outstanding immediately prior to the Effective Time (whether vested or unvested) held by a Company Optionholder shall be exchanged for a Replacement Option (the "**Option Exchange**") to acquire from the Purchaser, such number of Purchaser Shares as is equal to the product of: (A) the number of Company Shares subject to such Company Out-Of-The Money Option immediately prior to the Effective Time; multiplied by (B) the Exchange Ratio, provided that, if the foregoing would result in the issuance of a fraction of a Purchaser Share on any particular exercise of Replacement Options by a Company Optionholder, then the number of Purchaser Shares otherwise issued shall be rounded down to the nearest whole number of Purchaser Shares, and:
  - (i) the exercise price per Purchaser Share subject to a Replacement Option shall be an amount equal to the product of: (A) the exercise price per Company Share subject to each such Company Out-Of-The-Money Option immediately before the Effective Time; divided by (B) the Exchange Ratio, rounded up to the nearest whole cent, provided that the exercise price per Purchaser Share subject to a Replacement Option held by a Company Optionholder shall be and be deemed to be automatically adjusted in any case where the Company Optionholder's Replacement Options have an aggregate Replacement Option In-The-Money Amount to reduce such Replacement Option In-The-Money Amount to nil, with the intention that that subsection 7(1.4) of the Tax Act will apply to each Option Exchange;
  - (ii) each such Replacement Option shall have the same terms and conditions with respect to expiry date and otherwise as were applicable in respect of such Company Out-Of-The-Money Option, except that each Replacement Option shall be fully

vested and no services shall be required from any holder of Replacement Options to continue to hold or exercise any Replacement Option; and

- (iii) the Company Optionholder will cease to be the holder of such Company Out-Of-The-Money Option, will cease to have any rights as a holder in respect of such Company Out-Of-The-Money Option, will be removed from the applicable register of the Company Options, and all Award Agreements relating thereto will be cancelled, and none of the Company, Trichome or the Purchaser shall have any further liabilities or obligations with respect thereto;
- (c) each Company In-The-Money Option (whether vested or unvested) held by a Company Optionholder will be surrendered to the Company and cancelled in exchange for:
- (i) a number of Company Shares (including for greater certainty, fractional Company Shares) having a Fair Market Value equal to the aggregate In-The-Money Amount of the Company Optionholder's Company In-The-Money Options and the Company Shares will be deemed to be issued to such Company Optionholder at an issue price equal to the Fair Market Value thereof as fully paid and non-assessable Company Shares, provided that no share certificates shall be issued with respect to such Company Shares; and
  - (ii) the Company Optionholder will cease to be the holder of such Company In-The-Money Option, will cease to have any rights as a holder in respect of such Company In-The-Money Option, will be removed from the applicable register of the Company Options, and all Award Agreements relating thereto will be cancelled, and none of the Company, Trichome or the Purchaser shall have any further liabilities or obligations with respect thereto;
- (d) the Company Option Plan shall be terminated, and none of the Company, Trichome or the Purchaser shall have any further liabilities or obligations thereunder;
- (e) each Company Out-Of-The Money Warrant outstanding immediately prior to the Effective Time held by a Company Warrantholder shall be exchanged for a Replacement Warrant to acquire from the Purchaser, the number of Purchaser Shares equal to the product of: (A) the number of Company Shares subject to such Company Out-Of-The Money Warrant immediately prior to the Effective Time; multiplied by (B) the Exchange Ratio, provided that, if the foregoing would result in the issuance of a fraction of a Purchaser Share on any particular exercise of Replacement Warrant by a Company Warrantholder, then the number of Purchaser Shares otherwise issued shall be rounded down to the nearest whole number of Purchaser Shares, and:
- (i) the exercise price per Purchaser Share subject to a Replacement Warrant shall be an amount equal to the product of: (A) the exercise price per Company Share subject to each such Company Out-Of-The Money Warrant immediately before the Effective Time; divided by (B) the Exchange Ratio, rounded up to the nearest whole cent;
  - (ii) each such Replacement Warrant shall be on the same terms as the Company Warrant it is replacing; and

- (iii) the Company Warrantholder will cease to be the holder of such Company Out-Of-The-Money Warrant, will cease to have any rights as a holder in respect of such Company Out-Of-The-Money Warrant, will be removed from the applicable register of the Company Warrants, and all agreements relating thereto will be cancelled, and none of the Company, Trichome or the Purchaser shall have any further liabilities or obligations with respect thereto;
- (f) each Company In-The-Money Warrant held by a Company Warrantholder will be surrendered to the Company and cancelled in exchange for:
  - (i) a number of Company Shares (including for greater certainty, fractional Company Shares), having a Fair Market Value equal to the aggregate In-The-Money Amount of the Company Warrantholder's Company In-The-Money Warrants, and the Company Shares will be deemed to be issued to such Company Warrantholder at an issue price equal to the Fair Market Value thereof as fully paid and non-assessable Company Shares, provided that no share certificates shall be issued with respect to such Company Shares; and
  - (ii) the Company Warrantholder will cease to be the holder of such Company In-The-Money Warrant, will cease to have any rights as a holder in respect of such Company In-The-Money Warrant, will be removed from the applicable register of the Company Warrants, and all agreements relating thereto will be cancelled, and none of the Company, Trichome or the Purchaser shall have any further liabilities or obligations with respect thereto;
- (g) each Company Exchangeable Share outstanding immediately prior to the Effective Time held by a Company Exchangeable Shareholder shall be exchanged, in accordance with the terms of the Company Exchangeable Shares, for a Company Share; and
  - (i) each Company Exchangeable Shareholder shall cease to be the holder of such Company Exchangeable Shares, will cease to have any rights as a holder in respect of such Company Exchangeable Shares;
  - (ii) the name of each such Company Exchangeable Shareholder shall be removed from the register of the Company Exchangeable Shareholders maintained by or on behalf of MYM International Brands Inc.; and
  - (iii) the Company shall be deemed to be the transferee of such Company Exchangeable Shares, free and clear of all Liens, and shall be entered in the register of Company Exchangeable Shareholders maintained by or on behalf of MYM International Brands Inc.;
- (h) each Company Share (other than Company Shares held by a Dissenting Holder in respect of which Dissent Rights have been validly exercised under Section (a)) held by a Company Shareholder shall be assigned and transferred by the Company Shareholder to the Purchaser and in consideration therefor, the Purchaser will issue, for an issue price equal to the Fair Market Value thereof, that number of fully paid Purchaser Shares equal to the Exchange Ratio; and
  - (i) each Company Shareholder shall cease to be the holder of such Company Shares, will cease to have any rights as a holder in respect of such Company Shares, other

than the right to be paid the Consideration per Company Share in accordance with this Plan of Arrangement;

- (ii) the name of each such Company Shareholder shall be removed from the register of the Company Shareholders maintained by or on behalf of the Company; and
  - (iii) the Purchaser shall be deemed to be the transferee of such Company Shares, free and clear of all Liens, and shall be entered in the register of Company Shareholders maintained by or on behalf of the Company;
- (i) the Purchaser shall sell all of the Company Shares to Trichome in exchange for ■ Trichome Shares, and
- (i) the Purchaser shall cease to be the holder of such Company Shares and will cease to have any rights as a holder in respect of such Company Shares;
  - (ii) the name of the Purchaser shall be removed from the register of the Company Shareholders maintained by or on behalf of the Company; and
  - (iii) Trichome shall be deemed to be the transferee of such Company Shares, free and clear of all Liens, and shall be entered in the register of Company Shareholders maintained by or on behalf of the Company.

## **2.5 No Fractional Purchaser Shares**

In no event shall any fractional Purchaser Shares be issued under this Plan of Arrangement. Where the aggregate number of Purchaser Shares to be issued to any Person as Consideration under this Plan of Arrangement would result in a fraction of a Purchaser Share being issuable, then the number of Purchaser Shares to be issued to such Person shall, without additional compensation, be rounded down to the nearest whole Purchaser Share.

## **2.6 U.S. Securities Laws**

Notwithstanding any provision herein to the contrary, the Purchaser and the Company agree that the Plan of Arrangement will be carried out with the intention that all Consideration Shares, all Replacement Options issued in exchange for the Company Out-Of-The Money Options, and all Replacement Warrants issued in exchange for the Company Out-Of-The Money Warrants, in connection with the Arrangement shall be exempt from registration requirements of the U.S. Securities Act of 1933, as amended, pursuant to Section 3(a)(10) thereof, and all such Consideration Shares, Replacement Options and Replacement Warrants to be issued and exchanged pursuant to the Arrangement shall not be subject to resale restrictions under the U.S. Securities Act (other than in the case of such Consideration Shares, Replacement Options and Replacement Warrants issued to any “affiliate” within the meaning of Rule 405 under the U.S. Securities Act) of the Purchaser, or person was such an “affiliate” within 90 days of the Effective Time.

## **ARTICLE 3 RIGHTS OF DISSENT**

### **3.1 Dissent Rights**

Each registered holder of Company Shares may exercise dissent rights with respect to any Company Shares held by such holder (the “**Dissent Rights**”) in connection with the Arrangement pursuant to Division 2 of

Part 8 of the BCBCA and in the manner set forth in Sections 242 to 247 of the BCBCA, as modified by the Interim Order and this Section 3.1, provided that the written notice of dissent objection to the Arrangement Resolution contemplated by Section 242(1)(a) of the BCBCA must be received by the Company not later than 5:00 p.m. two (2) Business Days immediately preceding the date of the Company Meeting (as it may be adjourned or postponed from time to time). Each Dissenting Holder that duly exercises such holder's Dissent Rights shall be deemed to have transferred the Company Shares held by such holder and in respect of which Dissent Rights have been validly exercised to the Purchaser free and clear of all Liens (other than the right to be paid fair value for such Company Shares, as set out in this Section 3.1), as provided in Section 2.4(a) and if they:

- (a) ultimately are entitled to be paid fair value for such Company Shares: (i) shall be deemed not to have participated in the transactions in Article 2 (other than Section 2.4(a)); (ii) will be entitled to be paid the fair value of such Company Shares by the Purchaser, which fair value, notwithstanding anything to the contrary contained in Section 245 of the BCBCA, shall be determined as of the close of business on the Business Day before the Arrangement Resolution was adopted; and (iii) will not be entitled to any other payment or consideration, including any payment that would be payable under the Arrangement had such holder not exercised their Dissent Rights in respect of such Company Shares; or
- (b) ultimately are not entitled, for any reason, to be paid fair value for such Company Shares, shall be deemed to have participated in the Arrangement on the same basis as a Company Shareholder that is not a Dissenting Holder and shall be entitled to receive only the Consideration contemplated by Section 2.4(f)(ii) hereof that such Dissenting Holder would have received pursuant to the Arrangement if such Dissenting Holder had not exercised its Dissent Rights.

### **3.2 Recognition of Dissenting Holders**

- (a) In no circumstances shall the Purchaser, Trichome or the Company or any other Person be required to recognize a Person exercising Dissent Rights unless such Person is the registered holder of those Company Shares in respect of which such rights are sought to be exercised.
- (b) For greater certainty, in no case shall the Purchaser, Trichome, the Company or any other Person be required to recognize Dissenting Holders as holders of Company Shares in respect of which Dissent Rights have been validly exercised after the completion of the transfer under Section 2.4(a), and the names of such Dissenting Holders shall be removed from the applicable registers of holders of Company Shares in respect of which Dissent Rights have been validly exercised at the same time as the event described in Section 2.4(a) occurs.
- (c) None of the following shall be entitled to exercise Dissent Rights: (i) Company Optionholders; (ii) Company Warranholders; (iii) Company Exchangeable Shareholders; (iv) the Company Lender; and (v) holders of Company Shares who vote or have instructed a proxyholder to vote such Company Shares in favour of the Arrangement Resolution (but only in respect of such Company Shares).



**ARTICLE 4**  
**CERTIFICATES AND PAYMENTS**

**4.1 Payment and Delivery of Consideration**

- (a) Not later than one (1) Business Day prior to the Effective Date, the Purchaser shall deposit in escrow with the Depository (the terms and conditions of such escrow to be satisfactory to the Parties, acting reasonably) sufficient Purchaser Shares to satisfy the aggregate Consideration payable to Company Shareholders (other than Company Shareholders who have validly exercised Dissent Rights and who have not withdrawn their notice of objection) pursuant to this Plan of Arrangement.
- (b) Upon surrender to the Depository for cancellation of a certificate which immediately prior to the Effective Time represented outstanding Company Shares that were transferred pursuant to Section 2.4(f)(ii), together with a duly completed and executed Letter of Transmittal, and such additional documents and instruments as the Depository may reasonably require, the applicable Company Shareholder(s) shall be entitled to receive, in exchange therefor, and the Depository shall deliver to such Person(s): a certificate(s) representing the number of Purchaser Shares to which such holder is entitled to receive under the Arrangement, which Purchaser Shares will be registered in such name or names and either (A) delivered to the address or addresses as such Company Shareholder directed in their Letter of Transmittal; or (B) made available for pick-up at the offices of the Depository in accordance with the instructions of the Company Shareholder in the Letter of Transmittal, and any certificate representing Company Shares so surrendered shall forthwith thereafter be cancelled.
- (c) Until surrendered as contemplated by this Section 4.1, each certificate that, immediately prior to the Effective Time, represented Company Shares (other than Company Shares in respect of which Dissent Rights have been validly exercised and not withdrawn) shall be deemed, after the Effective Time, to represent only the right to receive, upon such surrender, the Consideration in lieu of such certificate as contemplated in this Section 4.1, less any amounts withheld pursuant to Section 4.3. Any such certificate formerly representing Company Shares, not duly surrendered on or before the sixth (6<sup>th</sup>) anniversary of the Effective Date shall cease to represent a claim by or interest of any former Company Shareholder of any kind or nature against or in the Company, Trichome or the Purchaser. On such date, all Consideration to which such former holder was entitled shall be deemed to have been surrendered to the Purchaser and shall be delivered by the Depository to the Purchaser or as directed by the Purchaser.
- (d) Any payment made by way of cheque by the Depository pursuant to this Plan of Arrangement that has not been deposited or has been returned to the Depository or that otherwise remains unclaimed, in each case, on or before the sixth (6<sup>th</sup>) anniversary of the Effective Time, and any right or claim to payment hereunder that remains outstanding on the second anniversary of the Effective Time, shall cease to represent a right or claim of any kind or nature and the right of the holder to receive the Consideration pursuant to this Plan of Arrangement shall terminate and be deemed to be surrendered and forfeited to the Purchaser for no consideration.

## **4.2 Lost Certificates**

In the event any certificate which, immediately prior to the Effective Time, represented one or more outstanding Company Shares that were transferred pursuant to Section 2.4 shall have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the Person claiming such certificate to be lost, stolen or destroyed, the Depositary will issue in exchange for such lost, stolen or destroyed certificate, the Consideration that such Company Shareholder has the right to receive in accordance with Section 2.4. When authorizing such exchange for any lost, stolen or destroyed certificate, the Person to whom such Consideration is to be delivered shall, if as a condition precedent to the delivery of such Consideration, give a bond satisfactory to the Purchaser and the Depositary (each acting reasonably) in such sum as the Purchaser may direct (acting reasonably), or otherwise indemnify the Purchaser and the Company in a manner satisfactory to the Purchaser (acting reasonably) against any claim that may be made against the Purchaser and the Company with respect to the certificate alleged to have been lost, stolen or destroyed.

## **4.3 Withholding Taxes**

The Purchaser, the Company or the Depositary, as applicable, shall be entitled to deduct and withhold from any amount payable to any Person under the Plan of Arrangement (including, without limitation, any amounts payable pursuant to Section 3.1), such amounts as the Purchaser, the Company or the Depositary, is required to deduct and withhold with respect to such payment under the Tax Act, or any provision of any other Law. To the extent that amounts are so withheld, such withheld amounts shall be treated for all purposes hereof as having been paid to the Person in respect of which such withholding was made, provided that such amounts are actually remitted to the appropriate Governmental Entity. Each of the Purchaser, the Company and the Depositary shall be permitted to sell or otherwise dispose of, on behalf of any Person, such portion of the Purchaser Shares or any other consideration deliverable under the Arrangement to such Person as is necessary to provide sufficient funds to enable the Purchaser, the Company or the Depositary to deduct, withhold or remit any amount for purposes of this Section 4.3 and the Purchaser, the Company or the Depositary, as the case may be, shall notify the applicable Person of the details of such disposition, including the gross and net proceeds and any adjustments thereto, and shall remit any unapplied balance of the net proceeds of such sale or other disposition to the Person.

## **4.4 No Liens**

Any exchange or transfer of securities pursuant to this Plan of Arrangement shall be free and clear of any Liens or other claims of third parties of any kind.

# **ARTICLE 5 AMENDMENTS**

## **5.1 Amendments to Plan of Arrangement**

- (a) The Company and the Purchaser may amend, modify and/or supplement this Plan of Arrangement at any time and from time to time prior to the Effective Time, provided that each such amendment, modification and/or supplement must: (i) be set out in writing; (ii) be approved by the Purchaser and the Company (subject to the Arrangement Agreement), each acting reasonably; (iii) filed with the Court and, if made following the Company Meeting, approved by the Court; and (iv) communicated to Company Shareholders if and as required by the Court.
- (b) Any amendment, modification or supplement to this Plan of Arrangement may be proposed by the Company or the Purchaser at any time prior to the Company Meeting (provided that

the Purchaser or the Company (subject to the Arrangement Agreement), as applicable, shall have consented thereto), with or without any other prior notice or communication, and if so proposed and accepted by the Persons voting at the Company Meeting (other than as may be required under the Interim Order), shall become part of this Plan of Arrangement for all purposes.

- (c) Any amendment, modification or supplement to this Plan of Arrangement that is approved or directed by the Court following the Company Meeting shall be effective only if: (i) it is consented to in writing by each of the Company and the Purchaser (in each case, acting reasonably); and (ii) if required by the Court, it is consented to by some or all of the Company Shareholders voting in the manner directed by the Court.
- (d) Any amendment, modification or supplement to this Plan of Arrangement may be made with the mutual agreement of the Company and the Purchasers prior to the Effective Date or following the Effective Date unilaterally by the Purchaser, provided in either case that it concerns a matter which, in the reasonable opinion of the Purchaser, is of an administrative nature required to better give effect to the implementation of this Plan of Arrangement and in no way is adverse to the economic interests of any of the Company Optionholders, Company Warranholders, Company Exchangeable Shareholders, and Company Shareholders and such amendments, modifications or supplements to the Plan of Arrangement need not be filed with the Court or communicated to Company Optionholders, Company Warranholders, Company Exchangeable Shareholders, and Company Shareholders unless required by the Court.

## **ARTICLE 6 FURTHER ASSURANCES**

### **6.1 Further Assurances**

Notwithstanding that the transactions and events set out in this Plan of Arrangement shall occur and shall be deemed to occur in the order set out in this Plan of Arrangement without any further act or formality, each of the Parties shall make, do and execute, or cause to be made, done and executed, all such further acts, deeds, agreements, transfers, assurances, instruments or documents as may reasonably be required by either of them in order to further document or evidence any of the transactions set out in this Plan of Arrangement.

**SCHEDULE B**  
**ARRANGEMENT RESOLUTION**

1. The arrangement (the “**Arrangement**”) under the provisions of Division 5 of Part 9 of the *Business Corporations Act* (British Columbia) (the “**BCBCA**”) involving MYM Nutraceuticals Inc. (the “**Company**”), a corporation existing pursuant to the BCBCA, and certain of its security holders, pursuant to the arrangement agreement among the Company and IM Cannabis Corp., a corporation existing pursuant to the *Business Corporations Act* (British Columbia) and dated March 31, 2021, as it may be modified, supplemented or amended from time to time in accordance with its terms (the “**Arrangement Agreement**”), as more particularly described and set forth in the management information circular of the Company dated [■], 2021 (the “**Circular**”), and all transactions contemplated thereby, are hereby authorized, approved and adopted.
2. The plan of arrangement of the Company and certain of its security holders, and implementing the Arrangement, as it has been or may be modified, supplemented or amended in accordance with the Arrangement Agreement and its terms (the “**Plan of Arrangement**”), the full text of which is set out as Appendix [■] to the Circular, is hereby authorized, approved and adopted.
3. The: (i) Arrangement Agreement and all the transactions contemplated therein; (ii) actions of the directors of the Company in approving the Arrangement and the Arrangement Agreement; and (iii) actions of the directors and officers of the Company in executing and delivering the Arrangement Agreement and any modifications, supplements or amendments thereto, and causing the performance by the Company of its obligations thereunder, are hereby ratified, confirmed and approved.
4. The Company is hereby authorized to apply for a final order from the Supreme Court of British Columbia (the “**Court**”) to approve the Arrangement on the terms set forth in the Arrangement Agreement and the Plan of Arrangement (as they may be amended, modified or supplemented and as described in the Circular).
5. Notwithstanding that this resolution has been passed (and the Arrangement adopted) by the holders of common shares of the Company (the “**Company Shareholders**”), or that the Arrangement has been approved by the Court, the directors of the Company are hereby authorized and empowered, without further notice to or approval of the Company Shareholders: (i) to amend, modify or supplement the Arrangement Agreement or the Plan of Arrangement to the extent permitted by their terms; and (ii) subject to the terms of the Arrangement Agreement, not to proceed with the Arrangement and any related transactions.
6. Any officer or director of the Company is hereby authorized and directed, for and on behalf of the Company, to execute, whether under corporate seal of the Company or otherwise, and to deliver any records, information or other documents required by the Registrar under the BCBCA in accordance with the Arrangement Agreement.
7. Any officer or director of the Company is hereby authorized and directed, for and on behalf of the Company, to execute or cause to be executed and to deliver or cause to be delivered, for filing with the Registrar under the BCBCA, and all such documents and instruments and to perform or cause to be performed all such other acts and things as, in such person’s opinion, may be necessary or desirable to give full force and effect to the foregoing resolutions and the matters authorized thereby, such determination to be conclusively evidenced by the execution and delivery of any such document or instrument or the doing of any such other act or thing.

**SCHEDULE C**  
**REPRESENTATIONS AND WARRANTIES OF THE COMPANY**

1. **Fairness Opinion and Directors' Approvals.** As of the date hereof:
  - (a) The Company Special Committee has received an oral Fairness Opinion from the Financial Advisor and it expects to receive, prior to mailing the Company Circular, the written Fairness Opinion of the Financial Advisor in each case to the effect that, as of the date of such opinion, and subject to the assumptions and limitations set out therein, the Consideration to be received by Company Shareholders in connection with the Arrangement is fair, from a financial point of view, to Company Shareholders, and such written Fairness Opinion will be included in the Company Circular;
  - (b) the Company Board has, after consultation with its financial and legal advisors, unanimously (i) determined that the Arrangement is in the best interests of the Company and is fair to the Company Shareholders; (ii) resolved to recommend to the Company Shareholders that they vote in favour of the Arrangement Resolution; and (iii) approved the Arrangement pursuant to the Plan of Arrangement and the execution and performance of this Agreement.
2. **Organization and Qualification.** The Company and each of its Subsidiaries is a corporation duly incorporated, amalgamated, continued or an entity duly created and validly existing under all applicable Laws of its jurisdiction of its incorporation, amalgamation, continuance or creation and has all necessary corporate or other power, authority and capacity to own its material property and assets as now owned and to carry on its business as it is now being conducted, except where the failure to be so authorized would not, individually or in the aggregate, have a Company Material Adverse Effect.
3. **Authority Relative to this Agreement.** The Company has all necessary corporate power, authority and capacity to enter into this Agreement and all other agreements and instruments to be executed by the Company as contemplated by this Agreement, and to perform its obligations hereunder and under such agreements and instruments. The execution and delivery of this Agreement by the Company and the performance by the Company of its obligations under this Agreement have been duly authorized by the Company Board and, except for obtaining the Required Approval, the Interim Order and the Final Order and any required approval of the CSE in the manner contemplated herein, no other corporate proceedings on its part are necessary to authorize this Agreement or the Arrangement, other than, with respect to the Company Circular and other matters relating thereto, the approval of the Company Board. This Agreement has been duly executed and delivered by the Company, and constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to the qualification that such enforceability may be limited by bankruptcy, insolvency, reorganization or other laws of general application relating to or affecting rights of creditors and that equitable remedies, including specific performance, are discretionary and may not be ordered.
4. **No Violation.** Neither the authorization, execution and delivery of this Agreement by the Company nor the completion of the transactions contemplated by this Agreement or the Arrangement, nor the performances of its obligations hereunder or thereunder, nor compliance by the Company with any of the provisions hereof or thereof will, in respect of the Company and any of its Subsidiaries, result in a violation or breach of, constitute a default (or an event which, with notice or lapse of time or both, would become a default), require any consent or approval to be obtained or notice to be given under, or give rise to any third party right of termination, cancellation, suspension,

acceleration, penalty or payment obligation or right to purchase or sale under, any provision of the following:

- (a) their respective Constatng Documents;
- (b) any Authorization or Material Contract to which the Company or any of its Subsidiaries is a party or to which any of them or any of their respective properties or assets, may be subject or by which the Company or any of its Subsidiaries is bound, other than the requirement to file a change of control form with Health Canada with respect to the Cannabis Licences and either confirmation from Health Canada that Health Canada has no objection to the Arrangement or silence from Health Canada that, in the circumstances, the Company reasonably interprets as indicating a lack of objection to the Arrangement;
- (c) result (with or without notice or the passage of time) in a violation or breach of or constitute a default under any provisions of any Laws applicable to the Company or any of its Subsidiaries or any of their respective property or assets;
- (d) cause the suspension or revocation of any Authorization currently in effect and held by the Company or any of its Subsidiaries, except to the extent that the Cannabis Licences are subject to Health Canada's discretion in view of the change of control resulting from the Arrangement;
- (e) except as disclosed in the Company Disclosure Letter, give rise to any rights of first refusal or trigger any change in control provisions under any note, bond, mortgage, indenture, Contract, licence, franchise or Authorization to which the Company or any of its Subsidiaries is a party, other than the change of control requirements with respect to the Cannabis Licences; or
- (f) result in the imposition of any Liens (other than Permitted Liens) upon any assets of the Company or the assets of any of its Subsidiaries,

except, in the case of clauses (b), (c), (d) and (f) above, for such violations, conflicts, breaches, defaults, terminations, accelerations or creations of Liens (other than Permitted Liens) which, or any consents, approvals or notices which if not given or received, would not, individually or in the aggregate, have a Company Material Adverse Effect, or significantly impede the ability of the Company to consummate the transactions contemplated by the Arrangement.

5. **Governmental Approvals.** The execution, delivery and performance by the Company of this Agreement and the consummation by the Company of the Arrangement requires no consent, waiver or approval or any action by or in respect of, or filing with, or notification to, any Governmental Entity other than: (i) the Interim Order and any approvals required by the Interim Order; (ii) the Final Order; (iii) compliance with any applicable Securities Laws and stock exchange rules and regulations; (iv) receipt of any required Regulatory Approvals; (v) filing a change of control form with Health Canada with respect to the Cannabis Licences; and (vi) any actions, filings or notifications, the absence of which would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect.

6. **Capitalization.**

- (a) The authorized share capital of the Company consists of an unlimited number of Company Shares. As of the date hereof, there are issued and outstanding 253,240,568 Company Shares.
- (b) As of the date hereof: (i) 32,145,000 Company Shares are issuable upon the exercise of Company Options, the exercise prices, expiration dates and other material terms of which (including the vesting schedules) are set forth in the Company Disclosure Letter; (ii) an aggregate of 74,088,804 Company Shares are issuable upon the exercise of Company Warrants, the exercise prices, expiration dates and other material terms of which are set forth in the Company Disclosure Letter; and (iii) an aggregate of 113,893,254 Company Shares are issuable upon the exchange of the Company Exchangeable Shares. The Company has included in the Company Data Room a true and complete copy of the Contracts, agreements, instruments, plans and debentures, as the case may be, governing the Company Convertible Securities.
- (c) Except for the Company Convertible Securities, there are no securities, options, warrants, stock appreciation rights, restricted stock units, conversion privileges, calls, entitlements or other rights, agreements, arrangements, subscriptions, rights, entitlements, understandings or commitments (pre-emptive, contingent or otherwise) of any character whatsoever to which the Company or any of its Subsidiaries is a party or by which any of the Company or any of its Subsidiaries may be bound, obligating or which may obligate the Company or any of its Subsidiaries to issue, grant, deliver, extend or enter into any such security, option, warrant, stock appreciation right, restricted stock unit, conversion privilege, capital stock, equity interest or other right, agreement, arrangement or commitment.
- (d) All outstanding Company Shares have been duly authorized and validly issued, are fully paid and non-assessable, and all Company Shares issuable upon the exercise, conversion or settlement, as the case may be, of Company Convertible Securities in accordance with their respective terms have been duly authorized for issuance and, upon issuance, will be validly issued as fully paid and non assessable, and are not and will not be subject to, or issued in violation of, any pre-emptive rights. All securities of the Company have been issued in compliance with all applicable Laws and Securities Laws.
- (e) There are no securities of the Company or any of its Subsidiaries outstanding which have the right to vote generally (or are convertible into or exchangeable for securities other than Company Shares having the right to vote generally) with the holders of the Company Shares on any matter. There are no outstanding contractual or other obligations of the Company or any Subsidiary to repurchase, redeem or otherwise acquire any of its securities or with respect to the voting or disposition of any outstanding securities of any of its Subsidiaries. There are no outstanding bonds, debentures or other evidences of indebtedness of the Company or any of its Subsidiaries having the right to vote generally with the holders of the outstanding Company Shares on any matters.
- (f) Neither the Company nor any of its Subsidiaries has any obligations, liabilities and indebtedness that would, in accordance with IFRS, be classified as debt on a balance sheet other than the Company Loan, lease obligations under IFRS 16 Leases, indebtedness incurred in the Ordinary Course and intercompany debt between the Company and its Subsidiaries.

7. **Ownership of Subsidiaries.** The Company Disclosure Letter includes complete and accurate lists of all Subsidiaries owned, directly or indirectly, by the Company, each of which is wholly-owned, except as disclosed in the Company Disclosure Letter. All of the issued and outstanding shares and other ownership interests in the Subsidiaries of the Company are duly authorized, validly issued, fully paid and, where the concept exists, non-assessable, and all such shares and other ownership interests held directly or indirectly by the Company are legally and beneficially owned free and clear of all Liens (other than Permitted Liens), and, except as disclosed in the Company Disclosure Letter, there are no outstanding options, warrants, rights, entitlements, understandings or commitments (pre-emptive, contingent or otherwise) or outstanding contractual or other obligations of the Company or any Subsidiary regarding the right to purchase or acquire, or securities convertible into or exchangeable for, any such shares or other ownership interests of any of the Subsidiaries. Other than as disclosed in the Company Disclosure Letter, there are no Contracts, commitments, understandings or restrictions which require any Subsidiaries of the Company to issue, sell or deliver any shares or other ownership interests, or any securities or obligations convertible into or exchangeable for, any shares or other ownership interests. Except for ownership of equity interests in the Subsidiaries and other than those ownership interests disclosed in the Company Disclosure Letter, the Company, does not own, directly or indirectly, any equity interests of any kind in any other Person.
8. **Reporting Status and Securities Laws Matters.** The Company is a “reporting issuer” or the equivalent and not on the list of reporting issuers in default under applicable Securities Laws of each of the provinces of Canada, except Quebec. The Company is in compliance, in all material respects, with all applicable Securities Laws and there are no current, pending or, to the knowledge of the Company, threatened proceedings before any Securities Authority or other Governmental Entity relating to any alleged non-compliance with Securities Laws. The Company Shares are listed on, and the Company is in compliance in all material respects with, the rules and policies of the CSE. No de-listing, suspension of trading in or cease trading order with respect to any securities of the Company and, to the knowledge of the Company, no inquiry or investigation (formal or informal) of any Securities Authority or the CSE is in effect or ongoing or, to the knowledge of the Company, expected to be implemented or undertaken.
9. **Company Filings.** The Company has filed all documents required to be filed by it in accordance with applicable Securities Laws with the Securities Authorities and/or the CSE. The Company has timely filed or furnished all Company Filings required to be filed or furnished by the Company with any Governmental Entity (including “documents affecting the rights of securityholders” and “material contracts” required to be filed by Part 12 of National Instrument 51-102 – *Continuous Disclosure Obligations*). Each of the Company Filings complied as filed in all material respects with applicable Securities Laws and did not, as of the date filed (or, if amended or superseded by a subsequent filing prior to the date of this Agreement, on the date of such filing), contain any Misrepresentation. The Company has not filed any confidential material change report which, at the date of this Agreement, remains confidential.
10. **Forward-Looking Information.** With respect to forward-looking information contained in the Company Filings:
  - (a) the Company had, at the time of disclosure of such forward-looking information, a reasonable basis for such forward-looking information; and
  - (b) all material forward-looking information is identified as such, and all such documents caution users of forward-looking information that actual results may vary from the forward-looking information.



11. **Financial Statements.** The consolidated annual audited financial statements of the Company as at and for the years ended May 31, 2020 and 2019 (including the notes thereto) and related management’s discussion and analysis, and the unaudited interim financial statements of the Company and related management’s discussion and analysis for the three and six months ended November 30, 2020 and 2019 (collectively, the “**Company Financial Statements**”) were prepared in accordance with IFRS consistently applied (except (a) as otherwise indicated in such financial statements and the notes thereto or, in the case of audited statements, in the related report of the Company’s independent auditors, or (b) in the case of unaudited interim statements, are subject to normal period-end adjustments and may omit notes which are not required by applicable Laws in the unaudited statements) and present fairly, in all material respects, the consolidated financial position, financial performance and cash flows of the Company for the dates and periods indicated therein (subject, in the case of any unaudited interim financial statements, to normal period-end adjustments) and reflect reserves required by IFRS in respect of all material contingent liabilities, if any, of the Company on a consolidated basis. There has been no material change in the Company’s accounting policies, except as described in the Company Financial Statements, since May 31, 2020.
12. **Books and Records; Disclosure.** The financial books, records and accounts of the Company and its Subsidiaries, in all material respects: (i) have been maintained in accordance with applicable Law and IFRS on a basis consistent with prior years; (ii) are stated in reasonable detail and accurately and fairly reflect the material transactions, acquisitions and dispositions of the assets of the Company and its Subsidiaries; and (iii) accurately and fairly reflect the basis for the Company Financial Statements.
13. **Independent Auditors.** The Company’s current auditors are independent with respect to the Company within the meaning of the rules of professional conduct applicable to auditors in Canada and there has never been a “reportable event” (within the meaning of National Instrument 51-102 – *Continuous Disclosure Obligations*) with the current or, to the best knowledge of the Company, any predecessor auditors of the Company during the last three years.
14. **Minute Books.** The corporate minute books of the Company and its Subsidiaries contain minutes of all meetings and resolutions of its boards of directors and committees of its board of directors (other than those portions of minutes of meetings reflecting discussions of the Arrangement) and shareholders, held according to applicable Laws and are complete and accurate in all material respects.
15. **No Undisclosed Liabilities.** The Company and its Subsidiaries have no outstanding indebtedness, liabilities or obligations, whether accrued, absolute, contingent or otherwise, and are not party to or bound by any suretyship, guarantee, indemnification or assumption agreement, or endorsement of, or any other similar commitment with respect to the obligations, liabilities or indebtedness of any Person, other than those specifically identified in the Company Financial Statements, which relate to the proposed Arrangement or incurred in the Ordinary Course and which are not material since the date of the most recent Company Financial Statements.
16. **No Material Change.** Except as disclosed in the public disclosure record of the Company and except for the Arrangement or any action taken in accordance with this Agreement, since May 31, 2020:
  - (a) the Company and each of its Subsidiaries has conducted its business only in the Ordinary Course;

- (b) there has not occurred any event, occurrence or development or a state of circumstances or facts which has had or would, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect;
  - (c) except as set out in the Company Disclosure Letter, there has not been any acquisition or sale by the Company or its Subsidiaries of any material property or assets;
  - (d) there has not been any incurrence, assumption or guarantee by the Company or its Subsidiaries of any material debt for borrowed money, any creation or assumption by the Company or its Subsidiaries of any Lien (other than a Permitted Lien) or any making by the Company or its Subsidiaries of any material loan, advance or capital contribution to or investment in any other Person;
  - (e) there has been no dividend or distribution of any kind declared, paid or made by the Company or any Company Shares;
  - (f) the Company has not effected or passed any resolution to approve a split, consolidation or reclassification of any of the outstanding Company Shares;
  - (g) except as disclosed in the Company Disclosure Letter, there has not been any material increase in or material modification of the compensation payable to or to become payable by the Company or its Subsidiaries to any of their respective directors, officers or employees or any grant to any such Persons of any increase in severance or change in control entitlements; and
  - (h) the Company has not removed any auditor or director or terminated any senior officer.
17. **Litigation.** There is no claim, action, suit, grievance, complaint, proceeding, arbitration, charge, audit, indictment or investigation that is pending or has been commenced or, to the knowledge of the Company, is threatened affecting the Company or its Subsidiaries or affecting any of their property or assets (whether owned or leased) at law or in equity, which would reasonably be expected to cause, individually or in the aggregate, a Company Material Adverse Effect, or would significantly impede the ability of the Company to consummate the Arrangement. Neither the Company, its Subsidiaries nor any of their respective assets or properties is subject to any outstanding judgment, order, writ, injunction or decree material to the Company and its Subsidiaries on a consolidated basis.
18. **Taxes.**
- (a) The Company and each of its Subsidiaries has duly and timely filed all material Tax Returns required to be filed prior to the date hereof with the appropriate Governmental Entities and all such Tax Returns are true and correct in all material respects.
  - (b) Except as disclosed in the Company Disclosure Letter, the Company and each of its Subsidiaries has duly and timely paid all material Taxes, including all instalments on account of Taxes for the current year that are due and payable by it whether or not assessed by the appropriate Governmental Entity.
  - (c) The Company and each of its Subsidiaries has duly and timely collected all material amount of all Taxes required to be collected and has duly and timely paid and remitted the same to the appropriate Governmental Entity.

- (d) There are no material proceedings, investigations, audits or claims now pending against the Company or its Subsidiaries in respect of any Taxes and no Governmental Entity has asserted in writing, or to the knowledge of the Company, has threatened to assert against the Company or its Subsidiaries any deficiency or claim for Taxes or interest thereon or penalties in connection therewith.
  - (e) There are no outstanding agreements, arrangements, waivers or objections extending the statutory period or providing for an extension of time with respect to the assessment or reassessment of Taxes or the filing of any Tax Return by, or any payment of Taxes by, the Company or any of its Subsidiaries.
  - (f) To the knowledge of the Company, there are no material Liens for Taxes upon any property or assets of the Company and its Subsidiaries (whether owned or leased), except Liens for current Taxes not yet due.
  - (g) Neither the Company nor any of its Subsidiaries are a party to any agreement, understanding or arrangement relating to allocating or sharing any material amount of Taxes.
  - (h) Except as set forth in the Company Disclosure Letter, the Company and each of its Subsidiaries has duly and timely withheld from any amount paid or credited by it to or for the account or benefit of any Person, including any employees and any non-resident Person, the amount of all material Taxes and other deductions required by any Laws to be withheld from any such amount and has duly and timely remitted the same to the appropriate Governmental Entity.
  - (i) The Company is a “taxable Canadian corporation” for the purposes of the Tax Act.
  - (j) All tax credits, refunds, rebates, overpayments and similar adjustments of Taxes claimed by the Company each of its Subsidiaries have been validly claimed and correctly calculated as required by applicable Laws, and each such entity has retained all documentation prescribed by applicable Laws and in accordance with applicable Laws to support such claims.
19. **Privacy Protection.** To its knowledge, the Company and its Subsidiaries have complied, in all material respects, with all applicable privacy legislation and neither has collected, received, stored, disclosed, transferred, used, misused or permitted unauthorized access to any information protected by privacy Laws. The Company and its Subsidiaries limit the collection, use, disclosure and processing of personal information to the scope of the consent collected and/or the contractual agreements in place governing the collection, use or disclosure of such personal information.
20. **Property.**
- (a) The Company Disclosure Letter includes a complete and accurate list of all real property owned by the Company or its Subsidiaries (“**Company Owned Properties**”).
  - (b) The Company or one its Subsidiaries have good and marketable title in fee simple to all Company Owned Properties free of any Liens other than Permitted Liens; none of the Company or any of its Subsidiaries is the owner of, or subject to any agreement or option to own any real or immovable property or any interest in real or immovable property, other than the Company Owned Properties; and none of the Company or any of its Subsidiaries

has received written notice that any of the Company Owner Properties is subject to any decree of or order by a Governmental Entity to be sold or is being condemned, expropriated or otherwise taken by any public authority, nor to the knowledge of the Company has any such condemnation, expropriation or taking been proposed.

- (c) Other than as set out in the Company Disclosure Letter, neither the Company nor any of its Subsidiaries is party to, or bound by, any agreement to sell, transfer or acquire any interest in any real property.
  - (d) Each property currently leased or subleased by the Company or its Subsidiaries from a third party (collectively, the “**Company Leased Properties**”) is listed in the Company Disclosure Letter, identifying the documents under which such leasehold interests are held (collectively, the “**Company Lease Documents**”). The Company or its Subsidiaries, as applicable, holds good and valid leasehold interests in the Company Leased Properties, free and clear of all Liens other than Permitted Liens. Each of the Company Lease Documents is valid, binding and in full force and effect as against the Company and its Subsidiaries, as applicable, and, to the knowledge of the Company, as against the other parties thereto. To the knowledge of the Company, and except as disclosed in the Company Disclosure Letter, neither the Company, its Subsidiaries nor any of the other parties to the Company Lease Documents, is in material breach or violation or default (in each case, with or without notice or lapse of time or both) under any of the Company Lease Documents which breach, violation or default has not been cured, and the Company and its Subsidiaries has not received or given any notice of default under any such agreement which remains uncured.
  - (e) To the knowledge of the Company, the Company and each of its Subsidiaries, as applicable, has good and valid title to, or a valid and enforceable leasehold interest in, all of its and their respective other material assets and property not listed above in paragraph (d) and the Company’s and the Subsidiaries’ ownership of or leasehold interest in any such property is not subject to any Liens, except for Permitted Liens.
  - (f) The Company Leased Properties are adequately serviced by utilities (or well water with adequate septic systems, if any) having adequate capacities for the normal operations of the Company’s and its Subsidiaries’ facilities.
21. **Sufficiency of Assets.** The Company and its Subsidiaries have valid, good and marketable title to all material personal property owned by them and principally used in respect of the Company Business, free and clear of all Liens other than Permitted Liens. The assets and property owned, leased or licensed by the Company and its Subsidiaries are sufficient, in all material respects, for conducting the business, as currently conducted, of the Company.
22. **Rights of Other Persons.** Except as set forth in the Company Disclosure Letter, no Person has any right of first refusal or option to purchase or any other right of participation in any of the material properties or assets owned by the Company or any of its Subsidiaries, or any part thereof.
23. **No Voting Control.** Except as disclosed in the Company Disclosure Letter, neither the Company nor any of its Subsidiaries is party to any agreement nor, to the knowledge of the Company, is there any agreement (other than the voting and support agreements entered into with respect to this Agreement), which in any manner affects the voting control of any securities of the Company or any of its Subsidiaries.

24. **Material Contracts.**

- (a) The Company Disclosure Letter lists or identifies all Material Contracts and the Company has made available to the Purchaser for inspection in the Company Data Room true and complete copies of all Material Contracts.
- (b) All of the Material Contracts are in full force and effect, and to the knowledge of the Company, the Company or one of its Subsidiaries is entitled to all rights and benefits thereunder in accordance with the terms thereof. The Company or its applicable Subsidiaries has not waived any rights under a Material Contract and except as disclosed in the Company Disclosure Letter, the Company is not aware of any material default or breach existing in respect thereof on the part of the Company or its applicable Subsidiaries or, to the knowledge of the Company, on the part of any other party thereto, and no event has occurred which, after the giving of notice or the lapse of time or both, would constitute such a default or breach or trigger a right of termination of any such Material Contracts.
- (c) All of the Material Contracts are valid and binding obligations of the Company or one of its Subsidiaries, as the case may be, enforceable in accordance with their respective terms, except as may be limited by bankruptcy, insolvency and other Laws affecting the enforcement of creditors' rights generally and subject to the qualification that equitable remedies may only be granted in the discretion of a court of competent jurisdiction.
- (d) As at the date hereof, except as set forth in the Company Disclosure Letter, neither the Company nor any of its Subsidiaries has received written notice that any part to a Material Contract intends to cancel, terminate or otherwise modify or not renew such Material Contract, and to the knowledge of the Company, no such action has been threatened.
- (e) Neither the entering into of this Agreement, nor the consummation of the Arrangement, will trigger any change of control or similar provisions in any of the Material Contracts except as to be disclosed in the manner set out in the Company Disclosure Letter.

25. **Authorizations.**

- (a) The Company Disclosure Letter sets forth all material Authorizations necessary for the conduct of the Company Business.
- (b) The Company and its Subsidiaries have obtained and are in material compliance with all material Authorizations required by applicable Laws, necessary to conduct their current business as now being conducted.
- (c) All material Authorizations for the Company and its Subsidiaries are in full force and effect and, to the knowledge of the Company, no suspension or cancellation thereof has been threatened or is contemplated.
- (d) No material Authorizations of the Company or any of its Subsidiaries will be materially affected by, or terminate or lapse by reason of, the transactions contemplated by this Agreement or any of the other agreements contemplated hereunder or executed herewith, except to the extent that the Company's Cannabis Licences are subject to Health Canada's discretion in view of the change of control resulting from the transactions contemplated by the Arrangement.

- (e) To the knowledge of the Company, there are no facts, events or circumstances that would reasonably be expected to result in a failure to obtain or failure to be in compliance with such Authorizations as are necessary to conduct the business of the Company and its Subsidiaries as it is currently being conducted.

26. **Environmental Matters.** In respect of the properties on which the Company or any Subsidiary operates a cannabis cultivation business, and to the knowledge of the Company in respect of properties on which neither the Company nor any Subsidiary operates a cannabis cultivation business, and except to the extent that any offence or breach or other matter referred to in this Section 26 does not, and would not reasonably be expected to, have a Company Material Adverse Effect:

- (a) The Company and each of its Subsidiaries have, in all respects, carried on its businesses and operations in compliance with all applicable Environmental Laws.
- (b) Neither the Company nor any of its Subsidiaries have received any order, request or written notice from any Person either alleging a violation of any Environmental Law or requiring that the Company or any of its Subsidiaries carry out work, incur any costs or assume any liabilities, related to a material violation of Environmental Laws or to any agreements with any Governmental Entity with respect to or pursuant to Environmental Laws.
- (c) To the knowledge of the Company, there are no hazardous substances or other conditions that could reasonably be expected to result in liability of or adversely affect the Company or any of its Subsidiaries under or related to any Environmental Law on, at, in, under or from any of the Company Leased Properties (including the workplace environment) currently or, to the knowledge of the Company, previously owned, leased or operated by the Company or any of its Subsidiaries.
- (d) There are no pending claims or, to the knowledge of the Company, threatened claims, against the Company or any of its Subsidiaries arising out of any Environmental Laws.

27. **Compliance with Laws.**

- (a) The Company and each of its Subsidiaries has complied with and is not in violation, in any material respect, of any applicable Laws.
- (b) Neither the Company nor any of its Subsidiaries have received any written notices or other written correspondence from any Governmental Entity (i) regarding any violation (or any investigation, inspection, audit, or other proceeding by any Governmental Entity involving allegations of any violation) of any Law (other than Environmental Laws) or (ii) of any circumstances that may have existed or currently exist which could lead to a loss, suspension, or modification of, or a refusal to issue or re-issue, any material Authorization other than where such correspondence would not reasonably be expected to have a Company Material Adverse Effect or significantly impact the ability of the Company to consummate the Arrangement. To the knowledge of the Company, no material investigation, inspection, audit or other proceeding by any Governmental Entity involving allegations of any material violation of any Law (other than Environmental Laws) is threatened or contemplated.
- (c) Neither the Company, its Subsidiaries nor, to the knowledge of the Company, any of their respective directors, executives, representatives, agents or employees: (i) has used or is

using any corporate funds for any illegal contributions, gifts, entertainment or other expenses relating to political activity that would be illegal; (ii) has used or is using any corporate funds for any direct or indirect illegal payments to any foreign or domestic governmental officials or employees; (iii) has violated or is violating any provision of the United States Foreign Corrupt Practices Act of 1977, the *Corruption of Foreign Public Officials Act* (Canada) or any similar Laws of other jurisdictions; (iv) has established or maintained, or is maintaining, any illegal fund of corporate monies or other properties; or (v) has made any bribe, illegal rebate, illegal payoff, influence payment, kickback or other illegal payment of any nature.

- (d) The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the “**Money Laundering Laws**”) and no action, suit or proceeding by or before any Governmental Entity or any arbitrator non Governmental Entity involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.
- (e) None of the Company or any of its Subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee or affiliate of the Company or any of its Subsidiaries, has had any sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department, the Government of Canada or any other relevant sanctions authority (collectively, “**Sanctions**”) imposed upon any such Person, and the Company and its Subsidiaries are not in violation of any of the Sanctions or Law or executive order relating thereto, or are conducting business with any person subject to any Sanctions.

28. **United States Operations.** Neither the Company nor any of its Subsidiaries conducts cannabis or cannabis-related operations or holds interests in cannabis or cannabis-related operations in the United States (including, without limiting the generality of the foregoing, employees, facilities, royalty entitlements or investments in a United States-based cannabis business), or sells or distributes cannabis into or within the United States.

29. **United States Securities Law Matters.**

- (a) The Company does not have, nor is it required to have, any class of securities registered pursuant to Section 12(b) or 12(g) of the U.S. Exchange Act, nor is the Company subject to any reporting obligation (whether active or suspended) pursuant to Section 15(d) of the U.S. Exchange Act; and
- (b) The Company is not an investment company registered or required to be registered under the U.S. Investment Company Act of 1940, as amended, and is a “foreign private issuer” (as such term is defined in Rule 3b-4 under the U.S. Exchange Act).

30. **Employment & Labour Matters.**

- (a) The Company Disclosure Letter sets forth a complete list of all employees of the Company and its Subsidiaries, together with their titles, service dates, current salaries or hourly rate of pay, and bonus targets, as of the date of this Agreement. No such employee is on long-term disability leave, extended absence or worker’s compensation leave as of the date of this Agreement. All current assessments under applicable workers compensation

legislation in relation to the employees listed in the Company Disclosure Letter have been paid or accrued by the Company and its Subsidiaries, as applicable, and the Company and its Subsidiaries are not subject to any material special or penalty assessment under such legislation which has not been paid.

- (b) Except for those written employment contracts with employees of the Company and any of its Subsidiaries identified in the Company Disclosure Letter (true and complete copies of which have been made available in the Company Data Room), there are no written employment contracts entered into with any such employees, for clarity, written employment contracts do not include employee handbooks, benefit plan documents or similar contracts. Except for those agreements or provision described in the Company Disclosure Letter, no employee of the Company or any of its Subsidiaries is party to a change of control, golden parachute, or similar agreement or provision or would receive payments under such agreement or provision as a result of the Arrangement.
- (c) Neither the Company nor any Subsidiary is party to any collective bargaining agreement, Contract or legally binding commitment to any trade unions or employee organization or group. To the knowledge of the Company, there are no threatened or apparent union organizing activities involving employees of the Company or any of its Subsidiaries. Neither the Company or any of its Subsidiaries are currently negotiating any collective bargaining agreements.
- (d) The Company Disclosure Letter sets forth a complete list of the agreements with individuals as they relate to the operations of the Company Business between the Company or any of its Subsidiaries and providing for payment by the Company or any of its Subsidiaries of amounts not less than \$100,000 in the preceding 12 months (true and complete copies of which have been made available in the Company Data Room other than for those individuals for which no written agreements exist). To the knowledge of the Company, there are no material claims or proceedings or threatened material claims or proceedings of any kind from any such contractors.

### 31. **Intellectual Property.**

- (a) To the knowledge of the Company, the Company and its Subsidiaries own all right, title and interest in and to, or is validly licensed (and are not in material breach of such Intellectual Property licences), all Intellectual Property that is material to the conduct of the business, as currently conducted, of the Company and its Subsidiaries (collectively, the “**Company Intellectual Property Rights**”). All such Company Intellectual Property Rights are sufficient, in all material respects, for conducting the business, as currently conducted, of the Company and its Subsidiaries and, to the knowledge of the Company, all such Company Intellectual Property Rights are valid and enforceable (subject to the effects of bankruptcy, insolvency, reorganization, moratorium or Laws relating to or affecting creditors’ rights generally). To the knowledge of the Company, the operation of the Company Business, including the manufacture, marketing, use, and sale of the products and services of the Company and its Subsidiaries, and the use and exploitation of the Company Intellectual Property Rights do not infringe upon, misappropriate, or otherwise violate the Intellectual Property rights of any third party. To the knowledge of the Company, no third party is infringing upon, misappropriating, or otherwise violating Company Intellectual Property Rights.



- (b) The Company Disclosure Letter sets forth an accurate and complete list of all registered or applied for trademarks, trade names, service marks, domain names, patents and copyrights owned or purported to be owned by the Company and its Subsidiaries.
- (c) The Company and its Subsidiaries have taken commercially reasonable steps to maintain their rights to the Company Intellectual Property Rights and to protect and preserve the confidentiality of, and their exclusive right to use, all of their trade secrets and material confidential information and know-how and, to the knowledge of the Company, no such trade secrets, information or know-how have been improperly used or accessed by, or disclosed (other than under obligations of confidentiality) to any other Person.
32. **Related Party Transactions.** With the exception of employment and consulting or independent contractor agreements contained in the Company Data Room and except as set forth in the Company Disclosure Letter, there are no Contracts or other transactions currently in place between the Company or any of its Subsidiaries, on the one hand, and: (i) any officer or director of the Company or any of its Subsidiaries; or (ii) any holder of record or beneficial owner of 10% or more of the Company Shares; or (iii) any affiliate or associate of the foregoing.
33. **Brokers.** Other than as disclosed in the Company Disclosure Letter, no broker, investment banker, financial advisor or other Person is entitled to any broker's finder's, financial advisor's or other similar fee or commission in connection with the transactions contemplated hereby based upon arrangements made by or on behalf of the Company or any of its Subsidiaries.
34. **Insurance.** As of the date hereof, the Company and each of its Subsidiaries have such policies of insurance as are included in the Company Data Room. All insurance maintained by the Company and its Subsidiaries is in full force and effect and in good standing and is in amounts and in respect of such risks as are normal and usual for companies of similar size operating in the cannabis industry. The Company Disclosure Letter sets forth and describes all material pending claims under any insurance policies.
35. **No Shareholder Rights Plan.** As of the date hereof, there is no shareholder rights plan, "poison pill", anti-takeover plan or similar device in effect to which the Company or any of its Subsidiaries is subject, party or otherwise bound.
36. **Collateral Benefit.** To the knowledge of the Company, except as disclosed in the Company Disclosure Letter, no related party of the Company (within the meaning of MI 61-101) together with its associated entities, beneficially owns or exercises control or direction over 1% or more of the outstanding Company Shares, except for related parties who will not receive a "collateral benefit" (within the meaning of MI 61-101) as a consequence of the Arrangement and the transactions contemplated herein.
37. **Arrangements with Shareholders.** Other than the Support and Voting Agreements and this Agreement, the Company does not have any agreement, arrangement or understanding (whether written or oral) with respect to the Purchaser or any of its securities, businesses or operations with any shareholder of the Purchaser, any interested party of the Purchaser or any related party of any interested party of the Purchaser, or any joint actor with any such purposes (and for this purpose, the terms "interested party", "related party" and "joint actor" shall have the meaning ascribed to such terms in MI 61-101).
38. **Competition Act.** For purposes of Part IX of the *Competition Act* (Canada), neither the aggregate value of the Company's and its Subsidiaries' assets, nor the gross revenues from sales in or from

Canada generated from such assets, in each case as determined in accordance with the *Competition Act* (Canada) and the regulations promulgated thereunder, exceeds \$93,000,000.

**SCHEDULE D**  
**REPRESENTATIONS AND WARRANTIES OF THE PURCHASER**

1. **Organization and Qualification.** The Purchaser and its Subsidiaries and Focus are corporations or companies duly formed and validly existing under the Laws of their respective jurisdictions of formation and have all necessary corporate or other power, authority and capacity to own their material property and assets as now owned and to carry on their business as they are now being conducted, except where the failure to be so authorized would not, individually or in the aggregate, have a Purchaser Material Adverse Effect.
2. **Authority Relative to this Agreement.** The Purchaser has all necessary corporate power, authority and capacity to enter into this Agreement and all other agreements and instruments to be executed by the Purchaser as contemplated by this Agreement, and to perform its obligations hereunder and under such agreements and instruments. The execution and delivery of this Agreement by the Purchaser and the performance by the Purchaser of its obligations under this Agreement have been duly authorized by the Purchaser Board and except for obtaining the Required Approval, the Interim Order and the Final Order and any required approval of the CSE or Nasdaq in the manner contemplated herein, no other corporate proceedings on its part are necessary to authorize this Agreement, the Arrangement or the issuance of the Consideration Shares. This Agreement has been duly executed and delivered by the Purchaser, and constitutes a legal, valid and binding obligation of the Purchaser, enforceable against the Purchaser in accordance with its terms, subject to the qualification that such enforceability may be limited by bankruptcy, insolvency, reorganization or other laws of general application relating to or affecting rights of creditors and that equitable remedies, including specific performance, are discretionary and may not be ordered.
3. **No Violation.** Neither the authorization, execution and delivery of this Agreement by the Purchaser nor the completion of the transactions contemplated by this Agreement or the Arrangement, nor the performances of its obligations hereunder or thereunder, nor compliance by the Purchaser with any of the provisions hereof or thereof will, in respect of the Purchaser or its Subsidiaries or Focus, result in a violation or breach of, constitute a default (or an event which, with notice or lapse of time or both, would become a default), require any consent or approval to be obtained or notice to be given under, or give rise to any third party right of termination, cancellation, suspension, acceleration, penalty or payment obligation or right to purchase or sale under, any provision of the following:
  - (a) their Constatng Documents;
  - (b) any Authorization or Contract material to the Purchaser to which the Purchaser, any of its Subsidiaries or Focus is a party or to which any of their properties or assets are bound;
  - (c) result (with or without notice or the passage of time) in a violation or breach of or constitute a default under any provisions of any Laws applicable to the Purchaser, any of its Subsidiaries or Focus or their property or assets; or
  - (d) result in the imposition of any Liens (other than Permitted Liens) upon any assets of the Purchaser or the assets of any of its Subsidiaries;

except, in the case of clauses (b) and (c) above, for such violations, conflicts, breaches, defaults, terminations, accelerations which, or any consents, approvals or notices which if not given or received, would not, individually or in the aggregate, have a Purchaser Material Adverse Effect, or

significantly impede the ability of the Purchaser to consummate the transactions contemplated by the Arrangement.

4. **Governmental Approvals.** The execution, delivery and performance by the Purchaser of this Agreement and the consummation by the Purchaser of the Arrangement requires no consent, waiver or approval or any action by or in respect of, or filing with, or notification to, any Governmental Entity other than: (i) the Interim Order and any approvals required by the Interim Order; (ii) the Final Order; (iii) compliance with any applicable Securities Laws and stock exchange rules and regulations; (iv) receipt of any required Regulatory Approvals; and (v) any actions, filings or notifications, the absence of which would not reasonably be expected to have, individually or in the aggregate, a Purchaser Material Adverse Effect.
5. **Capitalization.**
  - (a) The authorized share structure of the Purchaser consists of an unlimited number of Purchaser Shares without par value. As of the date hereof, there are issued and outstanding 50,498,009 Purchaser Shares.
  - (b) (i) the issued share capital of Adjupharm GmbH, a Subsidiary of the Purchaser, is comprised of 25,000 common shares of which the Purchaser owns 23,125 common shares; (ii) the issued share capital of Focus is comprised of 4,865 common shares, of which the Purchaser owns nil common shares; (iii) the issued share capital of Trichome is comprised of 41,202,583 common shares, of which the Purchaser owns 41,202,583 common shares; and (iv) the issued share capital of Trichome JWC Acquisition Corp. is comprised of 7,616,442 common shares, of which Trichome owns 7,616,442 common shares.
  - (c) Except for (i) outstanding stock options exercisable for an aggregate of up to 3,582,389 Purchaser Shares (assuming vesting of all options); (ii) outstanding Purchaser Share purchase warrants to purchase up to an aggregate of 2,339,125 Purchaser Shares; and (iii) compensation options exercisable for an aggregate of up to 252,905 Purchaser Shares, there are no securities, options, warrants, stock appreciation rights, restricted stock units, conversion privileges, calls, entitlements or other rights, agreements, arrangements, subscriptions, rights, entitlements, understandings or commitments (pre-emptive, contingent or otherwise) of any character whatsoever to which the Purchaser or any of its Subsidiaries or Focus is a party or by which any of the Purchaser or any of its Subsidiaries or Focus may be bound, obligating or which may obligate the Purchaser or any of its Subsidiaries or Focus to issue, grant, deliver, extend or enter into any such security, option, warrant, stock appreciation right, restricted stock unit, conversion privilege, capital stock, equity interest or other right, agreement, arrangement or commitment.
  - (d) All outstanding Purchaser Shares and all shares of all of the Purchaser's Subsidiaries and Focus have been duly authorized and validly issued, are fully paid and non-assessable, and all Purchaser Shares and all shares of all of the Purchaser's Subsidiaries and Focus issuable upon the exercise, conversion or settlement, as the case may be, of convertible securities of the Purchaser, any of its Subsidiaries or Focus in accordance with their respective terms have been duly authorized for issuance and, upon issuance, will be validly issued as fully paid and non-assessable shares, and are not and will not be subject to, or issued in violation of, any pre-emptive rights. All securities of the Purchaser, all of the Purchaser's Subsidiaries and Focus have been issued in compliance with all applicable Laws and Securities Laws.

- (e) There are no securities of the Purchaser or any of its Subsidiaries outstanding which have the right to vote generally (or are convertible into or exchangeable for securities having the right to vote generally) with the holders of the Purchaser Shares on any matter. There are no outstanding contractual or other obligations of the Purchaser or any Subsidiary to repurchase, redeem or otherwise acquire any of its securities or with respect to the voting or disposition of any outstanding securities of any of its Subsidiaries. There are no outstanding bonds, debentures or other evidences of indebtedness of the Purchaser or any of its Subsidiaries having the right to vote generally with the holders of the outstanding Purchaser Shares on any matters.
6. **Consideration Shares.** The Consideration Shares to be issued pursuant to the Arrangement (and Purchaser Shares to be issued pursuant to Replacement Options and Replacement Warrants) have been duly authorized and reserved for issuance and, upon issuance, will be validly issued as fully paid and non-assessable shares in the capital of the Purchaser, will not have been issued in violation of any pre-emptive rights or contractual rights to purchase securities, and, subject to compliance by the Company with its obligations pursuant to this Agreement, will not be subject to any statutory hold or restricted period under applicable Securities Laws other than in respect of “control persons” and “affiliates” and the Purchaser Shares will be listed for trading on the CSE and Nasdaq.
7. **Ownership of Subsidiaries.** The Purchaser Disclosure Letter includes complete and accurate lists of all Subsidiaries owned, directly or indirectly, by the Purchaser and the ownership percentage thereof. All of the issued and outstanding shares and other ownership interests in the Subsidiaries of the Purchaser are duly authorized, validly issued, fully paid and, where the concept exists, non-assessable, and all such shares and other ownership interests held directly or indirectly by the Purchaser are legally and beneficially owned free and clear of all Liens (other than Permitted Liens), and, except as disclosed in the Purchaser Disclosure Letter, there are no outstanding options, warrants, rights, entitlements, understandings or commitments (pre-emptive, contingent or otherwise) or outstanding contractual or other obligations of the Purchaser or any Subsidiary regarding the right to purchase or acquire, or securities convertible into or exchangeable for, any such shares or other ownership interests of any of the Subsidiaries. Other than as disclosed in the Purchaser Disclosure Letter, there are no Contracts, commitments, understandings or restrictions which require any Subsidiaries of the Company to issue, sell or deliver any shares or other ownership interests, or any securities or obligations convertible into or exchangeable for, any shares or other ownership interests. Except for ownership of equity interests in the Subsidiaries and other than those ownership interests disclosed in the Purchaser Disclosure Letter, the Purchaser, does not own, directly or indirectly, any equity interests of any kind in any other Person.
8. **Reporting Status and Securities Laws Matters.** The Purchaser is a “reporting issuer” or the equivalent and not on the list of reporting issuers in default under applicable Canadian provincial Securities Laws of the Provinces of British Columbia, Alberta and Ontario. The Purchaser is in compliance, in all material respects, with all applicable Securities Laws and there are no current, pending or, to the knowledge of the Purchaser, threatened proceedings before any Securities Authority or other Governmental Entity relating to any alleged non-compliance with Securities Laws. The Purchaser Shares are listed on, and the Purchaser is in compliance in all material respects with, the rules and policies of the CSE and Nasdaq. No de-listing, suspension of trading in or cease trading order with respect to any securities of the Purchaser and, to the knowledge of the Purchaser, no inquiry or investigation (formal or informal) of any Securities Authority or the CSE or Nasdaq is in effect or ongoing or, to the knowledge of the Purchaser, expected to be implemented or undertaken.

9. **Purchaser Filings.** The Purchaser has filed all documents required to be filed by it in accordance with applicable Securities Laws with the Securities Authorities and/or the CSE and Nasdaq. The Purchaser has timely filed or furnished all Purchaser Filings required to be filed or furnished by the Purchaser with any Governmental Entity (including “documents affecting the rights of securityholders” and “material contracts” required to be filed by Part 12 of National Instrument 51-102 – *Continuous Disclosure Obligations*). Each of the Purchaser Filings complied as filed in all material respects with applicable Securities Laws and did not, as of the date filed (or, if amended or superseded by a subsequent filing prior to the date of this Agreement, on the date of such filing), contain any Misrepresentation. The Purchaser has not filed any confidential material change report which, at the date of this Agreement, remains confidential.
10. **Forward-Looking Information.** With respect to forward-looking information contained in the Purchaser Filings:
- (a) the Purchaser had, at the time of disclosure of such forward-looking information, a reasonable basis for such forward-looking information; and
  - (b) all material forward-looking information is identified as such, and all such documents caution users of forward-looking information that actual results may vary from the forward-looking information.
11. **Financial Statements.** The consolidated annual audited financial statements of the Purchaser as at and for the year ended December 31, 2019 (including the notes thereto) and related management’s discussion and analysis, and the unaudited interim financial statements of the Purchaser and related management’s discussion and analysis for the three and nine month period ended September 30, 2020 (collectively, the “**Purchaser Financial Statements**”) were prepared in accordance with IFRS consistently applied (except (a) as otherwise indicated In such financial statements and the notes thereto or, in the case of audited statements, in the related report of the Purchaser’s independent auditors, or (b) in the case of unaudited interim statements, are subject to normal period-end adjustments and may omit notes which are not required by applicable Laws in the unaudited statements) and present fairly, in all material respects, the consolidated financial position, financial performance and cash flows of the Purchaser for the dates and periods indicated therein (subject, in the case of any unaudited interim financial statements, to normal period-end adjustments) and reflect reserves required by IFRS in respect of all material contingent liabilities, if any, of the Purchaser on a consolidated basis. There has been no material change in the Purchaser’s accounting policies, except as described in the Purchaser Financial Statements, since December 31, 2019.
12. **Books and Records; Disclosure.** The financial books, records and accounts of the Purchaser and its Subsidiaries, in all material respects: (i) have been maintained in accordance with applicable Law and IFRS on a basis consistent with prior years; (ii) are stated in reasonable detail and accurately and fairly reflect the material transactions, acquisitions and dispositions of the assets of the Purchaser and its Subsidiaries; and (iii) accurately and fairly reflect the basis for the Purchaser Financial Statements.
13. **Independent Auditors.** The Purchaser’s current auditors are independent with respect to the Purchaser within the meaning of the rules of professional conduct applicable to auditors in Canada and there has never been a “reportable event” (within the meaning of National Instrument 51-102 – *Continuous Disclosure Obligations*) with the current or, to the best knowledge of the Purchaser, any predecessor auditors of the Purchaser during the last three years.

14. **No Undisclosed Liabilities.** The Purchaser has no material outstanding indebtedness, liabilities or obligations, whether accrued, absolute, contingent or otherwise, and are not party to or bound by any suretyship, guarantee, indemnification or assumption agreement, or endorsement of, or any other similar commitment with respect to the obligations, liabilities or indebtedness of any Person, other than those specifically identified in the Purchaser Financial Statements, which relate to the proposed Arrangement or incurred in the Ordinary Course and which are not material since the date of the most recent Purchaser Financial Statements.
15. **No Material Change.** Since September 30, 2020, other than the transactions contemplated in this Agreement or as disclosed in the public disclosure record of the Purchaser or as set out in the Purchaser Disclosure Letter:
- (a) the business of the Purchaser and each of its Subsidiaries and Focus has been conducted in the Ordinary Course;
  - (b) there has not occurred any event, occurrence or development or state of circumstances or facts which has had or would, individually or in the aggregate, reasonably be expected to have a Purchaser Material Adverse Effect;
  - (c) there has not been any acquisition or sale by the Purchaser or its Subsidiaries or Focus of any material property or assets;
  - (d) there has not been any incurrence, assumption or guarantee by the Purchaser or its Subsidiaries of any material debt for borrowed money, any creation or assumption by the Purchaser or its Subsidiaries of any Lien (other than a Permitted Lien) or any making by the Purchaser of its Subsidiaries of any material loan, advance or capital contribution or investment in any other Person;
  - (e) there has been no dividend or distribution of any kind declared, paid or made by the Purchaser on any Purchaser Shares;
  - (f) the Purchaser has not effected or passed any resolution to approve a split, consolidation or reclassification or any of the outstanding Purchaser Shares; and
  - (g) the Purchaser has not removed any auditor or director or terminated any senior officer.
16. **Litigation.** Except as disclosed in the Purchaser Disclosure Letter, there is no claim, action, suit, grievance, complaint, proceeding, arbitration, charge, audit, indictment or investigation that is pending or has been commenced or, to the knowledge of the Purchaser, is threatened affecting the Purchaser, its Subsidiaries or Focus or affecting any of their property or assets (whether owned or leased) at law or in equity, which would reasonably be expected to cause, individually or in the aggregate, a Purchaser Material Adverse Effect, or would significantly impede the ability of the Purchaser to consummate the Agreement. Neither the Purchaser, its Subsidiaries nor any of their respective assets or properties is subject to any outstanding judgment, order, writ, injunction or decree material to the Purchaser and its Subsidiaries on a consolidated basis.
17. **Shareholder Approval.** No vote or approval by the holders of Purchaser Shares or the holder of any other securities of the Purchaser is necessary to approve this Agreement, the Arrangement or the transactions contemplated hereby.

18. **Investment Canada Act.** The Purchaser is either a: (i) “WTO Investor” or (ii) a “Trade Agreement Investor”, in each case, within the meaning of the *Investment Canada Act* (Canada).
19. **Compliance with Laws.**
- (a) Except as disclosed in the Purchaser Disclosure Letter, the Purchaser and each of its Subsidiaries and Focus have complied with and are not in violation, in any material respect, of any applicable Laws.
  - (b) Except as disclosed in the Purchaser Disclosure Letter, neither the Purchaser nor any of its Subsidiaries nor Focus have received any written notices or other written correspondence from any Governmental Entity (i) regarding any violation (or any investigation, inspection, audit, or other proceeding by any Governmental Entity involving allegations of any violation) of any Law or (ii) of any circumstances that may have existed or currently exist which could lead to a loss, suspension, or modification of, or a refusal to issue or re-issue, any material Authorization other than where such correspondence would not reasonably be expected to have a Purchaser Material Adverse Effect or significantly impact the ability of the Purchaser to consummate the Arrangement. To the knowledge of the Purchaser, no investigation, inspection, audit or other proceeding by any Governmental Entity involving allegations of any material violation of any Law is threatened or contemplated.
  - (c) Neither the Purchaser, its Subsidiaries nor, to the knowledge of the Purchaser, any of their respective directors, executives, representatives, agents or employees: (i) has used or is using any corporate funds for any illegal contributions, gifts, entertainment or other expenses relating to political activity that would be illegal; (ii) has used or is using any corporate funds for any direct or indirect illegal payments to any foreign or domestic governmental officials or employees; (iii) has violated or is violating any provision of the United States Foreign Corrupt Practices Act of 1977, the *Corruption of Foreign Public Officials Act* (Canada) or any similar Laws of other jurisdictions; (iv) has established or maintained, or is maintaining, any illegal fund of corporate monies or other properties; or (v) has made any bribe, illegal rebate, illegal payoff, influence payment, kickback or other illegal payment of any nature.
  - (d) The operations of the Purchaser and its Subsidiaries and Focus are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the Money Laundering Laws and no action, suit or proceeding by or before any Governmental Entity or any arbitrator non Governmental Entity involving the Purchaser or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Purchaser, threatened.
  - (e) None of the Purchaser or any of its Subsidiaries or Focus or, to the knowledge of the Purchaser, any director, officer, agent, employee or affiliate of the Purchaser or any of its Subsidiaries or Focus, has had any Sanctions imposed upon any such Person, and the Purchaser and its Subsidiaries are not in violation of any of the Sanctions or Law or executive order relating thereto, or are conducting business with any person subject to any Sanctions.
20. **United States Operations.** Neither the Purchaser nor any of its Subsidiaries nor Focus nor any Subsidiaries of Focus conducts cannabis or cannabis-related operations or holds interests in cannabis or cannabis-related operations in the United States (including, without limiting the generality of the foregoing, employees, facilities, royalty entitlements or investments in a United



States-based cannabis business), sells, distributes or otherwise handles cannabis into or within the United States or has any interest in any business that receives revenue from any such business that sells, distributes or otherwise handles cannabis into or within the United States.

21. **United States Securities Law Matters.** The Purchaser Shares are registered pursuant to Section 12(b) of the U.S. Exchange Act and the Purchaser has made all required filings with the U.S. Securities and Exchange Commission under the U.S. Exchange Act on a timely basis. The Purchaser is not an investment company registered or required to be registered under the U.S. Investment Company Act of 1940, as amended, and is a “foreign private issuer” (as such term is defined in Rule 3b-4 under the U.S. Exchange Act).
22. **Directors and Officers.** To the knowledge of the Purchaser, none of its directors or senior executive officers would be disqualified from serving as a director or senior executive officer of an entity that is a licensed producer under the *Cannabis Act* (Canada) or of an entity that is the parent of such an entity, subject to Health Canada’s issuance of the required security clearances to such directors or senior executive officers under the *Cannabis Act* (Canada).
23. **Purchaser Fairness Opinion.** As of the date hereof the board of directors of the Purchaser has received an oral Purchaser Fairness Opinion from the Purchaser Financial Advisor and it expects to receive, prior to mailing the Company Circular, the written Purchaser Fairness Opinion of the Purchaser Financial Advisor in each case to the effect that, as of the date of such opinion, and subject to the assumptions and limitations set out therein, the Consideration to be paid to the Company Shareholders in connection with the Arrangement is fair, from a financial point of view, to the Purchaser.

**SCHEDULE E**  
**REPRESENTATIONS AND WARRANTIES OF TRICHOME**

1. **Organization and Qualification.** Trichome is duly formed and validly existing under the Laws of the Province of British Columbia and has all necessary corporate or other power, authority and capacity to own its material property and assets as now owned and to carry on their business as they are now being conducted.
2. **Authority Relative to this Agreement.** Trichome has all necessary corporate power, authority and capacity to enter into this Agreement and all other agreements and instruments to be executed by Trichome as contemplated by this Agreement, and to perform its obligations hereunder and under such agreements and instruments. The execution and delivery of this Agreement by Trichome and the performance by Trichome of its obligations under this Agreement have been duly authorized by Trichome and except for obtaining the Required Approval, the Interim Order and the Final Order and any required approval of the CSE or Nasdaq in the manner contemplated herein, no other corporate proceedings on its part are necessary to authorize this Agreement or the Arrangement. This Agreement has been duly executed and delivered by Trichome, and constitutes a legal, valid and binding obligation of Trichome, enforceable against Trichome in accordance with its terms, subject to the qualification that such enforceability may be limited by bankruptcy, insolvency, reorganization or other laws of general application relating to or affecting rights of creditors and that equitable remedies, including specific performance, are discretionary and may not be ordered.
3. **No Violation.** Neither the authorization, execution and delivery of this Agreement by Trichome nor the completion of the transactions contemplated by this Agreement or the Arrangement, nor the performances of its obligations hereunder or thereunder, nor compliance by Trichome with any of the provisions hereof or thereof will, in respect of Trichome, result in a violation or breach of, constitute a default (or an event which, with notice or lapse of time or both, would become a default), require any consent or approval to be obtained or notice to be given under, or give rise to any third party right of termination, cancellation, suspension, acceleration, penalty or payment obligation or right to purchase or sale under, any provision of the following:
  - (a) its Constating Documents;
  - (b) any Authorization or Contract material to Trichome to which Trichome is a party or to which any of its properties or assets are bound;
  - (c) result (with or without notice or the passage of time) in a violation or breach of or constitute a default under any provisions of any Laws applicable to Trichome, or its property or assets;  
or
  - (d) result in the imposition of any Liens (other than Permitted Liens) upon any assets of Trichome;except, in the case of clauses (b) and (c) above, for such violations, conflicts, breaches, defaults, terminations, accelerations which, or any consents, approvals or notices which if not given or received, would not, individually or in the aggregate, have a material adverse effect, or significantly impede the ability of Trichome to consummate the transactions contemplated by the Arrangement.
4. **Governmental Approvals.** The execution, delivery and performance by Trichome of this Agreement and the consummation by Trichome of the Arrangement requires no consent, waiver or approval or any action by or in respect of, or filing with, or notification to, any Governmental Entity

other than: (i) the Interim Order and any approvals required by the Interim Order; (ii) the Final Order; (iii) compliance with any applicable Securities Laws and stock exchange rules and regulations; (iv) receipt of any required Regulatory Approvals; and (v) any actions, filings or notifications, the absence of which would not reasonably be expected to have, individually or in the aggregate, a material adverse effect.